U.S. patent application number 11/887492 was filed with the patent office on 2009-06-25 for 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases.
This patent application is currently assigned to COLEY PHARMACEUTICAL GROUP, INC.. Invention is credited to Jason D. Bonk, Chad A. Haraldson, David S. Hays, Ryan B. Prince.
Application Number | 20090163533 11/887492 |
Document ID | / |
Family ID | 36763054 |
Filed Date | 2009-06-25 |
United States Patent
Application |
20090163533 |
Kind Code |
A1 |
Hays; David S. ; et
al. |
June 25, 2009 |
1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of
Cytokine Biosynthesis for the Treatment of Viral Infections and
Neoplastic Diseases
Abstract
Pyrazolo[3,4-c] ring compounds of Formula (I), e.g.,
pyrazolo[3,4-c]pyridines, pyrazolo[3,4-c]quinolines,
6,7,8,9-tetrahydro pyrazolo[3,4-c]quinolines, and
pyrazolo[3,4-c]naphthyridines, substituted at the 1-position,
pharmaceutical compositions containing the compounds,
intermediates, methods of making and methods of use of these
compounds as immunomodulators, for inducing cytokine biosynthesis
in animals and in the treatment of diseases including viral and
neoplastic diseases are disclosed.
Inventors: |
Hays; David S.; (Woodbury,
MN) ; Prince; Ryan B.; (St. Paul, MN) ;
Haraldson; Chad A.; (Apple Valley, MN) ; Bonk; Jason
D.; (Hudson, WI) |
Correspondence
Address: |
WOLF GREENFIELD & SACKS, P.C.
600 ATLANTIC AVENUE
BOSTON
MA
02210-2206
US
|
Assignee: |
COLEY PHARMACEUTICAL GROUP,
INC.
New York
NY
|
Family ID: |
36763054 |
Appl. No.: |
11/887492 |
Filed: |
March 31, 2006 |
PCT Filed: |
March 31, 2006 |
PCT NO: |
PCT/US06/12263 |
371 Date: |
November 14, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60667869 |
Apr 1, 2005 |
|
|
|
60733037 |
Nov 3, 2005 |
|
|
|
Current U.S.
Class: |
514/293 ;
514/303; 546/119; 546/82 |
Current CPC
Class: |
A61P 35/00 20180101;
A61P 43/00 20180101; C07D 471/04 20130101; A61P 31/12 20180101;
C07D 471/14 20130101 |
Class at
Publication: |
514/293 ;
546/119; 546/82; 514/303 |
International
Class: |
A61K 31/4375 20060101
A61K031/4375; C07D 471/04 20060101 C07D471/04; C07D 471/14 20060101
C07D471/14; A61P 35/00 20060101 A61P035/00; A61P 31/12 20060101
A61P031/12 |
Claims
1. A compound of the Formula I: ##STR00083## wherein: Z is selected
from the group consisting of: ##STR00084## a bond, C.sub.1-5
alkylene, ##STR00085## X is selected from the group consisting of a
bond, --C.sub.2-3 alkylene-, and --O--C.sub.2-3 alkylene-; R.sub.1
is selected from the group consisting of: hydrogen, hydroxy,
fluorine, alkoxy, --N(R.sub.9).sub.2, --NH-Q-R.sub.4,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9,
C(R.sub.6)--N(R.sub.8)--R.sub.4,
--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, --C(R.sub.6)--O-alkyl,
--O--C(R.sub.6)--R.sub.4, and ##STR00086## with the proviso that
when Z is a bond, C.sub.1-5 alkylene, ##STR00087## and X is a bond,
then R.sub.1 is other than hydrogen; m is an integer from 1 to 5;
R.sub.A and R.sub.B are each independently selected from the group
consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.9).sub.2; or when taken together, R.sub.A
and R.sub.B form a fused aryl ring or heteroaryl ring containing
one heteroatom selected from the group consisting of N and S
wherein the aryl or heteroaryl ring is unsubstituted or substituted
by one or more R groups; or when taken together, R.sub.A and
R.sub.B form a fused 5 to 7 membered saturated ring, optionally
containing one heteroatom selected from the group consisting of N
and S, and unsubstituted or substituted by one or more R groups; R
is selected from the group consisting of: halogen, hydroxy, alkyl,
haloalkyl, alkoxy, and --N(R.sub.9).sub.2; R.sub.2 is selected from
the group consisting of: hydrogen, alkyl, alkoxyalkylenyl,
hydroxyalkylenyl, haloalkylenyl, and
R.sub.A--C(R.sub.6)--O--C.sub.1-4 alkylenyl; R.sub.4 is selected
from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,
aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo; R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S; R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl; R.sub.11 is selected from the group consisting of hydrogen,
alkyl, halogen, and trifluoromethyl; A is selected from the group
consisting of --O--, --C(O)--, --S(O).sub.0-2--, --CH.sub.2--, and
--N(R.sub.4)--; Q is selected from the group consisting of a bond,
--C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--, --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--; V is selected
from the group consisting of --C(R.sub.6)--, --O--C(R.sub.6)--,
--N(R.sub.8)--C(R.sub.6)--, and --S(O).sub.2--; W is selected from
the group consisting of a bond, --C(O)--, and --S(O).sub.2--; and a
and b are independently integers from 1 to 6 with the proviso that
a+b is .ltoreq.7; or a pharmaceutically acceptable salt
thereof.
2. A compound of the Formula II: ##STR00088## wherein: Z is
selected from the group consisting of: ##STR00089## a bond,
C.sub.1-5 alkylene, ##STR00090## X is selected from the group
consisting of a bond, --C.sub.2-3 alkylene-, --O--C.sub.2-3
alkylene-; R.sub.1 is selected from the group consisting of:
hydrogen, hydroxy, fluorine, alkoxy, --N(R.sub.9).sub.2,
--NH-Q-R.sub.4, --S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9,
--C(R.sub.6)--N(R.sub.8)--R.sub.4,
--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, --C(R.sub.6)--O-alkyl,
--O--C(R.sub.6)--R.sub.4, and ##STR00091## with the proviso that
when Z is a bond, C.sub.1-5 alkylene, ##STR00092## and X is a bond,
then R.sub.1 is other than hydrogen; m is an integer from 1 to 5;
R.sub.A' and R.sub.B' are each independently selected from the
group consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.5).sub.2; R.sub.2 is selected from the
group consisting of: hydrogen, alkyl, alkoxyalkylenyl,
hydroxyalkylenyl, haloalkylenyl, and
R.sub.4--C(R.sub.6)--O--C.sub.1-4 alkylenyl; R.sub.4 is selected
from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,
aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo; R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S; R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl; R.sub.11 is selected from the group consisting of hydrogen,
alkyl, halogen, and trifluoromethyl; A is selected from the group
consisting of --O--, --C(O)--, --S(O).sub.0-2--, --CH.sub.2--, and
--N(R.sub.4)--; Q is selected from the group consisting of a bond,
--C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--, --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--; V is selected
from the group consisting of --C(R.sub.6)--, --O--C(R.sub.6)--,
--N(R.sub.8)--C(R.sub.6)--, and --S(O).sub.2--; W is selected from
the group consisting of a bond, --C(O)--, and --S(O).sub.2--; and a
and b are independently integers from 1 to 6 with the proviso that
a+b is .ltoreq.7; or a pharmaceutically acceptable salt
thereof.
3. A compound of the Formula III: ##STR00093## wherein: Z is
selected from the group consisting of: ##STR00094## a bond,
C.sub.1-5 alkylene, ##STR00095## X is selected from the group
consisting of a bond, --C.sub.2-3 alkylene-, --O--C.sub.2-3
alkylene-; R.sub.1 is selected from the group consisting of:
hydrogen, hydroxy, fluorine, alkoxy, --N(R.sub.9).sub.2,
--NH-Q-R.sub.4, --S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9,
--C(R.sub.6)--N(R.sub.8)--R.sub.4,
--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, --C(R.sub.6)--O-alkyl,
--O--C(R.sub.6)--R.sub.4, and ##STR00096## with the proviso that
when Z is a bond, C.sub.1-5 alkylene, ##STR00097## and X is a bond,
then R.sub.1 is other than hydrogen; m is an integer from 1 to 5; R
is selected from the group consisting of: halogen, hydroxy, alkyl,
haloalkyl, alkoxy, and --N(R.sub.9).sub.2; n is an integer from 0
to 4; R.sub.2 is selected from the group consisting of: hydrogen,
alkyl, alkoxyalkylenyl, hydroxyalkylenyl, haloalkylenyl, and
R.sub.4--C(R.sub.6)--O--C.sub.1-4 alkylenyl; R.sub.4 is selected
from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,
aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo; R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S; R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl; R.sub.11 is selected from the group consisting of hydrogen,
alkyl, halogen, and trifluoromethyl; A is selected from the group
consisting of --O--, --C(O)--, --S(O).sub.0-2--, --CH.sub.2--, and
--N(R.sub.4)--; Q is selected from the group consisting of a bond,
--C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--, --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--; V is selected
from the group consisting of --C(R.sub.6)--, --O--C(R.sub.6)--,
--N(R.sub.8)--C(R.sub.6)--, and --S(O).sub.2--; W is selected from
the group consisting of a bond, --C(O)--, and --S(O).sub.2--; and a
and b are independently integers from 1 to 6 with the proviso that
a+b is .ltoreq.7; or a pharmaceutically acceptable salt
thereof.
4. A compound of the Formula IV: ##STR00098## wherein: Z is
selected from the group consisting of: ##STR00099## a bond,
C.sub.1-5 alkylene, ##STR00100## X is selected from the group
consisting of a bond, --C.sub.2-3 alkylene-, --O--C.sub.2-3
alkylene-; R.sub.1 is selected from the group consisting of:
hydrogen, hydroxy, fluorine, alkoxy, --N(R.sub.9).sub.2,
--NH-Q-R.sub.4, --S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9,
--C(R.sub.6)--N(R.sub.8)--R.sub.4,
--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, --C(R.sub.6)--O-alkyl,
--O--C(R.sub.6)--R.sub.4, and ##STR00101## with the proviso that
when Z is a bond, C.sub.1-5 alkylene, ##STR00102## and X is a bond,
then R.sub.1 is other than hydrogen; m is an integer from 1 to 5; R
is selected from the group consisting of: halogen, hydroxy, alkyl,
haloalkyl, alkoxy, and --N(R.sub.9).sub.2; n is an integer from 0
to 4; R.sub.2 is selected from the group consisting of: hydrogen,
alkyl, alkoxyalkylenyl, hydroxyalkylenyl, haloalkylenyl, and
R.sub.4--C(R.sub.6)--O--C.sub.1-4 alkylenyl; R.sub.4 is selected
from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,
aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo; R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S; R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl; R.sub.11 is selected from the group consisting of hydrogen,
alkyl, halogen, and trifluoromethyl; A is selected from the group
consisting of --O--, --C(O)--, --S(O).sub.0-2--, --CH.sub.2--, and
--N(R.sub.4)--; Q is selected from the group consisting of a bond,
--C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--, --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--; V is selected
from the group consisting of --C(R.sub.6)--, --O--C(R.sub.6)--,
--N(R.sub.8)--C(R.sub.6)--, and --S(O).sub.2--; W is selected from
the group consisting of a bond, --C(O)--, and --S(O).sub.2--; and a
and b are independently integers from 1 to 6 with the proviso that
a+b is .ltoreq.7; or a pharmaceutically acceptable salt
thereof.
5. A compound selected from the group consisting of the Formulas V,
VI, VII, and VIII: ##STR00103## wherein: Z is selected from the
group consisting of: ##STR00104## a bond, C.sub.1-5 alkylene,
##STR00105## X is selected from the group consisting of a bond,
--C.sub.2-3 alkylene-, --O--C.sub.2-3 alkylene-; R.sub.1 is
selected from the group consisting of: hydrogen, hydroxy, fluorine,
alkoxy, --N(R.sub.9).sub.2, --NH-Q-R.sub.4, --S(O).sub.0-2-alkyl,
--S(O).sub.2--NH--R.sub.9, --C(R.sub.6)--N(R.sub.8)--R.sub.4,
--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, --C(R.sub.6)--O-alkyl,
--O--C(R.sub.6)--R.sub.4, and ##STR00106## with the proviso that
when Z is a bond, C.sub.1-5 alkylene, ##STR00107## and X is a bond,
then R.sub.1 is other than hydrogen; m is an integer from 1 to 5; R
is selected from the group consisting of: halogen, hydroxy, alkyl,
haloalkyl, alkoxy, and --N(R.sub.9).sub.2; p is an integer from 0
to 3; R.sub.2 is selected from the group consisting of: hydrogen,
alkyl, alkoxyalkylenyl, hydroxyalkylenyl, haloalkylenyl, and
R.sub.4--C(R.sub.6)--O--C.sub.1-4 alkylenyl; R.sub.4 is selected
from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,
aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo; R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S; R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl; R.sub.11 is selected from the group consisting of hydrogen,
alkyl, halogen, and trifluoromethyl; A is selected from the group
consisting of --O--, --C(O)--, --S(O).sub.0-2--, --CH.sub.2--, and
--N(R.sub.4)--; Q is selected from the group consisting of a bond,
--C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--, --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--; V is selected
from the group consisting of --C(R.sub.6)--, --O--C(R.sub.6)--,
--N(R.sub.8)--C(R.sub.6)--, and --S(O).sub.2--; W is selected from
the group consisting of a bond, --C(O)--, and --S(O).sub.2--; and a
and b are independently integers from 1 to 6 with the proviso that
a+b is .ltoreq.7; or a pharmaceutically acceptable salt
thereof.
6. A compound of the Formula XIII: ##STR00108## wherein: Z is
selected from the group consisting of: ##STR00109## a bond,
C.sub.1-5 alkylene, ##STR00110## X is selected from the group
consisting of a bond, --C.sub.2-3 alkylene-, and --O--C.sub.2-3
alkylene-; R.sub.1 is selected from the group consisting of:
hydrogen, hydroxy, fluorine, alkoxy, --N(R.sub.9).sub.2,
--NH-Q-R.sub.4, --S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9,
--C(R.sub.6)--N(R.sub.8)--R.sub.4,
--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, --C(R.sub.6)--O-alkyl,
--O--C(R.sub.6)--R.sub.4, and ##STR00111## with the proviso that
when Z is a bond, C.sub.1-5 alkylene, ##STR00112## and X is a bond,
then R.sub.1 is other than hydrogen; m is an integer from 1 to 5;
R.sub.A and R.sub.B are each independently selected from the group
consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.9).sub.2; or when taken together, R.sub.A
and R.sub.B form a fused aryl ring or heteroaryl ring containing
one heteroatom selected from the group consisting of N and S
wherein the aryl or heteroaryl ring is unsubstituted or substituted
by one or more R groups; or when taken together, R.sub.A and
R.sub.B form a fused 5 to 7 membered saturated ring, optionally
containing one heteroatom selected from the group consisting of N
and S, and unsubstituted or substituted by one or more R groups; R
is selected from the group consisting of: halogen, hydroxy, alkyl,
haloalkyl, alkoxy, and --N(R.sub.9).sub.2; R.sub.2 is selected from
the group consisting of: hydrogen, alkyl, alkoxyalkylenyl,
hydroxyalkylenyl, haloalkylenyl, and
R.sub.4--C(R.sub.6)--O--C.sub.1-4 alkylenyl; R.sub.4 is selected
from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,
aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo; R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S; R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl; R.sub.11 is selected from the group consisting of hydrogen,
alkyl, halogen, and trifluoromethyl; A is selected from the group
consisting of --O--, --C(O)--, --S(O).sub.0-2--, --CH.sub.2--, and
--N(R.sub.4)--; Q is selected from the group consisting of a bond,
--C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--, --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--; V is selected
from the group consisting of --C(R.sub.6)--, --O--C(R.sub.6)--,
--N(R.sub.8)--C(R.sub.6)--, and --S(O).sub.2--; W is selected from
the group consisting of a bond, --C(O)--, and --S(O).sub.2--; a and
b are independently integers from 1 to 6 with the proviso that a+b
is .ltoreq.7; G.sub.1 is selected from the group consisting of:
--C(O)--R', .alpha.-aminoacyl, .alpha.-aminoacyl-.alpha.-aminoacyl,
--C(O)--O--R', --C(O)--N(R'')R', --C(.dbd.NY')--R',
--CH(OH)--C(O)--OY', --CH(OC.sub.1-4 alkyl)Y.sub.0,
--CH.sub.2Y.sub.2, and --CH(CH.sub.3)Y.sub.2; R' and R'' are
independently selected from the group consisting of C.sub.1-10
alkyl, C.sub.3-7 cycloalkyl, phenyl, and benzyl, each of which may
be unsubstituted or substituted by one or more substituents
independently selected from the group consisting of halogen,
hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkyl, C.sub.1-4 alkoxy,
aryl, heteroaryl, aryl-C.sub.1-4 alkylenyl, heteroaryl-C.sub.1-4
alkylenyl, halo-C.sub.1-4 alkylenyl, halo-C.sub.1-4 alkoxy,
--O--C(O)--CH.sub.3, --C(O)--O--CH.sub.3, --C(O)--NH.sub.2,
--O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2, with the proviso that R'' can also be
hydrogen; .alpha.-aminoacyl is an .alpha.-aminoacyl group derived
from an amino acid selected from the group consisting of racemic,
D-, and L-amino acids; Y' is selected from the group consisting of
hydrogen, C.sub.1-6 alkyl, and benzyl; Y.sub.0 is selected from the
group consisting of C.sub.1-6 alkyl, carboxy-C.sub.1-6 alkylenyl,
amino-C.sub.1-4 alkylenyl, mono-N--C.sub.1-6 alkylamino-C.sub.1-4
alkylenyl, and di-N,N--C.sub.1-6 alkylamino-C.sub.1-4 alkylenyl;
and Y.sub.2 is selected from the group consisting of
mono-N--C.sub.1-6 alkylamino, di-N,N--C.sub.1-6 alkylamino,
morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and 4-C.sub.1-4
alkylpiperazin-1-yl; or a pharmaceutically acceptable salt
thereof.
7. A compound of the Formula XIV: ##STR00113## wherein: Z is
selected from the group consisting of: ##STR00114## a bond,
C.sub.1-5 alkylene, ##STR00115## m is an integer from 1 to 5;
R.sub.A and R.sub.B are each independently selected from the group
consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.9).sub.2; or when taken together, R.sub.A
and R.sub.B form a fused aryl ring or heteroaryl ring containing
one heteroatom selected from the group consisting of N and S
wherein the aryl or heteroaryl ring is unsubstituted or substituted
by one or more R groups; or when taken together, R.sub.A and
R.sub.B form a fused 5 to 7 membered saturated ring, optionally
containing one heteroatom selected from the group consisting of N
and S, and unsubstituted or substituted by one or more R groups; R
is selected from the group consisting of: halogen, hydroxy, alkyl,
haloalkyl, alkoxy, and --N(R.sub.9).sub.2; R.sub.2 is selected from
the group consisting of: hydrogen, alkyl, alkoxyalkylenyl,
hydroxyalkylenyl, haloalkylenyl, and
R.sub.4--C(R.sub.6)--O--C.sub.1-4 alkylenyl; R.sub.4 is selected
from the group consisting of hydrogen, alkyl, alkenyl, alkynyl,
aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo; R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S; R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl; R.sub.11 is selected from the group consisting of hydrogen,
alkyl, halogen, and trifluoromethyl; Q is selected from the group
consisting of a bond, --C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--,
--S(O).sub.2--, --C(R.sub.6)--N(R.sub.8)--W--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--O--, and
--C(R.sub.6)--N(OR.sub.9)--; W is selected from the group
consisting of a bond, --C(O)--, and --S(O).sub.2--; G.sub.2 is
selected from the group consisting of: --X.sub.2--C(O)--R',
.alpha.-aminoacyl, .alpha.-aminoacyl-.alpha.-aminoacyl,
--X.sub.2--C(O)--O--R', --C(O)--N(R'')R', and --S(O).sub.2--R';
X.sub.2 is selected from the group consisting of a bond;
--CH.sub.2--O--; --CH(CH.sub.3)--O--; --C(CH.sub.3)--O--; and, in
the case of --X.sub.2--C(O)--O--R', --CH.sub.2--NH--; R' and R''
are independently selected from the group consisting of C.sub.1-10
alkyl, C.sub.3-7 cycloalkyl, phenyl, and benzyl, each of which may
be unsubstituted or substituted by one or more substituents
independently selected from the group consisting of halogen,
hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkyl, C.sub.1-4 alkoxy,
aryl, heteroaryl, aryl-C.sub.1-4 alkylenyl, heteroaryl-C.sub.1-4
alkylenyl, halo-C.sub.1-4 alkylenyl, halo-C.sub.1-4 alkoxy,
--O--C(O)--CH.sub.3, --C(O)--O--CH.sub.3, --C(O)--NH.sub.2,
--O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2, with the proviso that R'' can also be
hydrogen; and .alpha.-aminoacyl is an .alpha.-aminoacyl group
derived from an amino acid selected from the group consisting of
racemic, D-, and L-amino acids; or a pharmaceutically acceptable
salt thereof.
8. The compound or salt of claim 2 wherein R.sub.A' and R.sub.B'
are independently hydrogen or alkyl.
9. The compound or salt of claim 8 wherein R.sub.A' and R.sub.B'
are both methyl.
10. The compound or salt of claim 3 or claim 4 wherein R is
hydroxy.
11. The compound or salt of claim 3 or claim 4 wherein n is 0.
12. The compound or salt of claim 5 wherein the compound is
selected from the group consisting of the Formulas V and VIII:
##STR00116## or a pharmaceutically acceptable salt thereof.
13. The compound or salt of claim 5 or claim 12 wherein p is 0.
14. The compound or salt of any one of claims 1 through 13 wherein
m is an integer from 1 to 3.
15. The compound or salt of claim 14 wherein m is 1.
16. The compound or salt of any one of claims 1 through 15 wherein
Z is selected from the group consisting of a bond and C.sub.1-3
allylene.
17. The compound or salt of any one of claims 1 through 15 wherein
Z is selected from the group consisting of: ##STR00117##
18. The compound or salt of claim 17 wherein Z is ##STR00118##
19. The compound or salt of claim 17 wherein Z is ##STR00119##
20. The compound or salt of any one of claims 1 through 15, 17, or
19 wherein Q is selected from the group consisting of --C(O)--,
--C(O)--O--, --S(O).sub.2--, and --C(R.sub.6)--N(R.sub.8)--.
21. The compound or salt of claim 20 wherein R.sub.4 is selected
from the group consisting of alkyl, aryl, arylalkylenyl,
heteroaryl, and heterocyclyl, wherein the aryl group can be
unsubstituted or substituted by one or more substituents
independently selected from the group consisting of acetylamino,
alkyl, alkoxy, cyano, and halogen.
22. The compound or salt of any one of claims 1 through 6, 8
through 13, or 14 through 21 except as dependent on 7 wherein X is
a bond.
23. The compound or salt of any one of claims 1 through 6, 8
through 13, 14 through 21 except as dependent on 7, or 22 wherein
R.sub.1 is selected from the group consisting of hydroxy and
methoxy.
24. The compound or salt of any one of claims 1 through 6, 8
through 13, 14 through 21 except as dependent on 7, or 22 wherein
R.sub.1 is fluoro.
25. The compound or salt of any one of claims 1 through 6, 8
through 13, 14 through 21 except as dependent on 7, or 22 wherein
R.sub.1 is selected from the group consisting of --NH.sub.2,
--NH-Q-R.sub.4, --C(O)--NH.sub.2, and --C(O)--N(R.sub.8)--R.sub.4,
wherein: Q is selected from the group consisting of --C(O)--,
--S(O).sub.2--, --C(O)--O--, and --C(O)--NH--, R.sub.8 is selected
from the group consisting of hydrogen and alkyl, and R.sub.4 is
selected from the group consisting of alkyl and
alkoxyalkylenyl.
26. The compound or salt of any one of claims 1 through 6, 8
through 13, 14 except as dependent on 7, or 15 except as dependent
on 7 wherein Z is ##STR00120## X is a bond, and R.sub.1 is
hydrogen.
27. The compound or salt of claim 13 or claim 11 as dependent on
claim 3 wherein Z is ##STR00121## X is a bond, and R.sub.1 is
hydrogen.
28. The compound or salt of any one of claims 1 through 27 wherein
R.sub.2 is selected from the group consisting of C.sub.1-4 alkyl,
C.sub.1-4 alkyl-O--C.sub.2-4 alkylenyl, and hydroxyC.sub.2-4
alkylenyl.
29. The compound of salt of claim 28 wherein R.sub.2 is selected
from the group consisting of methyl, ethyl, n-propyl, n-butyl,
2-methoxyethyl, and 2-hydroxyethyl.
30. A pharmaceutical composition comprising a therapeutically
effective amount of a compound or salt of any one of claims 1-29 in
combination with a pharmaceutically acceptable carrier.
31. A method of inducing cytokine biosynthesis in an animal
comprising administering an effective amount of a compound or salt
of any one of claims 1-29 or the pharmaceutical composition of
claim 30 to the animal.
32. A method of treating a viral disease in an animal in need
thereof comprising administering a therapeutically effective amount
of a compound or salt of any one of claims 1-29 or the
pharmaceutical composition of claim 30 to the animal.
33. A method of treating a neoplastic disease in an animal in need
thereof comprising administering a therapeutically effective amount
of a compound or salt of any one of claims 1-29 or the
pharmaceutical composition of claim 30 to the animal.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present invention claims priority to U.S. Provisional
Application Ser. No. 60/667,869, filed Apr. 1, 2005, and U.S.
Provisional Application Ser. No. 60/733,037, filed Nov. 3, 2005,
both of which are incorporated herein by reference.
BACKGROUND
[0002] Certain compounds have been found to be useful as immune
response modifiers (IRMs), rendering them useful in the treatment
of a variety of disorders. However, there continues to be interest
in and a need for compounds that have the ability to modulate the
immune response, by induction of cytokine biosynthesis or other
mechanisms.
SUMMARY
[0003] The present invention provides a new class of compounds that
are useful in inducing cytokine biosynthesis in animals. Such
compounds are of the following Formula I:
##STR00001##
wherein R.sub.1, R.sub.2, R.sub.A, R.sub.B, X, Z, and m are as
defined below.
[0004] The compounds of Formula I are useful as immune response
modifiers due to their ability to induce cytokine biosynthesis
(e.g., induces the synthesis of at least one cytokine) and
otherwise modulate the immune response when administered to
animals. This makes the compounds useful in the treatment of a
variety of conditions such as viral diseases and tumors that are
responsive to such changes in the immune response.
[0005] The invention further provides pharmaceutical compositions
containing an effective amount of a compound of Formula I and
methods of inducing cytokine biosynthesis in an animal, treating a
viral infection or disease and/or treating a neoplastic disease in
an animal by administering an effective amount of a compound of
Formula I to the animal.
[0006] In addition, methods of synthesizing compounds of Formula I
and intermediates useful in the synthesis of these compounds are
provided.
[0007] As used herein, "a," "an," "the," "at least one," and "one
or more" are used interchangeably.
[0008] The terms "comprises" and variations thereof do not have a
limiting meaning where these terms appear in the description and
claims.
[0009] The above summary of the present invention is not intended
to describe each disclosed embodiment or every implementation of
the present invention. The description that follows more
particularly exemplifies illustrative embodiments. In several
places throughout the description, guidance is provided through
lists of examples, which examples can be used in various
combinations. In each instance, the recited list serves only as a
representative group and should not be interpreted as an exclusive
list.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS OF THE
INVENTION
[0010] The present invention provides compounds of the following
Formula I:
##STR00002##
and more specifically compounds of the following Formulas II, III,
IV, V, VI, VII, VIII, XIII, and XIV:
##STR00003## ##STR00004##
wherein R.sub.A, R.sub.B, R.sub.A', R.sub.B', R, R.sub.1, R.sub.2,
m, n, p, X, Z, G.sub.1, and G.sub.2 are as defined below; and
pharmaceutically acceptable salts thereof.
[0011] In one embodiment, the present invention provides a compound
of the Formula I:
##STR00005##
wherein:
[0012] Z is selected from the group consisting of:
##STR00006## [0013] a bond, [0014] C.sub.1-5 alkylene,
##STR00007##
[0015] X is selected from the group consisting of a bond,
--C.sub.2-3 alkylene-, and --O--C.sub.2-3 alkylene-;
[0016] R.sub.1 is selected from the group consisting of: [0017]
hydrogen, [0018] hydroxy, [0019] fluorine, [0020] alkoxy, [0021]
--N(R.sub.9).sub.2, [0022] --NH-Q-R.sub.4, [0023]
--S(O).sub.0-2-alkyl, [0024] --S(O).sub.2--NH--R.sub.9, [0025]
--C(R.sub.6)--N(R.sub.8)--R.sub.4, [0026]
--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, [0027] --C(R.sub.6)--O-alkyl,
[0028] --O--C(R.sub.6)--R.sub.4, and
[0028] ##STR00008## [0029] with the proviso that when Z is a bond,
C.sub.1-5 alkylene,
##STR00009##
[0029] and X is a bond,
[0030] then R.sub.1 is other than hydrogen;
[0031] m is an integer from 1 to 5;
[0032] R.sub.A and R.sub.B are each independently selected from the
group consisting of: [0033] hydrogen, [0034] halogen, [0035] alkyl,
[0036] alkenyl, [0037] alkoxy, [0038] alkylthio, and [0039]
--N(R.sub.9).sub.2;
[0040] or when taken together, R.sub.A and R.sub.B form a fused
aryl ring or heteroaryl ring containing one heteroatom selected
from the group consisting of N and S wherein the aryl or heteroaryl
ring is unsubstituted or substituted by one or more R groups;
[0041] or when taken together, R.sub.A and R.sub.B form a fused 5
to 7 membered saturated ring, optionally containing one heteroatom
selected from the group consisting of N and S, and unsubstituted or
substituted by one or more R groups;
[0042] R is selected from the group consisting of: [0043] halogen,
[0044] hydroxy, [0045] alkyl, [0046] haloalkyl, [0047] alkoxy, and
[0048] --N(R.sub.9).sub.2;
[0049] R.sub.2 is selected from the group consisting of: [0050]
hydrogen, [0051] alkyl, [0052] alkoxyalkylenyl, [0053]
hydroxyalkylenyl, [0054] haloalkylenyl, and [0055]
R.sub.4--C(R.sub.6)--O--C.sub.1-4 alkylenyl;
[0056] R.sub.4 is selected from the group consisting of hydrogen,
alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
[0057] R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
[0058] R.sub.8 is selected from the group consisting of hydrogen,
alkyl, alkoxyalkylenyl, and arylalkylenyl;
[0059] R.sub.9 is selected from the group consisting of hydrogen
and alkyl;
[0060] R.sub.11 is selected from the group consisting of hydrogen,
alkyl, halogen, and trifluoromethyl;
[0061] A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
[0062] Q is selected from the group consisting of a bond,
--C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--, --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
[0063] V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
[0064] W is selected from the group consisting of a bond, --C(O)--,
and --S(O).sub.2--; and
[0065] a and b are independently integers from 1 to 6 with the
proviso that a+b is .ltoreq.7; or a pharmaceutically acceptable
salt thereof.
[0066] In another embodiment, the present invention provides a
compound of the Formula II:
##STR00010##
wherein:
[0067] Z, X, R.sub.1, R.sub.2, and m are as defined in Formula I;
and
[0068] R.sub.A' and R.sub.B' are each independently selected from
the group consisting of: [0069] hydrogen, [0070] halogen, [0071]
alkyl, [0072] alkenyl, [0073] alkoxy, [0074] alkylthio, and [0075]
--N(R.sub.9).sub.2; or a pharmaceutically acceptable salt
thereof.
[0076] In another embodiment, the present invention provides a
compound of the Formula III:
##STR00011##
wherein:
[0077] Z, X, R.sub.1, R.sub.2, R, and m are as defined in Formula
I; and
[0078] n is an integer from 0 to 4;
or a pharmaceutically acceptable salt thereof.
[0079] In another embodiment, the present invention provides a
compound of the Formula IV:
##STR00012##
wherein:
[0080] Z, X, R.sub.1, R.sub.2, R, and m are as defined in Formula
I; and
[0081] n is an integer from 0 to 4;
or a pharmaceutically acceptable salt thereof.
[0082] In another embodiment, the present invention provides a
compound selected from the group consisting of the Formulas V, VI,
VII, and VIII:
##STR00013##
wherein:
[0083] Z, X, R.sub.1, R.sub.2, R, and m are as defined in Formula
I; and
[0084] p is an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.
[0085] In another embodiment, the present invention provides a
compound selected from the group consisting of the Formulas IX, X,
XI, and XII:
##STR00014##
wherein:
[0086] Z, X, R.sub.1, R.sub.2, R, and m are as defined in Formula
I; and
[0087] p is an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.
[0088] In another embodiment, the present invention provides a
compound of the Formula XIII:
##STR00015##
wherein:
[0089] R.sub.1, R.sub.2, R.sub.A, R.sub.B, X, Z, and m are as
defined in Formula I, [0090] G.sub.1 is selected from the group
consisting of: [0091] --C(O)--R.sup.1, [0092] .alpha.-aminoacyl,
[0093] .alpha.-aminoacyl-.alpha.-aminoacyl, [0094] --C(O)--O--R',
[0095] --C(O)--N(R'')R', [0096] --C(.dbd.NY')--R', [0097]
--CH(OH)--C(O)--OY', [0098] --CH(OC.sub.1-4 alkyl)Y.sub.0, [0099]
--CH.sub.2Y.sub.2, and [0100] --CH(CH.sub.3)Y.sub.2;
[0101] R' and R'' are independently selected from the group
consisting of C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, phenyl, and
benzyl, each of which may be unsubstituted or substituted by one or
more substituents selected from the group consisting of halogen,
hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkyl, C.sub.1-4 alkoxy,
aryl, heteroaryl, aryl-C.sub.1-4 alkylenyl, heteroaryl-C.sub.1-4
alkylenyl, halo-C.sub.1-4 alkylenyl, halo-C.sub.1-4 alkoxy,
--O--C(O)--CH.sub.3, --C(O)--O--CH.sub.3, --C(O)--NH.sub.2,
--O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2, with the proviso that R'' can also be
hydrogen;
[0102] .alpha.-aminoacyl is an .alpha.-aminoacyl group derived from
an amino acid selected from the group consisting of racemic, D-,
and L-amino acids;
[0103] Y' is selected from the group consisting of hydrogen,
C.sub.1-6 alkyl, and benzyl;
[0104] Y.sub.0 is selected from the group consisting of C.sub.1-6
alkyl, carboxy-C.sub.1-6 alkylenyl, amino-C.sub.1-4 alkylenyl,
mono-N--C.sub.1-6 alkylamino-C.sub.1-4 alkylenyl, and
di-N,N--C.sub.4 alkylamino-C.sub.1-4 alkylenyl; and
[0105] Y.sub.2 is selected from the group consisting of
mono-N--C.sub.1-6 alkylamino, di-N,N--C.sub.1-6 alkylamino,
morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and 4-C.sub.1-4
alkylpiperazin-1-yl;
or a pharmaceutically acceptable salt thereof.
[0106] In another embodiment, the present invention provides a
compound of the Formula XIV:
##STR00016##
wherein:
[0107] R.sub.A, R.sub.B, R.sub.2, Z, and m are as defined in
Formula I,
[0108] G.sub.2 is selected from the group consisting of: [0109]
--X.sub.2--C(O)--R', [0110] .alpha.-aminoacyl, [0111]
.alpha.-aminoacyl-.alpha.-aminoacyl, [0112] --X.sub.2--C(O)--O--R',
[0113] --C(O)--N(R'')R', and [0114] --S(O).sub.2--R';
[0115] X.sub.2 is selected from the group consisting of a bond;
--CH.sub.2--O--; --CH(CH.sub.3)--O--; --C(CH.sub.3).sub.2--O--;
and, in the case of --X.sub.2--C(O)--O--R', --CH.sub.2--NH--;
[0116] R' and R'' are independently selected from the group
consisting of C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, phenyl, and
benzyl, each of which may be unsubstituted or substituted by one or
more substituents independently selected from the group consisting
of halogen, hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkyl,
C.sub.1-4 alkoxy, aryl, heteroaryl, aryl-C.sub.1-4 alkylenyl,
heteroaryl-C.sub.1-4 alkylenyl, halo-C.sub.1-4 alkylenyl,
halo-C.sub.1-4 alkoxy, --O--C(O)--CH.sub.3, --C(O)--O--CH.sub.3,
--C(O)--NH.sub.2, --O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2, with the proviso that R'' can also be
hydrogen; and
[0117] .alpha.-aminoacyl is an .alpha.-aminoacyl group derived from
an amino acid selected from the group consisting of racemic, D-,
and L-amino acids;
or a pharmaceutically acceptable salt thereof.
[0118] As used herein, the terms "alkyl", "alkenyl", "alkynyl" and
the prefix "alk-" are inclusive of both straight chain and branched
chain groups and of cyclic groups, e.g., cycloalkyl and
cycloalkenyl. Unless otherwise specified, these groups contain from
1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20
carbon atoms, and alkynyl groups containing from 2 to 20 carbon
atoms. In some embodiments, these groups have a total of up to 10
carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, or up to
4 carbon atoms. Cyclic groups can be monocyclic or polycyclic and
preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic
groups include cyclopropyl, cyclopropylmethyl, cyclopentyl,
cyclohexyl, adamantyl, and substituted and unsubstituted bornyl,
norbornyl, and norbornenyl.
[0119] Unless otherwise specified, "alkylene", "-alkylene-",
"alkenylene", "-alkenylene-", "alkynylene", and "-alkynylene-" are
the divalent forms of the "alkyl", "alkenyl", and "alkynyl" groups
defined above. The terms "alkylenyl", "alkenylenyl", and
"alkynylenyl" are used when "alkylene", "alkenylene", and
"alkynylene", respectively, are substituted. For example, an
arylalkylenyl group comprises an "alkylene" moiety to which an aryl
group is attached.
[0120] The term "haloalkyl" is inclusive of groups that are
substituted by one or more halogen atoms, including perfluorinated
groups. This is also true of other groups that include the prefix
"halo-." Examples of suitable haloalkyl groups are chloromethyl,
trifluoromethyl, and the like.
[0121] The term "aryl" as used herein includes carbocyclic aromatic
rings or ring systems. Examples of aryl groups include phenyl,
naphthyl, biphenyl, fluorenyl and indenyl.
[0122] Unless otherwise indicated, the term "heteroatom" refers to
the atoms O, S, or N.
[0123] The term "heteroaryl" includes aromatic rings or ring
systems that contain at least one ring heteroatom (e.g., O, S, N).
In some embodiments, the term "heteroaryl" includes a ring or ring
system that contains 2-12 carbon atoms, 1-3 rings, 1-4 heteroatoms,
and O, S, and N as the heteroatoms. Exemplary heteroaryl groups
include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl,
indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl,
pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl,
carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl,
quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl,
isothiazolyl, purinyl, quinazolinyl, pyrazinyl, 1-oxidopyridyl,
pyridazinyl, triazinyl, tetrazinyl, oxadiazolyl, thiadiazolyl, and
so on.
[0124] The term "heterocyclyl" includes non-aromatic rings or ring
systems that contain at least one ring heteroatom (e.g., O, S, N)
and includes all of the fully saturated and partially unsaturated
derivatives of the above mentioned heteroaryl groups. In some
embodiments, the term "heterocyclyl" includes a ring or ring system
that contains 2-12 carbon atoms, 1-3 rings, 1-4 heteroatoms, and O,
S, and N as the heteroatoms. Exemplary heterocyclyl groups include
pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl,
1,1-dioxothiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl,
imidazolidinyl, isothiazolidinyl, tetrahydropyranyl, quinuclidinyl,
homopiperidinyl (azepanyl), 1,4-oxazepanyl, homopiperazinyl
(diazepanyl), 1,3-dioxolanyl, aziridinyl, azetidinyl,
dihydroisoquinolin-(1H)-yl, octahydroisoquinolin-(1H)-yl,
dihydroquinolin-(2H)-yl, octahydroquinolin-(2H)-yl,
dihydro-1H-imidazolyl, 3-azabicyclo[3.2.2]non-3-yl, and the
like.
[0125] The term "heterocyclyl" includes bicyclic and tricyclic
heterocyclic ring systems. Such ring systems include fused and/or
bridged rings and spiro rings. Fused rings can include, in addition
to a saturated or partially saturated ring, an aromatic ring, for
example, a benzene ring. Spiro rings include two rings joined by
one spiro atom and three rings joined by two spiro atoms.
[0126] When "heterocyclyl" contains a nitrogen atom, the point of
attachment of the heterocyclyl group may be the nitrogen atom.
[0127] The terms "arylene", "heteroarylene", and "heterocyclylene"
are the divalent forms of the "aryl", "heteroaryl", and
"heterocyclyl" groups defined above. The terms, "arylenyl",
"heteroarylenyl", and "heterocyclylenyl" are used when "arylene",
"heteroarylene", and "heterocyclylene", respectively, are
substituted. For example, an alkylarylenyl group comprises an
arylene moiety to which an alkyl group is attached.
[0128] The term "fused aryl ring" includes fused carbocyclic
aromatic rings or ring systems. Examples of fused aryl rings
include benzo, naphtho, fluoreno, and indeno.
[0129] The term "fused heteroaryl ring" includes the fused forms of
5 or 6 membered aromatic rings that contain one heteroatom selected
from S and N.
[0130] The term "fused 5 to 7 membered saturated ring" includes
rings which are fully saturated except for the bond where the ring
is fused.
[0131] When a group (or substituent or variable) is present more
than once in any formula described herein, each group (or
substituent or variable) is independently selected, whether
explicitly stated or not. For example, for the formula
--N(R.sub.9)-- each R.sub.9 group is independently selected. In
another example, when an R.sub.1 and a Z group both contain an
R.sub.4 group, each R.sub.4 group is independently selected.
[0132] The invention is inclusive of the compounds described herein
(including intermediates) in any of their pharmaceutically
acceptable forms, including isomers (e.g., diastereomers and
enantiomers), salts, solvates, polymorphs, prodrugs, and the like.
In particular, if a compound is optically active, the invention
specifically includes each of the compound's enantiomers as well as
racemic mixtures of the enantiomers. It should be understood that
the term "compound" includes any or all of such forms, whether
explicitly stated or not (although at times, "salts" are explicitly
stated).
[0133] The term "prodrug" means a compound that can be transformed
in vivo to yield an immune response modifying compound, including
any of the salt, solvated, polymorphic, or isomeric forms described
above. The prodrug, itself, may be an immune response modifying
compound, including any of the salt, solvated, polymorphic, or
isomeric forms described above. The transformation may occur by
various mechanisms, such as through a chemical (e.g., solvolysis or
hydrolysis, for example, in the blood) or enzymatic
biotransformation. A discussion of the use of prodrugs is provided
by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems,"
Vol. 14 of the A. C. S. Symposium Series, and in Bioreversible
Carriers in Drug Design, ed. Edward B. Roche, American
Pharmaceutical Association and Pergamon Press, 1987.
[0134] Compounds (including intermediates) of the present invention
may exist in different tautomeric forms, and all such forms are
embraced within the scope of the invention. The term "tautomer" or
"tautomeric form" refers to structural isomers of different
energies which are interconvertible via a low energy barrier. For
example, proton tautomers (prototropic tautomers) include
interconversions via migration of a proton, such as keto-enol and
imine-enamine isomerizations. When compounds of the present
invention have a hydrogen atom at the 2 position, proton migration
between the 2 and 3 positions may occur.
[0135] The compounds of the present invention may exist in
unsolvated as well as solvated forms with pharmaceutically
acceptable solvents such as water, ethanol, and the like. The
present invention embraces both solvated and unsolvated forms.
[0136] For any of the compounds presented herein, each one of the
following variables (e.g., R.sub.A, R.sub.B, R.sub.A', R.sub.B', R,
R.sub.1, R.sub.2, m, n, p, A, Q, X, Z, and so on) in any of its
embodiments can be combined with any one or more of the other
variables in any of their embodiments and associated with any one
of the formulas described herein, as would be understood by one of
skill in the art. Each of the resulting combinations of variables
is an embodiment of the present invention.
[0137] In certain embodiments (e.g., of Formula I), R.sub.A and
R.sub.B are each independently selected from the group consisting
of hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
[0138] or when taken together, R.sub.A and R.sub.B form a fused
aryl ring or heteroaryl ring containing one heteroatom selected
from the group consisting of N and S wherein the aryl or heteroaryl
ring is unsubstituted or substituted by one or more R groups;
[0139] or when taken together, R.sub.A and R.sub.B form a fused 5
to 7 membered saturated ring, optionally containing one heteroatom
selected from the group consisting of N and S, and unsubstituted or
substituted by one or more R groups.
[0140] In certain embodiments (e.g., of Formula I), R.sub.A and
R.sub.B are each independently selected from the group consisting
of hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2.
[0141] In certain embodiments (e.g., of Formula I), R.sub.A and
R.sub.B form a fused aryl or heteroaryl ring.
[0142] In certain embodiments (e.g., of Formula I), R.sub.A and
R.sub.B form a fused aryl ring. In certain embodiments, the fused
aryl ring is benzo.
[0143] In certain embodiments (e.g., of Formula I), R.sub.A and
R.sub.B form a fused heteroaryl ring. In certain embodiments, the
fused heteroaryl ring is pyrido or thieno. In certain embodiments,
the fused heteroaryl ring is pyrido. In certain of these
embodiments, the pyrido ring is
##STR00017##
wherein the highlighted bond indicates the position where the ring
is fused.
[0144] In certain embodiments (e.g., of Formula I), R.sub.A and
R.sub.B form a fused 5 to 7 membered saturated ring. In certain
embodiments, the ring is a cyclohexene ring.
[0145] In certain embodiments (e.g., of Formula I), R.sub.A and
R.sub.B form a fused 5 to 7 membered saturated ring containing one
heteroatom selected from the group consisting of N and S. In
certain embodiments, the ring is tetrahydropyrido or dihydrothieno.
In certain embodiments the heteroatom is N. In certain embodiments,
the ring is tetrahydropyrido. In certain of these embodiments, the
ring is
##STR00018##
wherein the highlighted bond indicates the position where the ring
is fused.
[0146] In certain embodiments (e.g., of Formula II), R.sub.A' and
R.sub.B' are each independently selected from the group consisting
of hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2.
[0147] In certain embodiments (e.g., of Formula II), R.sub.A' and
R.sub.B' are independently hydrogen or alkyl.
[0148] In certain embodiments (e.g., of Formula II), R.sub.A' and
R.sub.B' are both methyl.
[0149] In certain embodiments (e.g., of any one of Formulas IX
through XII), R is selected from the group consisting of alkyl and
haloalkyl.
[0150] In certain embodiments (e.g., of any one of the above
embodiments of Formulas I, III through VIII, XIII, and XIV where R
is present), R is selected from the group consisting of alkyl,
alkoxy, halogen, and hydroxy.
[0151] In certain embodiments (e.g., of any one of the above
embodiments of Formulas I, III through VIII, XIII, and XIV where R
is present), R is hydroxy.
[0152] In certain embodiments (e.g., of Formulas III or IV), n is
0.
[0153] In certain embodiments (e.g., of any one of Formulas V
through XII), p is 0.
[0154] In certain embodiments, the compound or salt selected from
the group consisting of Formulas V, VI, VII, and VIII is the
compound of Formula V or Formula VIII:
##STR00019##
or a pharmaceutically acceptable salt thereof.
[0155] In certain embodiments (e.g., of any one of Formulas I
through XIV), m is an integer from 1 to 5.
[0156] In certain embodiments, including any one of the above
embodiments, m is an integer from 1 to 3. In certain embodiments, m
is 1.
[0157] In certain embodiments (e.g., of any one of Formulas I
through XIII), X is selected from the group consisting of a bond,
--C.sub.2-3 alkylene-, and --O--C.sub.2-3 alkylene-.
[0158] In certain embodiments, including any one of the above
embodiments, X is a bond.
[0159] In certain embodiments (e.g., of any one of Formulas I
through XIII), R.sub.1 is selected from the group consisting of
hydrogen, hydroxy, fluorine, alkoxy, --N(R.sub.9).sub.2,
--NH-Q-R.sub.4, --S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9,
--C(R.sub.6)--N(R.sub.8)--R.sub.4,
--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, --C(R.sub.6)--O-alkyl,
--O--C(R.sub.6)--R.sub.4, and
##STR00020##
with the proviso that when Z is a bond, C.sub.1-5 alkylene,
##STR00021##
and X is a bond, then R.sub.1 is other than hydrogen.
[0160] In certain embodiments, including any one of the above
embodiments wherein R.sub.1 is present, R.sub.1 is selected from
the group consisting of hydroxy and methoxy.
[0161] In certain embodiments, including any one of the above
embodiments wherein R.sub.1 is present, R.sub.1 is fluoro, except
where R.sub.1 is otherwise defined.
[0162] In certain embodiments, including any one of the above
embodiments wherein R.sub.1 is present, R.sub.1 is selected from
the group consisting of --NH.sub.2, --NH-Q-R.sub.4,
--C(O)--NH.sub.2, and --C(O)--N(R.sub.8)--R.sub.4, wherein Q is
selected from the group consisting of --C(O)--, --S(O).sub.2--,
--C(O)--O--, and --C(O)--NH--, R.sub.8 is selected from the group
consisting of hydrogen and alkyl, and R.sub.4 is selected from the
group consisting of alkyl and alkoxyalkylenyl, except where R.sub.1
is otherwise defined.
[0163] In certain embodiments (e.g., of any one of Formulas I
through XIV), Z is selected from the group consisting of:
##STR00022##
a bond, C.sub.1-5 alkylene,
##STR00023##
[0164] In certain embodiments, including any one of the above
embodiments, Z is selected from the group consisting of a bond and
C.sub.1-3 alkylene.
[0165] In certain embodiments, including any one of the above
embodiments, Z is selected from the group consisting of:
##STR00024##
except where Z is otherwise defined. In certain of these
embodiments, Z is
##STR00025##
[0166] In certain embodiments, including any one of the above
embodiments wherein X is a bond and Z is
##STR00026##
R.sub.1 is hydrogen.
[0167] In certain embodiments, including embodiments of Formula III
wherein n is 0, and embodiments of Formulas V, VI, VII, or VIII
wherein p is 0, and embodiments of Formulas IX, X, XI, or XI
wherein p is 0, Z is
##STR00027##
X is a bond, and R.sub.1 is hydrogen.
[0168] In certain embodiments, including any one of the above
embodiments, Z is
##STR00028##
except where Z is otherwise defined.
[0169] In certain embodiments, including any one of the above
embodiments wherein Q is present, Q is selected from the group
consisting of --C(O)--, --C(O)--O--, --S(O).sub.2--, and
--C(R.sub.6)--N(R.sub.8)--.
[0170] In certain embodiments, including any one of the above
embodiments wherein R.sub.4 is present, R.sub.4 is selected from
the group consisting of alkyl, aryl, arylalkylene, heteroaryl, and
heterocyclyl, wherein the aryl group can be unsubstituted or
substituted by one or more substituents independently selected from
the group consisting of acetylamino, alkyl, alkoxy, cyano, and
halogen.
[0171] In certain embodiments (e.g., of any one of Formulas I
through XIV), R.sub.2 is selected from the group consisting of
hydrogen, alkyl, alkoxyalkylenyl, hydroxyalkylenyl, haloalkylenyl,
and R.sub.4--C(R.sub.6)--O--C.sub.1-4 alkylenyl.
[0172] In certain embodiments, including any one of the above
embodiments, R.sub.2 is selected from the group consisting of
C.sub.1-4 alkyl, C.sub.1-4 alkyl-O--C.sub.2-4 alkylenyl, and
hydroxyC.sub.2-4 alkylenyl.
[0173] In certain embodiments, including any one of the above
embodiments, R.sub.2 is selected from the group consisting of
methyl, ethyl, n-propyl, n-butyl, 2-methoxyethyl, and
2-hydroxyethyl.
[0174] For certain embodiments, R.sub.4 is selected from the group
consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of allyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo.
[0175] For certain embodiments, R.sub.4 is selected from the group
consisting of alkyl and alkoxyalkylenyl.
[0176] For certain embodiments, R.sub.4 is selected from the group
consisting of alkyl, aryl, arylalkylene, heteroaryl, and
heterocyclyl, wherein the aryl group can be unsubstituted or
substituted by one or more substituents independently selected from
the group consisting of acetylamino, alkyl, alkoxy, cyano, and
halogen.
[0177] For certain embodiments, R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S. In certain embodiments, R.sub.6 is
.dbd.O. In certain embodiments, R.sub.6 is .dbd.S.
[0178] For certain embodiments, R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl.
In certain embodiments, R.sub.8 is selected from the group
consisting of hydrogen and alkyl. In certain embodiments, R.sub.8
is hydrogen. In certain embodiments, R.sub.8 is alkyl.
[0179] For certain embodiments, R.sub.9 is selected from the group
consisting of hydrogen and alkyl. In certain embodiments, R.sub.9
is alkyl. In certain embodiments, R.sub.9 is hydrogen.
[0180] For certain embodiments, R.sub.11 is selected from the group
consisting of hydrogen, alkyl, halogen, and trifluoromethyl.
[0181] For certain embodiments, A is selected from the group
consisting of --O--, --C(O)--, --S(O).sub.0-2--, --CH.sub.2--, and
--N(R.sub.4)--. For certain embodiments, A is --O--.
[0182] For certain embodiments, Q is selected from the group
consisting of a bond, --C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6)--,
--S(O).sub.2--, --C(R.sub.6)--N(R.sub.8)--W--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--O--, and
--C(R.sub.6)--N(OR.sub.9)--. For certain embodiments, Q is selected
from the group consisting of --C(O)--, --S(O).sub.2--, --C(O)--O--,
and --C(O)--NH--. For certain embodiments, Q is selected from the
group consisting of --C(O)--, --C(O)--O--, --S(O).sub.2--, and
--C(R.sub.6)--N(R.sub.8)--. For certain embodiments, Q is a
bond.
[0183] For certain embodiments, V is selected from the group
consisting of --C(R.sub.6)--, --O--C(R.sub.6)--,
--N(R.sub.8)--C(R.sub.6)--, and --S(O).sub.2--. In certain
embodiments, V is --C(R.sub.6)--. In certain embodiments, V is
--N(R.sub.8)--C(R.sub.6)--.
[0184] For certain embodiments, W is selected from the group
consisting of a bond, --C(O)--, and --S(O).sub.2--. In certain
embodiments, W is selected from the group consisting of a bond and
--C(O)--. In certain embodiments, W is a bond.
[0185] For certain embodiments, a and b are independently integers
from 1 to 6 with the proviso that a+b is .ltoreq.7. For certain
embodiments, a and b are each the integer 2.
[0186] For certain embodiments, G.sub.1 is selected from the group
consisting of --C(O)--R', .alpha.-aminoacyl,
.alpha.-aminoacyl-.alpha.-aminoacyl, --C(O)--O--R',
--C(O)--N(R'')R', --C(.dbd.NY')--R', --CH(OH)--C(O)--OY',
--CH(OC.sub.1-4 alkyl)Y.sub.0, --CH.sub.2Y.sub.2, and
--CH(CH.sub.3)Y.sub.2.
[0187] For certain embodiments, G.sub.2 is selected from the group
consisting of --X.sub.2--C(O)--R', .alpha.-aminoacyl,
.alpha.-aminoacyl-.alpha.-aminoacyl, --X.sub.2--C(O)--O--R',
--C(O)--N(R'')R', and --S(O).sub.2--R'.
[0188] For certain embodiments, R' is selected from the group
consisting of C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, phenyl, and
benzyl, each of which may be unsubstituted or substituted by one or
more substituents independently selected from the group consisting
of halogen, hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkyl,
C.sub.1-4 alkoxy, aryl, heteroaryl, aryl-C.sub.1-4 alkylenyl,
heteroaryl-C.sub.1-4 alkylenyl, halo-C.sub.1-4 alkylenyl,
halo-C.sub.1-4 alkoxy, --O--C(O)--CH.sub.3, --C(O)--O--CH.sub.3,
--C(O)--NH.sub.2, --O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2.
[0189] For certain embodiments, R'' is selected from the group
consisting of hydrogen, C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl,
phenyl, and benzyl, each of which may be unsubstituted or
substituted by one or more substituents independently selected from
the group consisting of halogen, hydroxy, nitro, cyano, carboxy,
C.sub.1-6 alkyl, C.sub.1-4 alkoxy, aryl, heteroaryl, aryl-C.sub.1-4
alkylenyl, heteroaryl-C.sub.1-4 alkylenyl, halo-C.sub.1-4
alkylenyl, halo-C.sub.1-4 alkoxy, --O--C(O)--CH.sub.3,
--C(O)--O--CH.sub.3, --C(O)--NH.sub.2,
--O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2.
[0190] For certain embodiments, X.sub.2 is selected from the group
consisting of a bond; --CH.sub.2--O--; --CH(CH.sub.3)--O--;
--C(CH.sub.3).sub.2--O--; and, in the case of
--X.sub.2--C(O)--O--R', --CH.sub.2--NH--.
[0191] For certain embodiments, .alpha.-aminoacyl is an
.alpha.-aminoacyl group derived from an amino acid selected from
the group consisting of racemic, D-, and L-amino acids. For certain
of these embodiments, the amino acid is a naturally occurring amino
acid.
[0192] For certain embodiments, Y' is selected from the group
consisting of hydrogen, C.sub.1-6 alkyl, and benzyl.
[0193] For certain embodiments, Y.sub.0 is selected from the group
consisting of C.sub.1-6 alkyl, carboxy-C.sub.1-6 alkylenyl,
amino-C.sub.1-4 alkylenyl, mono-N--C.sub.1-6 alkylamino-C.sub.1-4
alkylenyl, and di-N,N--C.sub.1-6 alkylamino-C.sub.1-4
alkylenyl.
[0194] For certain embodiments, Y.sub.2 is selected from the group
consisting of mono-N--C.sub.1-6 alkylamino, di-N,N--C.sub.1-6
alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and
4-C.sub.1-4 alkylpiperazin-1-yl.
[0195] For certain embodiments, including any one of the above
embodiments of Formula XIII, G.sub.1 is selected from the group
consisting of --C(O)--R', .alpha.-aminoacyl, and --C(O)--O--R'. For
certain of these embodiments, R' contains one to ten carbon atoms.
For certain of these embodiments, .alpha.-aminoacyl is an
.alpha.-C.sub.2-11 aminoacyl group derived from an .alpha.-amino
acid selected from the group consisting of racemic, D-, and L-amino
acids containing a total of at least 2 carbon atoms and a total of
up to 11 carbon atoms, and may also include one or more heteroatoms
selected from the group consisting of O, S, and N.
[0196] For certain embodiments, including any one of the above
embodiments of Formula XIV, G.sub.2 is selected from the group
consisting of --C(O)--R' and .alpha.-aminoacyl, wherein R' is
C.sub.1-6 alkyl or phenyl which is unsubstituted or substituted by
one or more substituents independently selected from the group
consisting of halogen, hydroxy, nitro, cyano, carboxy, C.sub.1-6
alkyl, C.sub.1-4 alkoxy, aryl, heteroaryl, aryl-C.sub.1-4
alkylenyl, heteroaryl-C.sub.1-4 alkylenyl, halo-C.sub.1-4
alkylenyl, halo-C.sub.1-4 alkoxy, --O--C(O)--CH.sub.3,
--C(O)--O--CH.sub.3, --C(O)--NH.sub.2,
--O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2.
[0197] For certain embodiments, including any one of the above
embodiments of Formula XIV, G.sub.2 is selected from the group
consisting of .alpha.-amino-C.sub.2-5 alkanoyl, C.sub.2-6 alkanoyl,
C.sub.1-6 alkoxycarbonyl, and C.sub.1-6 alkylcarbamoyl.
[0198] For certain embodiments, including any one of the above
embodiments which include an .alpha.-aminoacyl group,
.alpha.-aminoacyl is an .alpha.-aminoacyl group derived from a
naturally occurring .alpha.-amino acid selected from the group
consisting of racemic, D-, and L-amino acids.
[0199] For certain embodiments, including any one of the above
embodiments which include an .alpha.-aminoacyl group,
.alpha.-aminoacyl is an .alpha.-aminoacyl group derived from an
.alpha.-amino acid found in proteins, wherein the amino acid is
selected from the group consisting of racemic, D-, and L-amino
acids.
[0200] In some embodiments, the present invention provides a
pharmaceutical composition comprising a therapeutically effective
amount of a compound or salt of any one of Formulas I, II, III, IV,
V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, or any one of the
above embodiments in combination with a pharmaceutically acceptable
carrier.
[0201] In some embodiments, the present invention provides a method
of inducing cytokine biosynthesis in an animal comprising
administering an effective amount of a compound or salt of any one
of Formulas I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII,
XIV, or any one of the above embodiments or administering any one
of the above pharmaceutical compositions to the animal. For certain
of these embodiments, the cytokine is selected from the group
consisting of IFN-.alpha., TNF-.alpha., IL-6, IL-10, and IL-12. For
certain of these embodiments, the cytokine is IFN-.alpha. or
TNF-.alpha..
[0202] In some embodiments, the present invention provides a method
of treating a viral disease in an animal comprising administering a
therapeutically effective amount of a compound or salt of any one
of Formulas I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII,
XIV, or any one of the above embodiments or administering any one
of the above pharmaceutical compositions to the animal.
[0203] In some embodiments, the present invention provides a method
of treating a neoplastic disease in an animal comprising
administering a therapeutically effective amount of a compound or
salt of any one of Formulas I, II, III, IV, V, VI, VII, VIII, IX,
X, XI, XII, XIII, XIV, or any one of the above embodiments or
administering any one of the above pharmaceutical compositions to
the animal.
Preparation of the Compounds
[0204] Compounds of the invention may be synthesized by synthetic
routes that include processes analogous to those well known in the
chemical arts, particularly in light of the description contained
herein. The starting materials are generally available from
commercial sources such as Aldrich Chemicals (Milwaukee, Wis., USA)
or are readily prepared using methods well known to those skilled
in the art (e.g. prepared by methods generally described in Louis
F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19,
Wiley, New York, (1967-1999 ed.); Alan R. Katritsky, Otto
Meth-Cohn, Charles W. Rees, Comprehensive Organic Functional Group
Transformations, v 1-6, Pergamon Press, Oxford, England, (1995);
Barry M. Trost and Ian Fleming, Comprehensive Organic Synthesis, v.
1-8, Pergamon Press, Oxford, England, (1991); or Belsteins Handbuch
der organischen Chemie, 4, Aufl. Ed. Springer-Verlag, Berlin,
Germany, including supplements (also available via the Beilstein
online database)).
[0205] For illustrative purposes, the reaction schemes depicted
below provide potential routes for synthesizing the compounds of
the present invention as well as key intermediates. For more
detailed description of the individual reaction steps, see the
EXAMPLES section below. Those skilled in the art will appreciate
that other synthetic routes may be used to synthesize the compounds
of the invention. Although specific starting materials and reagents
are depicted in the reaction schemes and discussed below, other
starting materials and reagents can be easily substituted to
provide a variety of derivatives and/or reaction conditions. In
addition, many of the compounds prepared by the methods described
below can be further modified in light of this disclosure using
conventional methods well known to those skilled in the art.
[0206] In the preparation of compounds of the invention it may
sometimes be necessary to protect a particular functionality while
reacting other functional groups on an intermediate. The need for
such protection will vary depending on the nature of the particular
functional group and the conditions of the reaction step. Suitable
amino protecting groups include acetyl, trifluoroacetyl,
tert-butoxycarbonyl (Boc), benzyloxycarbonyl, and
9-fluorenylmethoxycarbonyl (Fmoc). Suitable hydroxy protecting
groups include acetyl and silyl groups such as the tert-butyl
dimethylsilyl group. For a general description of protecting groups
and their use, see T. W. Greene and P. G. M. Wuts, Protective
Groups in Organic Synthesis, John Wiley & Sons, New York, USA,
1991.
[0207] Conventional methods and techniques of separation and
purification can be used to isolate compounds of the invention, as
well as various intermediates related thereto. Such techniques may
include, for example, all types of chromatography (high performance
liquid chromatography (HPLC), column chromatography using common
absorbents such as silica gel, and thin layer chromatography,
recrystallization, and differential (i.e., liquid-liquid)
extraction techniques.
[0208] For some embodiments, compounds of the invention can be
prepared according to Reaction Scheme I, where R, R.sub.2, Z, n and
m are as defined above and Boc is tert-butoxycarbonyl.
[0209] In step (1) of Reaction Scheme I, an indole of Formula XX is
acylated to provide an oxalated indole of Formula XXI. The reaction
can be carried out by adding ethyl chlorooxoacetate to a solution
of an indole of Formula XX in a suitable solvent such as diethyl
ether in the presence of pyridine. The reaction can be carried out
at a sub-ambient temperature such as 0.degree. C. Many indoles of
Formula XX are known. Some are commercially available and others
can be readily prepared using known synthetic methods.
[0210] In step (2) of Reaction Scheme I, an oxalated indole of
Formula XXI is rearranged to a pyrazolo[3,4-c]quinolin-4-one of
Formula XXII. The reaction can be carried out by adding a hydrazine
of Formula R.sub.2NHNH.sub.2 to a solution of an oxalated indole of
Formula XXI in a solvent or solvent mix such as ethanol/acetic acid
in the presence of hydrochloric acid. The reaction can be carried
out at an elevated temperature such as at reflux.
[0211] If step (2) is carried out using hydrazine, the resulting
pyrazolo[3,4-c]quinolin-4-one of Formula XXII where R.sub.2 is
hydrogen can be further elaborated using known synthetic methods.
For example, a pyrazolo[3,4-c]quinolin-4-one of Formula XXII where
R.sub.2 is hydrogen can alkylated. The alkylation is conveniently
carried out by treating a solution of a
pyrazolo[3,4-c]quinolin-4-one of Formula XXII, where R.sub.2 is
hydrogen, with a base such as sodium ethoxide followed by the
addition of an alkyl halide. The reaction can be run in a suitable
solvent such as ethanol and can be carried out at an elevated
temperature, for example, the reflux temperature of the solvent, or
at ambient temperature. Alternatively, a
pyrazolo[3,4-c]quinolin-4-one of Formula XXII where R.sub.2 is
hydrogen can undergo a Buchwald amination with an aryl halide or
heteroaryl halide. Numerous alkyl halides, aryl halides, and
heteroaryl halides are commercially available; others can be
prepared using known synthetic methods.
[0212] In step (3) of Reaction Scheme I, a
pyrazolo[3,4-c]quinolin-4-one of Formula XXII is chlorinated to
provide a 4-chloropyrazolo[3,4-c]quinoline of Formula XXIII. The
reaction can be carried out by combining a
pyrazolo[3,4-c]quinolin-4-one of Formula XXII with phosphorous
oxychloride and heating.
[0213] In step (4) of Reaction Scheme I, the chloro group of a
4-chloropyrazolo[3,4-c]quinoline of Formula XXIII is displaced to
provide a pyrazolo[3,4-c]quinolin-4-amine of Formula XXIV. The
reaction can be carried out by combining a compound of Formula
XXIII with a solution of ammonia in methanol and heating the
mixture in a sealed reactor.
[0214] In step (5) of Reaction Scheme I, the amino group of a
pyrazolo[3,4-c]quinolin-4-amine of Formula XXIV is protected with
two Boc groups using conventional methods.
[0215] In step (6) of Reaction Scheme I, a compound of Formula XXV
undergoes a lithiation-substitution reaction to provide a compound
of Formula XXVI, which is a subgenus of Formula XIII. The reaction
can be carried out by treating a compound of Formula XXV with
tert-butyllithium and subsequently adding a cyclic ketone. Other
organolithium reagents may be used. The reaction can be carried out
below room temperature in a suitable solvent such as diethyl ether,
THF, or tert-butyl methyl ether. Conveniently, the reaction can be
carried out at -78.degree. C. Numerous cyclic ketones useful in
this transformation are commercially available, such as
cyclohexanone, cyclopentanone, tetrahydro-4H-pyran-4-one, and
1-Boc-4-piperidone. Others can be made by known methods.
[0216] In step (7) of Reaction Scheme I, a Boc protected
pyrazolo[3,4-c]quinolin-4-amine of Formula XXVI undergoes acid
mediated cleavage to remove the Boc group to provide a compound of
Formula XXVII which is a subgenus of Formulas I and III.
##STR00029##
[0217] For some embodiments, compounds of the invention can be
prepared according to Reaction Scheme II, where R, R.sub.2, Z, n
and m are as defined above.
[0218] In Reaction Scheme II, compounds of Formula XXIX are
prepared from 7-azaindoles of Formula XXVIII using the methods of
steps (1) through (7) of Reaction Scheme I.
##STR00030##
[0219] For some embodiments, compounds of the invention can also be
prepared according to Reaction Scheme III, where R.sub.1, R.sub.2,
X, Z, and m are as defined above, and R.sub.A2 and R.sub.B2 taken
together form a fused benzene ring or fused pyridine ring wherein
the benzene ring or pyridine ring is unsubstituted or substituted
by one or more R groups.
[0220] In step (1) of Reaction Scheme III, a ketone of Formula XXX
is condensed with diethyl oxalate under Claisen condensation
conditions to provide a ketoester of Formula XXXI. The reaction can
be carried out by adding sodium tert-butoxide to a solution of
diethyl oxalate and the ketone of Formula XXX in ethanol at ambient
temperature.
[0221] In step (2) of Reaction Scheme III, a ketoester of Formula
XXXI reacts with a hydrazine of Formula R.sub.2NHNH.sub.2 to
provide a pyrazole carboxylate of Formula XXXI. The reaction is
conveniently carried out by slowly adding the hydrazine to a
solution of a compound of Formula XXXI in a suitable solvent such
as acetic acid. The reaction can be carried out at ambient
temperature.
[0222] In step (3) of Reaction Scheme III, the ester group of a
pyrazole carboxylate of Formula XXXII is converted to an amide. The
amination can be carried out by adding ammonium hydroxide to the
pyrazole carboxylate of Formula XXXII in a suitable solvent such as
methanol and heating at an elevated temperature such as 100.degree.
C. The reaction can be carried out in a pressure vessel.
[0223] Alternatively, step (3) can be carried out by first
hydrolyzing a pyrazole carboxylate of Formula XXXII to a carboxylic
acid and then converting the carboxylic acid to an amide. The ester
hydrolysis can be carried out under basic conditions by combining a
pyrazole carboxylate of Formula XXXII with lithium hydroxide or
sodium hydroxide in water and in a suitable solvent such as
methanol or ethanol. The reaction can be carried out at ambient
temperature, and the carboxylic acid product can be isolated using
conventional methods. The conversion of the carboxylic acid to a
pyrazole carboxamide of Formula XXXIII can be carried out by first
treating the carboxylic acid with oxalyl chloride at ambient
temperature in a suitable solvent such as dichloromethane to
generate an acid chloride, which can then be treated with ammonium
hydroxide at a sub-ambient temperature such as 0.degree. C.
Alternatively, the conversion of the carboxylic acid to a pyrazole
carboxamide of Formula XXXIII can be carried out under coupling
conditions by adding 1-hydroxybenzotriazole and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to a
solution of the carboxylic acid in a suitable solvent such as
N,N-dimethylformamide (DMF) at ambient temperature and then adding
concentrated ammonium hydroxide.
[0224] In step (4) of Reaction Scheme III, a pyrazole carboxamide
of Formula XXXIII is dehydrated to a pyrazole carbonitrile of
Formula XXXIV. Suitable dehydrating agents include thionyl
chloride, trifluoroacetic anhydride, and phosphorous oxychloride.
The reaction is conveniently carried out by treating the pyrazole
carboxamide of Formula XXXIII with phosphorous oxychloride and
heating the reaction at an elevated temperature such as 90.degree.
C. The reaction can also be carried out by combining the pyrazole
carboxamide of Formula XXXIII with trifluoroacetic anhydride in the
presence of a base such as triethylamine and in a suitable solvent
such as dichloromethane. The reaction can be carried out at ambient
temperature or at a sub-ambient temperature such as 0.degree.
C.
[0225] In step (5) of Reaction Scheme III, a pyrazole carbonitrile
of Formula XXXIV is brominated to provide a bromo-substituted
pyrazole carbonitrile of Formula XXXV. The bromination is
conveniently carried out by adding bromine to a solution of the
pyrazole carbonitrile of Formula XXXIV and potassium acetate in
acetic acid. The reaction can be carried out at ambient
temperature.
[0226] In step (6) of Reaction Scheme III, a bromo-substituted
pyrazole of Formula XXXV undergoes a transition-metal catalyzed
cross coupling reaction with a reagent of Formula XXXVI. Reagents
of Formula XXXVI, where M is, for example, --B(OH).sub.2,
--B(O-alkyl).sub.2, --Sn(alkyl).sub.3, and --Zn-Halide, are known
to undergo coupling reactions. Several reagents of Formula VI or
their protected analogs are commercially available, for example,
including 2-aminophenylboronic acid, 2-aminophenylboronic acid
hydrochloride, and
(2,2-dimethyl-N-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-4-
-yl]propanamide; others can be prepared using known synthetic
methods. For example, tert-butoxycarbonyl (Boc)-protected anilines
undergo directed ortho metalation in the presence of butyllithium
reagents. The resulting organolithium intermediate reacts with
electrophiles such as B(O-alkyl).sub.3 and ClSn(alkyl).sub.3 to
provide compounds of Formula XXXVI, where M is --B(O-alkyl).sub.2
or --B(OH).sub.2 and --Sn(alkyl).sub.3, respectively, after removal
of the Boc protecting group.
[0227] In step (6), a Suzuki coupling reaction is conveniently
carried out by heating a mixture of the bromo-substituted pyrazole
of Formula XXX, dichlorobis(triphenylphosphine)palladium(II) and a
boron reagent of Formula XXXVI, where M is --B(OH).sub.2 or
--B(O-alkyl).sub.2, in the presence of a base such as potassium
carbonate. The reaction is carried out in a suitable solvent such
as 1,2-dimethoxyethane and can be heated at an elevated temperature
such as 75-95.degree. C.
[0228] In step (7) of Reaction Scheme III, the amine and nitrile
functionalities of a pyrazole of Formula XXXVII react under acidic
conditions to form a pyrazolo[3,4-c]quinoline or
pyrazolo[3,4-c]naphthyridine of Formula XXXVIII. The intramolecular
addition is conveniently carried out by stirring acetyl chloride in
ethanol and adding the resulting acidic solution to the pyrazole of
Formula XXXVIII. The reaction is then heated at reflux to provide
the pyrazolo[3,4-c]quinoline or pyrazolo[3,4-c]naphthyridine of
Formula XXXVIII.
##STR00031##
[0229] In some embodiments, compounds of the invention can be
prepared according to Reaction Scheme IV where R.sub.1, R.sub.2, X,
Z, and m are as defined above and R.sub.A1 and R.sub.B1 are as
defined below.
[0230] In step (1) of Reaction Scheme IV, a bromo-substituted
pyrazole carbonitrile of Formula XXXV undergoes a Sonogashira
coupling reaction with (trimethylsilyl)acetylene to provide a
pyrazole carbonitrile of Formula XXXIX. The reaction can be carried
out according to the literature procedure, Sonogashira, K.; Tohda,
Y.; Hagihara, N., Tetrahedron Lett., 4467 (1975).
[0231] Alternatively, the iodo analog may be used as a starting
material for Reaction Scheme IV. The iodo analog can be prepared
from a pyrazole carbonitrile of Formula XXIV, shown in Reaction
Scheme III. The iodination can be carried out by treating a
pyrazole carbonitrile of Formula XXXIV with iodine monochloride in
a suitable solvent such as dichloromethane in the presence of a
base such as potassium carbonate. The reaction can be carried out
at ambient temperature.
[0232] In step (2) of Reaction Scheme IV, the trimethylsilyl group
of the pyrazole of Formula XXXIX is removed to provide the pyrazole
of Formula XL. Potassium carbonate in methanol or
tetrabutylammonium fluoride in tetrahydrofuran can be used to carry
out the transformation.
[0233] In step (3) of Reaction Scheme IV, the acetylene of the
pyrazole of Formula XL is alkylated using conventional synthetic
methods, Jacobs, T. L. in Organic Reactions, 5, 1, (1949), to
provide a pyrazole of Formula XLI. The reaction can be carried out
by deprotonation of the compound of Formula XL with a base and
reaction of the resulting carbanion with an electrophile of Formula
R.sub.B1-Halide, for example, iodomethane. Step (3) can be omitted
when R.sub.B1 is hydrogen.
[0234] For some embodiments, steps (1) through (3) of Reaction
Scheme IV may be replaced with one step from the iodo analog using
a Sonogashira coupling reaction. The coupling can be carried out by
combining an alkyne of Formula R.sub.B1--C.ident.C--H, copper(I)
iodide, dichlorobis(triphenylphosphine)palladium(II), and triethyl
amine in a suitable solvent such as acetonitrile and then heating
at an elevated temperature, such as the reflux temperature of the
solvent.
[0235] In step (4) of Reaction Scheme IV, a pyrazole of Formula XLI
reacts with ammonia to provide a pyrazolo[3,4-c]pyridin-4-amine of
Formula XLII. The reaction can be carried out by adding a solution
of ammonia in methanol to the pyrazole of Formula XLI and heating
at an elevated temperature, such as 150.degree. C. The reaction may
be carried out in a pressure vessel.
[0236] Steps (5) and (6) may be carried out to provide a compound
of Formula XLIV in which R.sub.A1 is other than hydrogen. In step
(5) of Reaction Scheme IV, a pyrazolo[3,4-c]pyridin-4-amine of
Formula XLII is brominated under conventional bromination
conditions to provide a bromo-substituted
pyrazolo[3,4-c]pyridine-4-amine of Formula XLIII. The reaction can
be carried out as described in step (5) of Reaction Scheme III.
[0237] In step (6) of Reaction Scheme IV, a bromo-substituted
pyrazolo[3,4-c]pyridin-4-amine of Formula XLIII undergoes a
transition metal catalyzed coupling reaction with a reagent of
Formula R.sub.A1-M, where R.sub.A1 is alkenyl, alkoxy, and
--N(R.sub.9).sub.2 to provide a pyrazolo[3,4-c]pyridine-4-amine of
Formula XLIV. Reagents of Formula R.sub.A1-M, where M is, for
example, --B(OH).sub.2, --B(O-alkyl).sub.2, --Sn(alkyl).sub.3, and
--Zn-Halide, are known to undergo coupling reactions. The
transformation can be carried out by first protecting the amino
group of the compound of Formula XLIII, treating the protected
compound with a reagent of Formula R.sub.A1-M in the presence of a
transition metal catalyst using conditions described in step (6) of
Reaction Scheme III, and deprotecting the amine to provide the
pyrazolo[3,4-c]pyridin-4-amine of Formula XLIV, which is a subgenus
of Formula II. Alternatively, step (6) can be carried out by
coupling a compound of Formula XLIII with an alkyne under
Sonogashira conditions as described in step (1) of this reaction
scheme. The resulting alkyne can be reduced under conventional
hydrogenation conditions to provide a compound of Formula XLIV,
where R.sub.A1 is alkenyl or alkyl. Step (6) may also be carried
out by (i) protecting the amino group of the compound of Formula
XLIII, for example, with a Boc group; (ii) performing a
lithium-halogen exchange; (iii) treating with an electrophile of
the Formula R.sub.A1-Halide, for example iodomethane; and (iv)
deprotecting the amine to provide a compound of Formula XLIV.
##STR00032##
[0238] For some embodiments, compounds of the invention can be
prepared according to Reaction Scheme V, where R.sub.1b and
R.sub.2b, are subsets of R.sub.1 and R.sub.2 as defined above that
do not include those substituents which would be susceptible to
reduction under the acidic hydrogenation conditions of the reaction
and R, X, Z, and n are as defined above.
[0239] In Reaction Scheme V, a pyrazolo[3,4-c]quinoline of Formula
XLV is reduced to provide a
6,7,8,9-tetrahydro-2H-pyrazolo[3,4-c]quinoline of Formula XLVI,
which is a subgenus of Formula IV. The reaction may be carried out
under heterogeneous hydrogenation conditions by adding platinum
(IV) oxide to a solution or suspension of a
pyrazolo[3,4-c]quinoline of Formula XLV in a suitable solvent such
as trifluoroacetic acid and placing the reaction under hydrogen
pressure.
[0240] Alternatively, the reduction may be carried out at an
earlier stage in the synthetic pathway.
##STR00033##
[0241] Pyrazolo[3,4-c]naphthyridines of the invention can be
prepared by using an azaindole as the starting material in Reaction
Scheme I. Azaindoles are known compounds. Some are commercially
available and others can be prepared using known synthetic methods.
Alternatively, pyrazolo[3,4-c]naphthyridines of the invention can
be prepared by using an aminopyridine boronic acid in Reaction
Scheme III. Aminopyridine boronic acids can be prepared using known
methods, for example, by directed ortho metalation of Boc-protected
aminopyridines and subsequent electrophilic substitution.
Alternatively, for some isomers, halogen-lithium exchange and
subsequent electrophilic substitution can be used. For example,
halogen-lithium exchange can be carried out on a 2-bromopyridine
that has a protected amino group in the 3-position; subsequent
electrophilic substitution with tributyltin chloride and
deprotection of the amino group provides
3-amino-2-tri-n-butylstannylpyridine.
[0242] 6,7,8,9-Tetrahydro-2H-pyrazolo[3,4-c]naphthyridines can be
prepared by reducing pyrazolo[3,4-c]naphthyridines using the method
of Reaction Scheme V.
[0243] For some embodiments, compounds can be further elaborated
using conventional synthetic methods. For example, as shown in
Scheme VI, a compound of Formula XLVII, can undergo acid mediated
cleavage of the Boc group in step (1) to give a secondary amine
that can be functionalized in step (2) with an acid chloride of
Formula R.sub.4C(O)Cl, an acid anhydride of Formula
(R.sub.4C(O)).sub.2O, an alkyl chloroformate of Formula
R.sub.4OC(O)Cl, a sulfonyl chloride of Formula R.sub.4S(O).sub.2Cl,
a sulfonic anhydride of Formula (R.sub.4S(O).sub.2).sub.2O, an
isocyanate of formula R.sub.4NCO, or an isothiocyanate of formula
R.sub.4NCS to provide a compound of Formula XLIX where R.sub.4 is
defined as above and Q is --C(O)--, --C(O)O--, --S(O).sub.2--,
--C(O)NH--, or --C(S)NH--. Numerous acid chlorides, alkyl
chloroformates, sulfonyl chlorides, sulfonic anhydrides,
isocyanates, and isothiocyanates are commercially available; others
can be prepared readily using known synthetic methods. The reaction
can be conveniently carried out by adding the acid chloride, alkyl
chloroformate, sulfonyl chloride, sulfonic anhydride, isocyanate,
or isothiocyanate to a solution or suspension of an amine of
Formula XLVIII, in a suitable solvent such as chloroform. The
reaction can be carried out at ambient temperature.
[0244] In addition, a compound of Formula XLVIII in Reaction Scheme
VI can undergo alkylation of the secondary amine. In step (3) the
compound of Formula XLVIII may be reacted with aldehydes, alkyl
halides or triflates to provide a compound Formula L in which
R.sub.8 is defined as above. For example, treatment of a compound
of Formula XLVIII with aqueous formaldehyde and a reducing agent
such as sodium cyanoborohydride in an appropriate solvent such as
methanol yields a compound of Formula L, where R.sub.8 is a methyl
group.
##STR00034##
[0245] Intermediates of Formula LIII can be prepared according to
Reaction Scheme VII, where R.sub.1, X, and Z are as defined
above.
[0246] In step (1) of Reaction Scheme VII, a ketone of the Formula
LI is reacted with diethyl (2-oxopropyl)phosphonate to provide an
olefin of Formula LII. The reaction can be carried out by adding a
ketone of Formula LI and diethyl (2-oxopropyl)phosphonate to a
solution of a base, such as potassium hydroxide, in a suitable
solvent or solvent mix such as ethanol and water. The reaction can
be carried out at a sub-ambient temperature such as 0.degree.
C.
[0247] In step (2) of Reaction Scheme VII, an olefin of Formula LII
is derivatized using conventional methods. A compound of Formula
LII where X is a bond and R.sub.1 is hydrogen can be prepared by
reducing the olefin using conventional heterogeneous hydrogenation
conditions. Also, a compound of Formula LII can be treated with
pivalonitrile in the presence of titanium tetrachloride; the
resulting nitrile-substituted compound can be converted by
convention methods to a compound of Formula LIII where X is a bond
and R.sub.1 is --C(O)--NH.sub.2. A compound of Formula LII can also
be treated with ammonium hydroxide followed by di-tert-butyl
dicarbonate to provide a compound of Formula LIII where X is a bond
and R.sub.1 is --NHBoc, which can be deprotected and treated
according to the methods of Reaction Scheme VI to provide a variety
of other compounds.
##STR00035##
[0248] For some embodiments, compounds of the invention can be
prepared according to Reaction Scheme VIII, where R.sub.A2,
R.sub.B2, R.sub.2, and Z are as defined above.
[0249] In step (1) of Reaction Scheme VIII, an olefin of Formula
LII is condensed with diethyl oxalate to provide a ketoester of
Formula LIV. The reaction can be carried out as described in step
(1) of Reaction Scheme III.
[0250] In step (2) of Reaction Scheme VIII, a ketoester of Formula
LIV reacts with a hydrazine of Formula R.sub.2NHNH.sub.2 to provide
a pyrazole carboxylate of Formula LV. The reaction can be carried
out as described in step (2) of Reaction Scheme III.
[0251] In step (3) of Reaction Scheme VIII, a pyrazole carboxylate
of Formula LV is converted to a pyrazole carboxamide of Formula
LVI. The reaction can be carried out as described in step (3) of
Reaction Scheme III.
[0252] In step (4) of Reaction Scheme VIII, the olefinic bond in a
compound of Formula LVI is oxidized to provide an epoxide of
Formula LVII. The reaction can be carried out by treating a
suspension of a compound of Formula LVI in a suitable solvent such
as chloroform with 3-chloroperoxybenzoic acid. The reaction can be
carried out at ambient temperature.
[0253] In step (5) of Reaction Scheme VIII, the epoxide ring in a
compound of Formula LVII is cleaved to provide a hydroxy
substituted pyrazole carboxamide of Formula LVIII. The reaction can
be carried out by treating a solution of a compound of Formula LVII
in a suitable solvent such as ethanol with palladium on carbon and
ammonium formate. The reaction can be carried out at ambient
temperature.
[0254] In step (6) of Reaction Scheme VIII, a pyrazole carboxamide
of Formula LVIII is dehydrated to a pyrazole carbonitrile of
Formula LIX. The reaction can be carried out as described in step
(4) of Reaction Scheme III.
[0255] In steps (7) through (9) of Reaction Scheme VIII, a pyrazole
carbonitrile of Formula LIX is converted to a
pyrazolo[3,4-c]quinoline or pyrazolo[3,4-c]naphthyridine of Formula
LX. The conversion can be carried out using the methods described
in steps (5) through (7) of Reaction Scheme III.
##STR00036##
[0256] For some embodiments, compounds of the invention can be
prepared according to Reaction Scheme IX, where R.sub.A2, R.sub.B2,
R.sub.2, and Z are as defined above.
[0257] In step (1) of Reaction Scheme IX, the hydroxy group in a
pyrazolo carbonitrile of Formula LIX is replaced with a fluoro
group to provide a pyrazolo carbonitrile of Formula LXI. The
reaction can be carried out by treating a solution of a compound of
Formula LIX in a suitable solvent such as dichloromethane with
[bis(2-methoxyethyl)amino]sulfur trifluoride. The trifluoride is
added in a controlled fashion at a sub-ambient temperature such as
0.degree. C.
[0258] In steps (2) through (4) of Reaction Scheme IX, a pyrazole
carbonitrile of Formula LXI is converted to a
pyrazolo[3,4-c]quinoline or pyrazolo[3,4-c]naphthyridine of Formula
LXII. The conversion can be carried out using the methods described
in steps (5) through (7) of Reaction Scheme III.
##STR00037##
[0259] Compounds of the invention can also be prepared using
variations of the routes shown in Reaction Schemes I through IX
that would be apparent to one of skill in the art. For example, a
compound of Formula LII wherein Z is --N(Boc)- can be readily
prepared from 1-Boc-4-piperidinone according to the method of step
(1) of Reaction Scheme VII. Steps (1) through (6) of Reaction
Scheme VIII can then be used to prepare a compound of Formula LIX
wherein Z is --N(Boc)-. The Boc group can then be cleaved and the
resulting amine can be treated with an acid chloride, alkyl
chloroformate, sulfonyl chloride, sulfonic anhydride, isocyanate,
or isothiocyanate according to the methods described in steps (1)
and (2) of Reaction Scheme VI. These Boc removal and amine
functionalization steps can conveniently be carried out after the
bromination in step (7) of Reaction Scheme VIII or after steps (1)
and (2) of Reaction Scheme IX. Finally, the coupling and
ring-closing methods of steps (8) and (9) of Reaction Scheme VIII
or steps (3) and (4) of Reaction Scheme IX can be used to provide
compounds of Formulas LX and LXII, respectively, wherein Z is
--N(Q-R.sub.4)--.
[0260] For some embodiments, compounds of the invention can be
prepared according to Reaction Scheme X, where R.sub.1, R.sub.2,
R.sub.A, R.sub.B, G.sub.1, Z, and m are as defined above. The amino
group of a pyrazolo compound of Formula I can be converted by
conventional methods to a functional group such as an amide,
carbamate, urea, amidine, or another hydrolyzable group. A compound
of this type can be made by the replacement of a hydrogen atom in
the amino group with a group such as --C(O)--R', .alpha.-aminoacyl,
.alpha.-aminoacyl-.alpha.-aminoacyl, --C(O)--O--R',
--C(O)--N(R'')--R', --C(.dbd.NY')--R', --CH(OH)--C(O)--OY',
--CH(OC.sub.1-4 alkyl)Y.sub.0, --CH.sub.2Y.sub.1, or
--CH(CH.sub.3)Y.sub.1; wherein R' and R'' are each independently
C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, phenyl, or benzyl, each of
which may be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
halogen, hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkyl, C.sub.1-4
alkoxy, aryl, heteroaryl, arylC.sub.1-4 alkylenyl,
heteroarylC.sub.1-4 alkylenyl, haloC.sub.1-4 alkylenyl,
haloC.sub.1-4 alkoxy, --O--C(O)--CH.sub.3, --C(O)--O--CH.sub.3,
--C(O)--NH.sub.2, --O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2; with the proviso that R'' may also be
hydrogen; each .alpha.-aminoacyl group is independently selected
from racemic, D, or L-amino acids; Y' is hydrogen, C.sub.1-6 alkyl,
or benzyl; Y.sub.0 is C.sub.1-6 alkyl, carboxyC.sub.1-6 alkylenyl,
aminoC.sub.1-4 alkylenyl, mono-N--C.sub.1-6 alkylaminoC.sub.1-4
alkylenyl, or di-N,N--C.sub.1-6 alkylaminoC.sub.1-4 alkylenyl; and
Y.sub.1 is mono-N--C.sub.1-6 alkylamino, di-N,N--C.sub.1-6
alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, or
4-C.sub.1-4 alkylpiperazin-1-yl. Particularly useful compounds of
Formula XIII are amides derived from carboxylic acids containing
one to ten carbon atoms, amides derived from amino acids, and
carbamates containing one to ten carbon atoms. The reaction can be
carried out, for example, by combining a compound of Formula I with
a chloroformate or acid chloride, such as ethyl chloroformate or
acetyl chloride, in the presence of a base such as triethylamine in
a suitable solvent such as dichloromethane at room temperature.
##STR00038##
[0261] For some embodiments, compounds of the invention can be
prepared according to Reaction Scheme XI, where R.sub.2, R.sub.A,
R.sub.B, G.sub.2, Z, and m are as defined above. The hydrogen atom
of the alcohol group of Formula LXIII can be replaced using
conventional methods with a group such as C.sub.1-6
alkanoyloxymethyl, 1-(C.sub.1-6 alkanoyloxy)ethyl,
1-methyl-1-(C.sub.1-6 alkanoyloxy)ethyl, C.sub.1-6
alkoxycarbonyloxymethyl, N--(C.sub.1-6 alkoxycarbonyl)aminomethyl,
succinoyl, C.sub.1-6 alkanoyl, .alpha.-aminoC.sub.1-4 alkanoyl,
arylacyl, --P(O)(OH).sub.2, --P(O)(O--C.sub.1-6 alkyl).sub.2,
C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbamoyl, and
.alpha.-aminoacyl or .alpha.-aminoacyl-.alpha.-aminoacyl, where
each .alpha.-aminoacyl group is independently selected from
racemic, D, and L-amino acids. Particularly useful compounds of
Formula XIV are esters made from carboxylic acids containing one to
six carbon atoms, unsubstituted or substituted benzoic acid esters,
or esters made from naturally occurring amino acids.
##STR00039##
[0262] For some embodiments, compounds of the invention can be
prepared using the synthetic routes described in the EXAMPLES
below.
Pharmaceutical Compositions and Biological Activity
[0263] Pharmaceutical compositions of the invention contain a
therapeutically effective amount of a compound or salt described
above in combination with a pharmaceutically acceptable
carrier.
[0264] The terms "a therapeutically effective amount" and
"effective amount" mean an amount of the compound or salt
sufficient to induce a therapeutic or prophylactic effect, such as
cytokine induction, immunomodulation, antitumor activity, and/or
antiviral activity. The exact amount of compound or salt used in a
pharmaceutical composition of the invention will vary according to
factors known to those of skill in the art, such as the physical
and chemical nature of the compound or salt, the nature of the
carrier, and the intended dosing regimen.
[0265] In some embodiments, the compositions of the invention will
contain sufficient active ingredient or prodrug to provide a dose
of about 100 nanograms per kilogram (ng/kg) to about 50 milligrams
per kilogram (mg/kg), preferably about 10 micrograms per kilogram
(.mu.g/kg) to about 5 mg/kg, of the compound or salt to the
subject.
[0266] In other embodiments, the compositions of the invention will
contain sufficient active ingredient or prodrug to provide a dose
of, for example, from about 0.01 mg/m.sup.2 to about 5.0
mg/m.sup.2, computed according to the Dubois method, in which the
body surface area of a subject (m.sup.2) is computed using the
subject's body weight: m.sup.2=(wt kg.sup.0.425.times.height
cm.sup.0.725).times.0.007184, although in some embodiments the
methods may be performed by administering a compound or salt or
composition in a dose outside this range. In some of these
embodiments, the method includes administering sufficient compound
to provide a dose of from about 0.1 mg/m.sup.2 to about 2.0
mg/m.sup.2 to the subject, for example, a dose of from about 0.4
mg/m.sup.2 to about 1.2 mg/m.sup.2.
[0267] A variety of dosage forms may be used, such as tablets,
lozenges, capsules, parenteral formulations, syrups, creams,
ointments, aerosol formulations, transdermal patches, transmucosal
patches and the like. These dosage forms can be prepared with
conventional pharmaceutically acceptable carriers and additives
using conventional methods, which generally include the step of
bringing the active ingredient into association with the
carrier.
[0268] The compounds or salts of the invention can be administered
as the single therapeutic agent in the treatment regimen, or the
compounds or salts described herein may be administered in
combination with one another or with other active agents, including
additional immune response modifiers, antivirals, antibiotics,
antibodies, proteins, peptides, oligonucleotides, etc.
[0269] Compounds or salts of the invention have been shown to
induce the production of certain cytokines in experiments performed
according to the tests set forth below. These results indicate that
the compounds or salts are useful for modulating the immune
response in a number of different ways, rendering them useful in
the treatment of a variety of disorders.
[0270] Cytokines whose production may be induced by the
administration of compounds or salts of the invention generally
include interferon-.alpha. (IFN-.alpha.) and tumor necrosis
factor-.alpha.(TNF-.alpha.) as well as certain interleukins (IL).
Cytokines whose biosynthesis may be induced by compounds or salts
of the invention include IFN-.alpha., TNF-.alpha., IL-1, IL-6,
IL-10 and IL-12, and a variety of other cytokines. Among other
effects, these and other cytokines can inhibit virus production and
tumor cell growth, making the compounds or salts useful in the
treatment of viral diseases and neoplastic diseases. Accordingly,
the invention provides a method of inducing cytokine biosynthesis
in an animal comprising administering an effective amount of a
compound or salt of the invention to the animal. The animal to
which the compound or salt is administered for induction of
cytokine biosynthesis may have a disease as described infra, for
example a viral disease or a neoplastic disease, and administration
of the compound or salt may provide therapeutic treatment.
Alternatively, the compound or salt may be administered to the
animal prior to the animal acquiring the disease so that
administration of the compound or salt may provide a prophylactic
treatment.
[0271] In addition to the ability to induce the production of
cytokines, compounds or salts described herein can affect other
aspects of the innate immune response. For example, natural killer
cell activity may be stimulated, an effect that may be due to
cytokine induction. The compounds or salts may also activate
macrophages, which in turn stimulate secretion of nitric oxide and
the production of additional cytokines. Further, the compounds or
salts may cause proliferation and differentiation of
B-lymphocytes.
[0272] Compounds or salts described herein can also have an effect
on the acquired immune response. For example, the production of the
T helper type I (T.sub.H1) cytokine IFN-.gamma. may be induced
indirectly and the production of the T helper type 2 (T.sub.H2)
cytokines IL-4, IL-5 and IL-13 may be inhibited upon administration
of the compounds or salts.
[0273] Whether for prophylaxis or therapeutic treatment of a
disease, and whether for effecting innate or acquired immunity, the
compound or salt or composition may be administered alone or in
combination with one or more active components as in, for example,
a vaccine adjuvant. When administered with other components, the
compound or salt or composition and other component or components
may be administered separately; together but independently such as
in a solution; or together and associated with one another such as
(a) covalently linked or (b) non-covalently associated, e.g., in a
colloidal suspension.
[0274] Conditions for which compounds or salts or compositions
identified herein may be used as treatments include, but are not
limited to:
[0275] (a) viral diseases such as, for example, diseases resulting
from infection by an adenovirus, a herpesvirus (e.g., HSV-I,
HSV-II, CMV, or VZV), a poxvirus (e.g., an orthopoxvirus such as
variola or vaccinia, or molluscum contagiosum), a picornavirus
(e.g., rhinovirus or enterovirus), an orthomyxovirus (e.g.,
influenzavirus), a paramyxovirus (e.g., parainfluenzavirus, mumps
virus, measles virus, and respiratory syncytial virus (RSV)), a
coronavirus (e.g., SARS), a papovavirus (e.g., papillomaviruses,
such as those that cause genital warts, common warts, or plantar
warts), a hepadnavirus (e.g., hepatitis B virus), a flavivirus
(e.g., hepatitis C virus or Dengue virus), or a retrovirus (e.g., a
lentivirus such as HIV);
[0276] (b) bacterial diseases such as, for example, diseases
resulting from infection by bacteria of, for example, the genus
Escherichia, Enterobacter, Salmonella, Staphylococcus, Shigella,
Listeria, Aerobacter, Helicobacter, Klebsiella, Proteus,
Pseudomonas, Streptococcus, Chlamydia, Mycoplasma, Pneumococcus,
Neisseria, Clostridium, Bacillus, Corynebacterium, Mycobacterium,
Campylobacter, Vibrio, Serratia, Providencia, Chromobacterium,
Brucella, Yersinia, Haemophilus, or Bordetella;
[0277] (c) other infectious diseases, such as chlamydia, fungal
diseases including but not limited to candidiasis, aspergillosis,
histoplasmosis, cryptococcal meningitis, or parasitic diseases
including but not limited to malaria, pneumocystis carnii
pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and
trypanosome infection;
[0278] (d) neoplastic diseases, such as intraepithelial neoplasias,
cervical dysplasia, actinic keratosis, basal cell carcinoma,
squamous cell carcinoma, renal cell carcinoma, Kaposi's sarcoma,
melanoma, leukemias including but not limited to acute myeloid
leukemia, acute lymphocytic leukemia, chronic myeloid leukemia,
chronic lymphocytic leukemia, multiple myeloma, Hodgkin's lymphoma,
non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma,
and hairy cell leukemia, and other cancers;
[0279] (e) T.sub.H2-mediated, atopic diseases, such as atopic
dermatitis or eczema, eosinophilia, asthma, allergy, allergic
rhinitis, and Ommen's syndrome;
[0280] (f) certain autoimmune diseases such as systemic lupus
erythematosus, essential thrombocythaemia, multiple sclerosis,
discoid lupus, alopecia areata; and
[0281] (g) diseases associated with wound repair such as, for
example, inhibition of keloid formation and other types of scarring
(e.g., enhancing wound healing, including chronic wounds).
[0282] Additionally, a compound or salt identified herein may be
useful as a vaccine adjuvant for use in conjunction with any
material that raises either humoral and/or cell mediated immune
response, such as, for example, live viral, bacterial, or parasitic
immunogens; inactivated viral, tumor-derived, protozoal,
organism-derived, fungal, or bacterial immunogens; toxoids; toxins;
self-antigens; polysaccharides; proteins; glycoproteins; peptides;
cellular vaccines; DNA vaccines; autologous vaccines; recombinant
proteins; and the like, for use in connection with, for example,
BCG, cholera, plague, typhoid, hepatitis A, hepatitis B, hepatitis
C, influenza A, influenza B, parainfluenza, polio, rabies, measles,
mumps, rubella, yellow fever, tetanus, diphtheria, hemophilus
influenza b, tuberculosis, meningococcal and pneumococcal vaccines,
adenovirus, HIV, chicken pox, cytomegalovirus, dengue, feline
leukemia, fowl plague, HSV-1 and HSV-2, hog cholera, Japanese
encephalitis, respiratory syncytial virus, rotavirus, papilloma
virus, yellow fever, and Alzheimer's Disease.
[0283] Compounds or salts identified herein may be particularly
helpful in individuals having compromised immune function. For
example, compounds or salts may be used for treating the
opportunistic infections and tumors that occur after suppression of
cell mediated immunity in, for example, transplant patients, cancer
patients and HIV patients.
[0284] Thus, one or more of the above diseases or types of
diseases, for example, a viral disease or a neoplastic disease may
be treated in an animal in need thereof (having the disease) by
administering a therapeutically effective amount of a compound or
salt of the invention to the animal.
[0285] An animal may also be vaccinated by administering an
effective amount of a compound or salt described herein, as a
vaccine adjuvant. In one embodiment, there is provided a method of
vaccinating an animal comprising administering an effective amount
of a compound or salt described herein to the animal as a vaccine
adjuvant.
[0286] An amount of a compound or salt effective to induce cytokine
biosynthesis is an amount sufficient to cause one or more cell
types, such as monocytes, macrophages, dendritic cells and B-cells
to produce an amount of one or more cytokines such as, for example,
IFN-.alpha., TNF-.alpha., IL-1, IL-6, IL-10 and IL-12 that is
increased (induced) over a background level of such cytokines. The
precise amount will vary according to factors known in the art but
is expected to be a dose of about 100 ng/kg to about 50 mg/kg,
preferably about 10 .mu.g/kg to about 5 mg/kg. In other
embodiments, the amount is expected to be a dose of, for example,
from about 0.01 mg/m.sup.2 to about 5.0 mg/m.sup.2, (computed
according to the Dubois method as described above) although in some
embodiments the induction or inhibition of cytokine biosynthesis
may be performed by administering a compound or salt in a dose
outside this range. In some of these embodiments, the method
includes administering sufficient compound or salt or composition
to provide a dose of from about 0.1 mg/m.sup.2 to about 2.0
mg/m.sup.2 to the subject, for example, a dose of from about 0.4
mg/m.sup.2 to about 1.2 mg/m.sup.2.
[0287] The invention also provides a method of treating a viral
infection in an animal and a method of treating a neoplastic
disease in an animal comprising administering an effective amount
of a compound or salt of the invention to the animal. An amount
effective to treat or inhibit a viral infection is an amount that
will cause a reduction in one or more of the manifestations of
viral infection, such as viral lesions, viral load, rate of virus
production, and mortality as compared to untreated control animals.
The precise amount that is effective for such treatment will vary
according to factors known in the art but is expected to be a dose
of about 100 ng/kg to about 50 mg/kg, preferably about 10 .mu.g/kg
to about 5 mg/kg. An amount of a compound or salt effective to
treat a neoplastic condition is an amount that will cause a
reduction in tumor size or in the number of tumor foci. Again, the
precise amount will vary according to factors known in the art but
is expected to be a dose of about 100 ng/kg to about 50 mg/kg,
preferably about 10 .mu.g/kg to about 5 mg/kg. In other
embodiments, the amount is expected to be a dose of, for example,
from about 0.01 mg/m.sup.2 to about 5.0 mg/m.sup.2, (computed
according to the Dubois method as described above) although in some
embodiments either of these methods may be performed by
administering a compound or salt in a dose outside this range. In
some of these embodiments, the method includes administering
sufficient compound or salt to provide a dose of from about 0.1
mg/m.sup.2 to about 2.0 mg/m.sup.2 to the subject, for example, a
dose of from about 0.4 mg/m.sup.2 to about 1.2 mg/m.sup.2.
[0288] In addition to the formulations and uses described
specifically herein, other formulations, uses, and administration
devices suitable for compounds of the present invention are
described in, for example, International Publication Nos. WO
03/077944 and WO 02/036592, U.S. Pat. No. 6,245,776, and U.S.
Publication Nos. 2003/0139364, 2003/185835, 2004/0258698,
2004/0265351, 2004/076633, and 2005/0009858.
[0289] Objects and advantages of this invention are further
illustrated by the following examples, but the particular materials
and amounts thereof recited in these examples, as well as other
conditions and details, should not be construed to unduly limit
this invention.
EXAMPLES
[0290] In the examples below automated flash chromatography on
silica gel was carried out using a HORIZON HPFC system (an
automated high-performance flash purification product available
from Biotage, Inc, Charlottesville, Va., USA) or an INTELLIFLASH
Flash Chromatography System (an automated flash purification system
available from AnaLogix, Inc, Burlington, Wis., USA). The eluent
used for each purification is given in the example. In some
chromatographic separations, the solvent mixture 80/18/2 v/v/v
chloroform/methanol/concentrated ammonium hydroxide (CMA) was used
as the polar component of the eluent. In these separations, CMA was
mixed with chloroform in the indicated ratio.
Example 1
1-[(4-Amino-2-propyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclobutanol
##STR00040##
[0291] Part A
[0292] A solution of ethyl chlorooxoacetate (22.53 g, 0.165 mol) in
diethyl ether (100 mL) was added over a period of 15 minutes to a
cooled (0.degree. C.) solution of 2-methylindole (19.7 g, 0.15 mol)
and pyridine (14.2 g, 0.18 mol) in diethyl ether (200 mL). The
reaction was stirred for two hours at 0.degree. C. under a nitrogen
atmosphere. Most of the diethyl ether had evaporated by the end of
the two-hour reaction time, and a solid was present. Water (100 mL)
was added, and the solid was isolated by filtration and washed with
1:1 diethyl ether/hexane. The solid (27.9 g) was then dissolved in
boiling toluene (250 mL) and recrystallized upon cooling to
6.degree. C. The crystals were isolated by filtration, washed with
toluene, dried for two hours on the vacuum filter funnel,
triturated with water at 75.degree. C. for five minutes, isolated
by filtration, and dried for three hours on the filter funnel to
provide 17.8 g ethyl (2-methyl-1H-indol-3-yl)(oxo)acetate of as a
rust-colored powder.
Part B
[0293] Ethyl (2-methyl-1H-indol-3-yl)(oxo)acetate (6.94 g, 30.0
mmol) and propylhydrazine oxalate (10.8 g, 66.0 mmol) were added to
a solution of acetyl chloride (5.18 g, 66.0 mmol) in acetic acid (5
mL) and ethanol (150 mL), and the reaction was heated at reflux
under nitrogen for 42.5 hours. The ethanol was removed under
reduced pressure, and 2 M aqueous sodium carbonate was added. The
mixture was stirred, and the resulting solid was isolated by
filtration, washed with water, and dried for 90 minutes on the
vacuum filter funnel to provide a dark semi-solid. The crude
product was stirred with tert-butyl methyl ether (50 mL) and
isolated by filtration, washed with tert-butyl methyl ether, and
dried on the vacuum filter funnel to provide 6.10 g of an orange
solid, which was stirred with boiling acetonitrile (50 mL),
isolated by filtration, and purified by automated flash
chromatography to provide 5.11 g of
1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ol as a white
solid.
Part C
[0294] A solution of
1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ol (5.11 g, 21.2
mmol) in phosphorus oxychloride (50 mL) was heated at reflux for 30
minutes, allowed to cool to room temperature, and stirred for two
days. The reaction mixture was poured into ice water (500 mL) with
stirring, and concentrated ammonium hydroxide (169 mL) and ice were
added. A solid was present and was isolated by filtration, washed
with water, and purified by automated flash chromatography (eluting
with 5% to 25% CMA in chloroform). The resulting orange solid (5.5
g) was recrystallized from acetonitrile (25 mL). The crystals were
washed with acetonitrile and dried for five hours to provide 3.85 g
of 4-chloro-1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinoline as a
white solid, mp 145-147.degree. C.
[0295] Anal. Calcd for C.sub.14H.sub.14N.sub.3Cl: C, 64.74; H,
5.43; N, 16.18. Found: C, 64.50; H, 5.64; N, 16.20.
[0296] This product was combined with material from another
run.
Part D
[0297] A Parr vessel was charged with
4-chloro-1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinoline (4.31 g) and
a solution of ammonia in methanol (50 mL of 7 N). The reaction was
heated at 150.degree. C. for 24 hours and allowed to cool to room
temperature. Most of the methanol was removed under reduced
pressure, and water was added. A precipitate formed and was
isolated by filtration, washed with water, and dried on the vacuum
filter funnel to provide 3.8 g of
1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine as a white
solid.
Part E
[0298] A solution of
1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine (3.78 g, 15.7
mmol), di-tert-butyl dicarbonate (8.6 g, 39.3 mmol), and
4-dimethylaminopyridine (DMAP) (96 mg, 0.79 mmol) in
tetrahydrofuran (THF) (100 mL) was heated at reflux for 14 hours
and allowed to cool to room temperature. The THF was removed under
reduced pressure, and the residue was purified by chromatography
using a HORIZON HPFC system (eluting with 50% ethyl acetate in
hexane) followed by recrystallization from tert-butyl methyl
ether/hexane. The crystals were washed with hexane and dried on the
vacuum filter funnel for two hours to provide 6.46 g of
di(tert-butyl)
1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarbonate
as an off-white solid.
Part F
[0299] A solution of di(tert-butyl)
1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarbonate
(1.32 g, 3.00 mmol) in anhydrous tetrahydrofuran (THF) (30 mL) was
cooled to -78.degree. C. under an argon atmosphere.
tert-Butyllithium (7.06 mL of a 1.7 M solution in pentane) was
added over a period of eight minutes, and the resulting
dark-colored solution was stirred at -78.degree. C. for 40 minutes.
Cyclobutanone (1.05 g, 15 mmol) was added over a period of two
minutes, and the -78.degree. C. bath was replaced with a 0.degree.
C. bath. The reaction mixture was stirred for 10 minutes, and then
saturated aqueous ammonium chloride (30 mL) was added. The aqueous
layer was separated and extracted three times with tert-butyl
methyl ether, and the combined organic fractions were dried over
magnesium sulfate, filtered, and concentrated under reduced
pressure. The residue (1.3 g) was purified by automated flash
chromatography and then boiled in 2 M hydrochloric acid for 30
minutes. The solution was allowed to cool to room temperature
overnight and then made basic with the addition of 2 M aqueous
sodium carbonate. The resulting solution was extracted four times
with chloroform, and the combined extracts were dried over
magnesium sulfate, filtered, and concentrated under reduced
pressure. The residue (1.2 g) was purified twice by automated flash
chromatography and recrystallized from acetonitrile to provide 297
mg of
1-[(4-amino-2-propyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclobutanol
as a white solid, mp 191-193.degree. C. MS (APCI) m/z 311
(M+H).sup.+;
[0300] Anal. Calcd for C.sub.18H.sub.22N.sub.4O: C, 69.65; H, 7.14;
N, 18.05. Found: C, 69.35; H, 7.14; N, 18.11.
Example 2
4-[(4-Amino-2-propyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahydro-2H--
pyran-4-ol
##STR00041##
[0302] A solution of di(tert-butyl)
1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarbonate
(1.32 g, 3.00 mmol) in anhydrous tetrahydrofuran (THF) (30 mL) was
cooled to -78.degree. C. under an argon atmosphere.
tert-Butyllithium (4.4 mL of a 1.7 M solution in pentane) was added
over a period of five minutes, and the resulting dark-colored
solution was stirred at -78.degree. C. for 30 minutes.
Tetrahydro-4H-pyran-4-one (901 mg, 9.0 mmol) was added, and
reaction mixture was stirred for 10 minutes. The -78.degree. C.
bath was replaced with a 0.degree. C. bath, and then saturated
aqueous ammonium chloride (30 mL) was added. The aqueous layer was
separated and extracted three times with tert-butyl methyl ether,
and the combined organic fractions were dried over magnesium
sulfate, filtered, and concentrated under reduced pressure. The
residue (1.3 g) was purified by automated flash chromatography
(eluting with ethyl acetate) and heated in refluxing 1 M hydrogen
chloride in ethanol (50 mL) for one hour. The solution was allowed
to cool to room temperature and then made basic with the addition
of 2 M aqueous sodium carbonate. The resulting solution was
extracted four times with chloroform, and the combined extracts
were dried over magnesium sulfate, filtered, and concentrated under
reduced pressure. The residue (1.2 g) was purified by automated
flash chromatography and recrystallized from acetonitrile to
provide 430 mg of
4-[(4-amino-2-propyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahydro-2H-
-pyran-4-ol as a white solid, mp 209-211.degree. C.
[0303] MS (APCI) m/z 341 (M+H).sup.+;
[0304] Anal. Calcd for C.sub.19H.sub.24N.sub.4O.sub.2: C, 67.04; H,
7.11; N, 16.46. Found: C, 66.98; H, 7.17; N, 16.39.
Example 3
2-Propyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c]quinolin-4-a-
mine
##STR00042##
[0305] Part A
[0306] A solution of potassium hydroxide (4.66 g, 83.1 mmol) in
ethanol (181 mL) and water (45 mL) was cooled to approximately
0.degree. C. Tetrahydro-4H-pyran-4-one (7.56 g, 75.5 mmol) and
diethyl (2-oxopropyl)phosphonate (16.1 g, 83.1 mmol) were
sequentially added. The reaction was allowed to warm to room
temperature and stirred for five hours. The reaction mixture was
washed with brine and the organic layer was separated. The aqueous
layer was extracted three times with tert-butyl methyl ether. The
combined organic fractions were dried over magnesium sulfate,
filtered, and concentrated under reduced pressure. The residue was
dissolved in a mixture of 20% ethyl acetate in hexane and
chloroform, dried again over magnesium sulfate, filtered,
concentrated under reduced pressure, and purified by automated
flash chromatography (eluting with 35% to 45% ethyl acetate in
hexane). The resulting colorless oil was dried under a stream of
nitrogen to provide 8.03 g of
1-tetrahydro-4H-pyran-4-ylideneacetone.
Part B
[0307] A solution of 1-tetrahydro-4H-pyran-4-ylideneacetone (4.0 g,
28.5 mmol) in ethyl acetate was added to a Parr vessel. The vessel
was purged with nitrogen, and 10% palladium on carbon (400 mg) was
added. The vessel was shaken under hydrogen pressure (50 psi,
3.4.times.10.sup.5 Pa) for approximately ten minutes, and the
reaction mixture was filtered through a layer of CELITE filter
agent. The filter cake was washed with ethyl acetate. The filtrate
was concentrated under reduced pressure, and the residue was dried
under a stream of nitrogen to provide 3.80 g of
1-tetrahydro-2H-pyran-4-ylacetone as a colorless oil.
Part C
[0308] A neat mixture of 1-tetrahydro-2H-pyran-4-ylacetone (3.80 g,
26.7 mmol) and diethyl oxalate (4.30 g, 29.4 mmol) was added in one
portion, followed by an ethanol rinse (10 mL), to a stirred
solution of sodium tert-butoxide (2.83 g, 29.4 mmol) in ethanol (20
mL). The mixture was stirred for one hour, cooled to approximately
0.degree. C., and treated with acetic acid (30.0 mL). After the
mixture was stirred for five minutes, propylhydrazine oxalate (4.38
g, 26.7 mmol) was added in one portion. The reaction was allowed to
warm to room temperature slowly and stirred overnight. Most of the
volatiles were removed under reduced pressure, and 2 M aqueous
sodium carbonate was added. The mixture was extracted four times
with tert-butyl methyl ether. The organic layers were combined,
dried over magnesium sulfate, filtered, and concentrated to yield
8.5 g of a yellow oil. The oil was purified twice by automated
flash chromatography (eluting with ethyl acetate in hexane), and
the resulting pale yellow oil was dried under a stream of nitrogen
to provide 6.43 g of ethyl
1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboxylate.
Part D
[0309] Lithium hydroxide monohydrate (3.8 g, 92 mmol) was added to
a solution of ethyl
1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboxylate
(6.43 g, 22.9 mmol) in methanol (30 mL) and water (10 mL). The
mixture was stirred for 20 hours. Most of the volatiles were
removed under reduced pressure, and water (100 mL) and acetic acid
(52 mL, 910 mmol) were sequentially added. The solution was cooled
to approximately 0.degree. C. After five minutes, a white solid
formed, and more water (100 mL) was added. The mixture was stirred
for 30 minutes, and the solid was isolated by filtration, washed
with water, and dried on the vacuum filter funnel to provide 4.88 g
of
1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboxylic
acid as a white solid.
Part E
[0310] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(4.06 g, 21.2 mmol) was added to a solution of
1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboxylic
acid (4.88 g, 19.3 mmol) and 1-hydroxybenzotriazole (2.87 g, 21.2
mmol) in N,N-dimethylformamide (DMF) (24.4 mL) at room temperature.
The mixture was stirred for two hours, cooled in an ice bath, and
treated with concentrated ammonium hydroxide (3.9 mL). A
precipitate formed, and the mixture was stirred 30 minutes at
0.degree. C. Water (100 mL) was added, and the mixture was stirred
for an additional ten minutes. The precipitate was isolated by
filtration, washed with water, and dried on the vacuum filter
funnel to provide 4.05 g of
1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboxamide
as white crystals.
Part F
[0311] A solution of trifluoroacetic anhydride (2.50 mL, 17.7 mmol)
in dichloromethane (32 mL) was added over a period of ten minutes
to a 0.degree. C. solution of
1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboxamide
(4.05 g, 16.1 mmol) and triethylamine (4.89 g, 48.3 mmol) in
dichloromethane (32 mL). After the addition was complete, the
cooling bath was removed and the solution was stirred for three
hours. The solution was washed with 2 M aqueous sodium carbonate.
The aqueous layer was extracted three times with tert-butyl methyl
ether. The organic layers were combined, dried over magnesium
sulfate, filtered, and concentrated under reduced pressure. The
crude product was purified by automated flash chromatography
(eluting with 40% to 70% ethyl acetate in hexane) to provide 3.98 g
of
1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbonitrile
as a pale yellow oil.
Part G
[0312] Potassium acetate (3.93 g, 40.0 mmol) and bromine (3.58 g,
22.4 mmol) were sequentially added to a solution of
1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbonitrile
(3.98 g, 16 mmol) in acetic acid (32 mL). The reaction was stirred
for 40 hours at room temperature. Saturated aqueous sodium
hydrogensulfite was added until the reaction became colorless. Most
of the acetic acid was removed under reduced pressure, and 2M
aqueous sodium carbonate was added. A precipitate formed, was
isolated by filtration, washed with water, and dried on the vacuum
filter funnel to provide 4.91 g of
4-bromo-1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboni-
trile as a white solid.
Part H
[0313] 2-Aminophenylboronic acid hydrochloride (1.39 g, 8.0 mmol)
and dichlorobis(triphenylphosphine)palladium(II) (140 mg, 0.20
mmol) were sequentially added to a mixture of
4-bromo-1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboni-
trile (1.25 g, 4.00 mmol), potassium carbonate (1.82 g, 13.2 mmol),
1,2-dimethoxyethane (DME) (15 mL), and water (7.5 mL). The flask
was placed under vacuum and back-filled with nitrogen four times.
The reaction was heated under a nitrogen atmosphere at 95.degree.
C. for one hour. The reaction was allowed to cool to room
temperature, and water and tert-butyl methyl ether were added. The
aqueous layer was separated and extracted with tert-butyl methyl
ether three times. The organic fractions were combined, dried over
magnesium sulfate, filtered, and concentrated to yield a brown
solid (1.75 g). The crude product was purified by automated flash
chromatography (eluting with ethyl acetate in hexane) to provide
1.10 g of
4-(2-aminophenyl)-1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-
-3-carbonitrile as a pale orange solid.
Part I
[0314] Acetyl chloride (50 mmol) was stirred with anhydrous ethanol
(50 ml), and the resulting solution was added to the material from
Part H. The resulting solution was heated at reflux for 16 hours.
Aqueous sodium carbonate (30 mL of 2 M) was added, and then most of
the ethanol was removed under reduced pressure. Water was added; a
solid was present and was isolated by filtration and washed with
water. The crude product was purified by automated flash
chromatography (eluting with 5% to 25% CMA in chloroform) followed
by recystallization from ethyl acetate. The crystals were dried on
the vacuum filter funnel for 2.5 hours to provide 853 mg of
2-propyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c]quinolin-4--
amine as a white solid, mp 218-220.degree. C. MS (APCI) m/z 325
(M+H).sup.+;
[0315] Anal. Calcd for C.sub.19H.sub.24N.sub.4O: C, 70.34; H, 7.46;
N, 17.27. Found: C, 70.11; H, 7.72; N, 17.28.
Example 4
2-Propyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c][1,8]naphthy-
ridin-4-amine
##STR00043##
[0316] Part A
[0317] tert-Butyl N-(2-pyridyl)carbamate is available from the
literature procedure (Moraczewski, A. L. et al, J. Org. Chem.,
1998, 63, 7258) or can be prepared by the following method. Under a
nitrogen atmosphere, sodium bis(trimethylsilyl)amide (225 mL of a
1.0 M solution in tetrahydrofuran) was added over a period of 20
minutes to a solution of 2-aminopyridine (10.61 g, 108.0 mmol) in
dry THF (150 mL). The solution was stirred for 15 minutes and then
cooled to 0.degree. C. A solution of di-tert-butyl dicarbonate
(24.60 g, 112.7 mmol) in THF (50 mL) was added slowly, and the
reaction was allowed to warm to ambient temperature slowly and
stirred overnight. The THF was removed under reduced pressure, and
the residue was partitioned between ethyl acetate (500 mL) and 0.1
M hydrochloric acid (250 mL). The organic layer was separated;
washed sequentially with 0.1 M hydrochloric acid (250 mL), water
(250 mL), and brine (250 mL); dried over magnesium sulfate;
filtered; and concentrated under reduced pressure. The crude
product was purified by automated flash chromatography (eluting
with 80:20 hexanes/ethyl acetate) to provide 17.43 g of tert-butyl
N-(2-pyridyl)carbamate as a white solid.
Part B
[0318] Under a nitrogen atmosphere, a solution of tert-butyl
N-(2-pyridyl)carbamate (15.71 g, 80.9 mmol) and N,N,
N',N'-tetramethylethylenediamine (TMEDA) (25.3 g, 218 mmol) in THF
(400 mL) was cooled to -78.degree. C. n-Butyllithium (81 mL of a
2.5 M solution in hexanes) was added dropwise over a period of 20
minutes. The solution was stirred for ten minutes, and then the
addition funnel was rinsed with additional THF (20 mL). The
solution was warmed to -6.degree. C., stirred for two hours, and
cooled again to -78.degree. C. Triisopropyl borate (57.7 g, 307
mmol) was added over a period of ten minutes. The resulting
solution was warmed to 0.degree. C. and then poured into saturated
aqueous ammonium chloride (500 mL). A yellow solid formed and was
stirred with diethyl ether (300 mL), isolated by filtration, washed
with diethyl ether and water, and air-dried overnight to provide
2-tert-butoxycarbonylamino-3-pyridylboronic acid as a yellow
solid.
Part C
[0319] Hydrochloric acid (10 mL of 1M) was added to a solution of
2-tert-butoxycarbonylamino-3-pyridylboronic acid (2.59 g, 10.9
mmol), and the resulting mixture was heated at 80.degree. C. for 45
minutes and allowed to cool to room temperature. Potassium
carbonate (3.87 g, 27.95 mmol) was added with stirring, and then
DME (20 mL),
4-bromo-1-propyl-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboni-
trile (1.70 g, 5.44 mmol), and
dichlorobis(triphenylphosphine)palladium(II) (190 mg, 0.27 mmol)
were added. The flask was placed under vacuum and back-filled with
nitrogen three times. The reaction was heated under a nitrogen
atmosphere at 95.degree. C. overnight. The reaction was allowed to
cool to room temperature, and the volatiles were removed under
reduced pressure. The residue was dissolved in chloroform (100 mL),
and the resulting solution was washed with water (100 mL), dried
over magnesium sulfate, filtered, and concentrated to yield a light
yellow solid. The crude product was purified by automated flash
chromatography (eluting with 0% to 30% CMA in chloroform) followed
by recrystallization from acetonitrile (30 mL). The crystals were
washed with cold acetonitrile and dried overnight in a vacuum oven
at 60.degree. C. to provide 0.43 g of
2-propyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c][1,8]naphth-
yridin-4-amine as white needles, mp 252-255.degree. C.
[0320] Anal. calcd for C.sub.18H.sub.23N.sub.5O: C, 66.44; H, 7.12;
N, 21.52. Found: C, 66.21; H, 7.35; N, 21.54.
Example 5
2-(2-Methoxyethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c]qu-
inolin-4-amine
##STR00044##
[0321] Part A
[0322] The method described in Part B of Example 3 was repeated
with 1-tetrahydro-4H-pyran-4-ylideneacetone (4.0 g, 28.5 mmol), and
the resulting 1-tetrahydro-2H-pyran-4-ylacetone was mixed with
diethyl oxalate (4.66 g, 31.9 mmol) and added to a solution of
sodium tert-butoxide (3.07 g, 31.9 mmol) in ethanol (22 mL). The
reaction was carried out according to the method described in Part
C of Example 3 with the following modifications.
Hydroxyethylhydrazine (2.43 g, 31.9 mmol) was used instead of
ethylhydrazine oxalate. Extractions were carried out seven times
with chloroform, and the crude product was not purified. Ethyl
1-(2-hydroxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-
-carboxylate (8.2 g) was obtained as a viscous yellow oil.
Part B
[0323] A solution of the material from Part A in THF (50 mL) was
cooled to approximately 0.degree. C. under nitrogen, and
iodomethane (4.12 g, 29 mmol) was added. Sodium hydride (1.16 g of
60% in mineral oil, 29 mmol) was added over a period of two
minutes. The mixture was stirred at 0.degree. C. for 20 minutes,
allowed to warm to room temperature, and stirred overnight.
Saturated aqueous ammonium chloride was added, and the mixture was
extracted four times with tert-butyl methyl ether. The combined
extracts were dried over magnesium sulfate, filtered, and
concentrated under reduced pressure to provide 10 g of a yellow
oil. The oil was purified by automated flash chromatography
(eluting with ethyl acetate) to provide 5.20 g of ethyl
1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbo-
xylate as a pale yellow oil.
Part C
[0324] Lithium hydroxide monohydrate (2.94 g, 70.2 mmol) was added
to a solution of ethyl
1-(2-methoxyethyl)-5-tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbox-
ylate (5.2 g, 17.5 mmol) in methanol (60 mL) and water (20 mL). The
mixture was stirred for overnight. Most of the volatiles were
removed under reduced pressure, and acetic acid (40 mL) and water
were added. The solution was cooled to approximately 0.degree. C.
and stirred for one hour. The volatiles were removed under reduced
pressure, and the residue was partitioned between water and
chloroform. The aqueous layer was separated and extracted four
times with chloroform and then adjusted to pH 4 with the addition
of 1 M hydrochloric acid. The aqueous fraction was extracted again
four times with chloroform. The combined organic fractions were
dried over magnesium sulfate and sodium sulfate, filtered, and
concentrated under reduced pressure. The residue was twice
dissolved in heptane and concentrated and twice dissolved in
toluene and concentrated to provide 5.42 g of
1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbo-
xylic acid containing some toluene and 3 mol % acetic acid.
Part D
[0325] 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(3.69 g, 19.3 mmol) was added to a solution of the material from
Part C and 1-hydroxybenzotriazole (2.61 g, 19.3 mmol) in DMF (27.1
mL) at room temperature. The mixture was stirred for one hour,
cooled in an ice bath, and treated with concentrated ammonium
hydroxide (3.5 mL). A precipitate formed, and the mixture was
stirred 15 minutes at 0.degree. C. Water (150 mL) was added, and
the mixture was stirred. The precipitate was isolated by
filtration, washed with water, and dried on the vacuum filter
funnel to provide 1.44 g of
1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbo-
xamide as a white solid. The filtrate was extracted six times with
chloroform, and the combined extracts were dried over sodium
sulfate, filtered, and concentrated under reduced pressure. The
residue was twice dissolved in xylenes and concentrated under
reduced pressure and then recrystallized from a mixture of 50%
ethyl acetate in hexane (50 mL) and ethyl acetate (150 mL). The
crystals were dried overnight on the vacuum filter funnel to
provide an additional 2.027 g of
1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbo-
xamide as white plates.
[0326] Anal. Calcd for C.sub.13H.sub.19N.sub.3O.sub.3: C, 58.41; H,
7.92; N, 15.72. Found: C, 58.52; H, 7.89; N, 15.86.
Part E
[0327] The method described in Part F of Example 3 was used to
treat
1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbo-
xamide (3.41 g, 12.7 mmol) with trifluoroacetic anhydride (1.98 mL,
14.0 mmol) in the presence of triethylamine (3.86 g, 38.1 mmol)
with the following modifications. Extractions were carried out four
times with chloroform, and the automated flash chromatography
column was eluted with ethyl acetate.
1-(2-Methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbo-
nitrile (3.16 g) was obtained as a colorless oil.
Part F
[0328] Potassium acetate (3.12 g, 31.7 mmol) and bromine (2.84 g,
17.7 mmol) were sequentially added to a solution of
1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carbo-
nitrile (3.16 g, 12.7 mmol) in acetic acid (25 mL). The reaction
was stirred for 16 hours at room temperature. Saturated aqueous
sodium hydrogensulfite was added until the reaction became
colorless. Water was added, and a precipitate formed, was isolated
by filtration, washed with water, and dried on the vacuum filter
funnel to provide 3.78 g of
4-bromo-1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-
-3-carbonitrile as a white solid containing about 2 mol % acetic
acid.
Part G
[0329] Potassium carbonate (1.82 g, 13.2 mmol), 1,2-dimethoxyethane
(DME) (15 mL), water (7.5 mL), and
dichlorobis(triphenylphosphine)palladium(II) (140 mg, 0.20 mmol)
were added to a mixture of 2-aminophenylboronic acid hydrochloride
(1.39 g, 8.0 mmol) and
4-bromo-1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-
-3-carbonitrile (1.31 g, 4.00 mmol). The flask was placed under
vacuum and back-filled with nitrogen four times. The reaction was
heated under a nitrogen atmosphere at 95.degree. C. for 90 minutes.
The aqueous layer was separated and extracted twice with tert-butyl
methyl ether. The organic fractions were combined, dried over
magnesium sulfate, filtered, and concentrated to yield a black oil
(2.2 g). The crude product was purified by automated flash
chromatography (eluting with ethyl acetate) to provide 1.14 g of
4-(2-aminophenyl)-1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1-
H-pyrazole-3-carbonitrile as a yellow, waxy solid.
Part H
[0330] The method described in Part I of Example 3 was followed.
Following recrystallization from ethyl acetate (40 mL), the
crystals were dried on the vacuum filter funnel for 19 hours to
provide 736 mg of
2-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c]q-
uinolin-4-amine as white crystals, mp 189-190.degree. C. MS (APCI)
m/z 341 (M+H).sup.+;
[0331] Anal. Calcd for C.sub.19H.sub.24N.sub.4O.sub.2: C, 67.04; H,
7.11; N, 16.46. Found: C, 67.03; H, 7.22; N, 16.55.
Example 6
2-(2-Methoxyethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c][1-
,8]naphthyridin-4-amine
##STR00045##
[0333] Hydrochloric acid (10 mL of 1M) was added to a solution of
2-tert-butoxycarbonylamino-3-pyridylboronic acid (2.59 g, 10.9
mmol), and the resulting mixture was heated at 80.degree. C. for 45
minutes and allowed to cool to room temperature. Potassium
carbonate (3.60 g, 26.0 mmol) was added with stirring, and then DME
(20 mL),
4-bromo-1-(2-methoxyethyl)-5-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-
-3-carbonitrile (1.75 g, 5.33 mmol), and
dichlorobis(triphenylphosphine)palladium(II) (190 mg, 0.27 mmol)
were added. The reaction was carried out as described in Part C of
Example 4. The crude product was purified by automated flash
chromatography (eluting with 0% to 35% CMA in chloroform) followed
by recrystallization from acetonitrile (30 mL) after hot
filtration. The crystals were washed with cold acetonitrile and
dried overnight in a vacuum oven at 60.degree. C. to provide 0.13 g
of
2-(2-methoxyethyl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c][-
1,8]naphthyridin-4-amine as light yellow needles, mp
230-233.degree. C.
[0334] Anal. calcd for C.sub.18H.sub.23N.sub.5O.sub.2: C, 63.32; H,
6.79; N, 20.51. Found: C, 63.37; H, 6.84; N, 20.59.
Example 7
1-[(4-Fluorotetrahydro-2H-pyran-4-yl)methyl]-2-methyl-2H-pyrazolo[3,4-c]qu-
inolin-4-amine
##STR00046##
[0335] Part A
[0336] Diethyl 2-oxopropylphosphonate (12.8 mL, 1.1 eq) was added
to a stirred solution of tetrahydropyran-4-one (6.06 g, 1.0 eq) in
ethanol (148 mL) and then the mixture was cooled to 0.degree. C.
with an ice bath. A solution of potassium hydroxide (3.74 g, 1.1
eq) in water (38 mL) was added over a period of about 2 minutes.
The ice bath was removed and the reaction mixture was stirred for 3
hours. The bulk of the ethanol was removed under reduced pressure
while maintaining the temperature at .ltoreq.20.degree. C. to
provide about 32 g of a yellow liquid. The liquid was diluted with
water (150 mL) and then extracted with dichloromethane (2.times.150
mL). The combined organics were dried over magnesium sulfate and
then concentrated under reduced pressure while maintaining the
temperature at .ltoreq.20.degree. C. to provide 12.05 g of a pale
yellow liquid. This material was purified by automated flash
chromatography (eluting with 20% ethyl acetate in hexanes for 2
column volumes, with a gradient of 2040% ethyl acetate in hexanes
over 5 column volumes, and with 40% ethyl acetate in hexanes for 2
column volumes) to provide 7.02 g of
1-tetrahydro-4H-pyran-4-ylideneacetone. Analysis by .sup.1H NMR
indicated clean product with residual ethyl acetate (14%).
Part B
[0337] A solution of sodium tert-butoxide (5.29 g, 1.1 eq) in
ethanol (51 mL) was added to a mixture of the material from Part A
(1.0 eq) and diethyl oxalate (7.45 mL, 1.1 eq). The vessel
containing the material from part A and diethyl oxalate was rinsed
with additional ethanol (27 mL) and the rinse was added to the
reaction mixture. The reaction mixture was stirred for 2 hours and
then cooled to 0.degree. C. Acetic acid (57 mL) was added and the
reaction mixture was stirred for 5 minutes. Methylhydrazine (2.64
mL, 1.0 eq) was added dropwise. After 15 minutes the ice bath was
removed and the reaction mixture was stirred overnight. The
reaction mixture was concentrated under reduced pressure and the
residue was partitioned between 50% aqueous sodium carbonate (450
mL) and dichloromethane (250 mL). The aqueous layer was back
extracted with dichloromethane (100 mL). The combined organics were
dried over magnesium sulfate and then concentrated under reduced
pressure at ambient temperature to provide 11.76 g of a yellow oil.
This material was purified by automated flash chromatography
(eluting with 30% ethyl acetate in hexanes for 1 column volume,
with a gradient of 30-70% ethyl acetate in hexanes over 6 column
volumes, and with 70% ethyl acetate in hexanes for 1 column volume)
to provide 4.99 g of ethyl
1-methyl-5-(tetrahydro-4H-pyran-4-ylidenemethyl)-1H-pyrazole-3-carboxylat-
e as a yellow oil. Analysis by HPLC, LCMS, TLC, and .sup.1H NMR
indicated clean product with residual ethyl acetate (14%).
Part C
[0338] A solution of sodium hydroxide (1.99 g, 2.5 eq) in water (5
mL) was added to a stirred solution of the material from Part B
(1.0 eq) in ethanol (50 mL). The reaction mixture was stirred for
30 minutes and then the bulk of the ethanol was removed under
reduced pressure. The residue was diluted with dichloromethane (250
mL) and water (50 mL). The aqueous layer was acidified (pH about
1-2) with hydrochloric acid (50 mL of 1 M). The layers were
separated and the aqueous layer was back extracted with
dichloromethane (4.times.125 mL). The combined organics were dried
over magnesium sulfate and then concentrated under reduced pressure
to provide 4.82 g of
1-methyl-5-(tetrahydro-4H-pyran-4-ylidenemethyl)-1H-pyrazole-3--
carboxylic acid.
Part D
[0339] 1-Hydroxybenzotriazole hydrate (3.23 g, 1.2 eq) and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC,
4.58 g, 1.2 eq) were added sequentially to a solution of the
material from Part C (1.0 eq) in DMF (25 mL). After 25 minutes the
EDC was dissolved. After 1 hour the reaction mixture was cooled to
0.degree. C. and concentrated ammonium hydroxide (5.3 mL, 4.0 eq)
was added. Solids formed several minutes later. The reaction
mixture was stirred for 30 minutes, diluted with water (100 mL),
and then stirred for 20 minutes. The solids were isolated by
filtration, rinsed with water (2.times.25 mL), and then dried to
provide 3.69 g of
1-methyl-5-(tetrahydro-4H-pyran-4-ylidenemethyl)-1H-pyrazole-3-carboxamid-
e as a white powder.
Part E
[0340] 3-Chloroperoxybenzoic acid (4.51 g, 1.1 eq based on 70%
titer) was added to a stirred suspension of the material from Part
D (1.0 eq) in chloroform (83 ml). After several minutes a solution
was obtained. The solution was stirred overnight, diluted with
additional chloroform (275 mL), and then washed with a solution of
saturated sodium bicarbonate:5% sodium hydroxide (20:1, 1.times.150
mL, then 1.times.100 mL). The organic layer was dried over
magnesium sulfate and then concentrated under reduced pressure to
provide a voluminous white foam. This material was concentrated
from ethanol to provide 3.94 g of
5-(1,6-dioxaspiro[2.5]oct-2-yl)-1-methyl-1H-pyrazole-3-carboxamide
as a white solid.
Part F
[0341] A suspension of the material from Part E (1.0 eq) in ethanol
(170 mL) was warmed until most of the solid was dissolved and then
cooled to 35.degree. C. 10% Palladium on carbon (400 mg) and
ammonium formate (5.24 g, 5.0 eq) were added sequentially. The
reaction mixture was allowed to cool to ambient temperature and
stirred for 4 hours. The reaction mixture was filtered through a
layer of CELITE filter agent. The filter cake was rinsed
sequentially with ethanol (3.times.25 mL), methanol (4.times.25
mL), and 1:1 methanol:chloroform (total of about 500 mL). The
filtrate was concentrated under reduced pressure to provide 5.74 g
of a white solid. This material was triturated with ethanol (45
mL), isolated by filtration, rinsed with ethanol (3.times.8 mL),
and then dried to provide 3.13 g of
5-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]-1-methyl-1H-pyraz-
ole-3-carboxamide as a white crystalline solid.
Part G
[0342] Triethylamine (5.13 mL, 3.0 eq) was added to a stirred
suspension of a portion of the material from Part F (2.91 g, 1.0
eq). The mixture was cooled to 0.degree. C. and trifluoroacetic
anhydride (5.14 mL, 3.0 eq) was added dropwise over a period of 5
minutes. The reaction mixture was stirred for 2 hours, quenched
with saturated sodium carbonate (50 mL), and then allowed to warm
to ambient temperature. Water (50 mL) and dichloromethane (200 mL)
were added sequentially. The organic layer was separated, dried
over magnesium sulfate, and then concentrated under reduced
pressure to provide a yellow oil. The oil was dissolved in methanol
(80 mL). Solid potassium carbonate (420 mg, 0.25 eq) was added and
the mixture was stirred for 30 minutes. Aqueous hydrochloric acid
(1.7 mL of 7 M, 1.0 eq) was added, the solution was stirred for 10
minutes, and then the bulk of the methanol was removed under
reduced pressure. The residue was partitioned between
dichloromethane (200 mL) and water (50 mL). The pH of the aqueous
layer was adjusted to 7-8 with saturated sodium bicarbonate. The
layers were separated and the aqueous layer was back extracted with
dichloromethane (2.times.75 mL). The combined organics were dried
over magnesium sulfate and then concentrated under reduced pressure
to provide 2.37 g of a light yellow semisolid. This material was
triturated with 5:95 methanol:chloroform (10 mL). A solid was
isolated by filtration and rinsed with 5:95 methanol:chloroform
(1.times.6 mL, then 1.times.2 mL) to provide 536 mg of
5-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]-1-methyl-1H-pyrazole-3-carb-
onitrile as a white solid (lot 1). The filtrate was concentrated to
provide a viscous yellow oil which was crystallized from warm
ethanol (about 15 mL). A solid was isolated by filtration, rinsed
with ethanol (2.times.5 mL), and then dried to provide 380 mg of
5-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]-1-methyl-1H-pyrazole-3-carb-
onitrile as prisms (lot 2). The filtrate was concentrated to a
semisolid. This material was purified by automated flash
chromatography (eluting with 5:95 methanol:chloroform for 8 column
volumes) to provide 0.47 g of
5-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]-1-methyl-1H-pyrazole-3-carb-
onitrile (lot 3) as a white solid.
Part H
[0343] A solution of material from Part G (lots 1 and 2, 1.0 eq) in
dichloromethane (41 mL) was cooled to 0.degree. C.
[Bis(2-methoxyethyl)amino]sulfur trifluoride (1.14 mL, 1.5 eq) was
added dropwise. The reaction mixture was stirred for 45 minutes,
quenched with saturated sodium bicarbonate (20 mL), and allowed to
warm to ambient temperature. Saturated sodium bicarbonate (50 mL)
and dichloromethane (50 mL) were added sequentially. The layers
were separated and the aqueous layer was back extracted with
dichloromethane (30 mL). The combined organics were dried over
magnesium sulfate and then concentrated under reduced pressure at
ambient temperature to provide 1.19 g of a light orange oil. This
material was purified by automated flash chromatography (eluting
with 10% ethyl acetate in 2:1 hexanes:dichloromethane for 2 column
volumes, a gradient of 10-30% ethyl acetate in 2:1
hexanes:dichloromethane over 8 column volumes, and 30% ethyl
acetate in 2:1 hexanes:dichloromethane for 4 column volumes) to
provide 401 mg of
5-[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]-1-methyl-1H-pyrazole-3-carbo-
nitrile as a clear colorless oil which crystallized on
standing.
Part I
[0344] Potassium acetate (437 mg, 2.5 eq) was added to a stirred
solution of the material from Part H (1.0 eq) in acetic acid (4
mL). After the potassium acetate had dissolved, bromine (0.13 mL,
1.4 eq) was added dropwise. The resulting red solution was stirred
for 18 hours. Additional potassium acetate (2 eq), acetic acid (0.5
mL), and bromine (1.4 eq) were added sequentially. The reaction
mixture was stirred for 2.5 hours and then quenched with saturated
sodium thiosulfate until colorless (about 4 mL). The reaction
mixture was concentrated under reduced pressure and then diluted
with water (10 mL) and saturated sodium carbonate (10 mL added
dropwise). The resulting foamy suspension was combined with
dichloromethane (50 mL). The aqueous layer was adjusted to about pH
8 with 5% sodium hydroxide. The layers were separated and the
aqueous layer was back extracted with dichloromethane (50 mL). The
combined organics were dried over magnesium sulfate and then
concentrated under reduced pressure to provide 0.59 g of a light
yellow solid. The bulk of the material was dissolved in 10:90
methanol:dichloromethane (40 mL), loaded onto silica gel, and then
purified by automated flash chromatography (eluting with
dichloromethane for 3 column volumes, a gradient of 0-10% ethyl
acetate in dichloromethane over 5 column volumes, and then 10%
ethyl acetate in dichloromethane for 10 column volumes) to provide
474 mg of
4-bromo-5-[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]-1-methyl-1H-pyraz-
ole-3-carbonitrile as a white solid.
Part J
[0345] Water (2.5 mL) was added dropwise to a stirred solution of
the material from Part I (1.0 eq) in 1,2-dimethoxyethane (7.5 mL).
2-Aminophenylboronic acid hydrochloride (460 mg, 1.7 eq) and
potassium carbonate (712 mg, 3.3 eq) were added sequentially. The
reaction mixture was purged with nitrogen and then
dichlorobis(triphenylphosphine)palladium(II) (22 mg, 0.02 eq) was
added. The reaction mixture was heated at 75.degree. C. for 9 hours
and then allowed to cool to ambient temperature over the weekend.
The reaction mixture was concentrated under reduced pressure and
the residue was partitioned between dichloromethane (50 mL) and
water (30 mL). The organic layer was separated, dried over
magnesium sulfate, and then concentrated under reduced pressure to
provide 2 g of a brown oil. This material was dissolved in ethanol
(10 mL) and a precipitate formed immediately. Hydrochloric acid
(0.90 mL of 7 M, 4.0 eq) was added and the resulting solution was
heated at 75.degree. C. for 4 hours. The reaction mixture was
cooled to ambient temperature and then concentrated under reduced
pressure. The residue was partitioned between dichloromethane (75
mL) and an aqueous mixture of saturated sodium bicarbonate (25 mL)
and water (25 mL). The aqueous layer was separated and then
extracted with dichloromethane (2.times.40 mL). The combined
organics were dried over magnesium sulfate and then concentrated
under reduced pressure to provide 0.66 g of a brown foam. This
material was purified by automated flash chromatography (eluting
with a gradient of 0-20% CMA in chloroform over 10 column volumes
and 20% CMA in chloroform for 3 column volumes) to provide 200 mg
of a tan solid. This material was triturated with hot ethanol
(about 8 mL), isolated by filtration, rinsed with ethanol
(3.times.5 mL), and then dried (0.15 torr (20 Pa), 130.degree. C.,
2 hours) to provide 143 mg of
1-[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]-2-methyl-2H-pyrazolo[3,4-c]q-
uinolin-4-amine as a tan powder, mp 252-254.degree. C. .sup.1H NMR
(500 MHz, DMSO-d.sub.6): .delta. 8.16 (d, J=7.8 Hz, 1H), 7.47 (dd,
J=1.2, 8.1 Hz, 1H), 7.32 (m, 1H), 7.17 (m, 1H), 6.65 (br s, 2H),
4.12 (s, 3H), 3.73 (m, 4H), 3.45 (m, 2H), 2.08 (m, 1H), 2.00 (m,
1H), 1.65 (m, 2H); MS (ESI) 315 m/z (M+H).sup.+; Anal. calcd for
C.sub.17H.sub.19FN.sub.4O.0.04 EtOH.0.25H.sub.2O: C, 63.97; H,
6.20; N, 17.47. Found: C, 63.97; H, 6.10; N, 17.49.
Example 8
4-[(4-Amino-2-methyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahydro-2H--
pyran-4-ol
##STR00047##
[0346] Part A
[0347] Potassium acetate (0.52 g, 2.5 eq) was added to a stirred
solution of
5-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]-1-methyl-1H-pyrazole-3-c-
arbonitrile (Example 7, Part G, lot 3, 0.47 g, 1.0 eq) in acetic
acid (7 mL). The reaction mixture was stirred until all of the
potassium acetate was dissolved. Bromine (0.15 mL, 1.4 eq) was
added dropwise and the reaction was stirred for 16 hours. The
reaction mixture was quenched with saturated sodium thiosulfate (4
mL) and then the bulk of the acetic acid was removed under reduced
pressure. The residue was diluted with water (15 mL) and saturated
sodium carbonate (about 10-12 mL) and then extracted with
dichloromethane (3.times.25 mL). The combined organics were dried
over magnesium sulfate and then concentrated under reduced pressure
to provide 0.72 g of a yellow solid. This material was purified by
automated flash chromatography (eluting with 30% CMA in chloroform
for 7 column volumes) to provide 528 mg of
4-bromo-5-[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]-1-methyl-1H-pyrazol-
e-3-carbonitrile as a colorless sticky semisolid.
Part B
[0348] The material from Part A (1.0 eq) was coupled with
2-aminophenylboronic acid hydrochloride (1.8 eq) and then cyclized
using the general method of Example 7 Part J. The crude product was
purified by automated flash chromatography (eluting with 20% CMA in
chloroform for 3 column volumes, a gradient of 20-40% CMA in
chloroform over 10 column volumes, and 40% CMA in chloroform for 3
column volumes) to provide a tan solid. This material was
triturated with hot ethyl acetate (about 8 mL), isolated by
filtration, rinsed with ethyl acetate (3.times.5 mL), and dried
under high vacuum to provide 106 mg of
4-[(4-amino-2-methyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahydro-2H-
-pyran-4-ol as a tan powder, mp 260-262 (dec).degree. C. .sup.1H
NMR (500 MHz, DMSO-d.sub.6): .delta.8.19 (dd, J=1.0, 8.0 Hz, 1H),
7.46 (dd, J=1.2, 8.1 Hz, 1H), 7.30 (m, 1H), 7.17 (m, 1H), 6.61 (s,
2H), 4.77 (s, 1H), 4.16 (s, 3H), 3.55 (m, 4H), 3.41 (s, 2H), 1.84
(m, 2H), 1.44 (br s, 1H), 1.39 (br s, 1H); MS (APCI) 313 m/z
(M+H).sup.+; Anal. calcd for
C.sub.17H.sub.20N.sub.4O.sub.2.0.25H.sub.2O: C, 64.44; H, 6.52; N,
17.68. Found: C, 64.11; H, 6.32; N, 17.60
Example 9
2-Ethyl-1-[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]-2H-pyrazolo[3,4-c]qui-
nolin-4-amine
##STR00048##
[0350]
2-Ethyl-1-[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]-2H-pyrazolo[3,-
4-c]quinolin-4-amine was prepared according to the general method
of Example 7 Parts A through J using 1.3 eq of ethylhydrazine
oxalate in lieu of methylhydrazine in part B. The crude product was
purified by automated flash chromatography (eluting with a gradient
of 0-20% CMA in chloroform over 5 column volumes and 20% CMA in
chloroform for 5 column volumes) to provide 170 mg of a tan solid.
This material was triturated with methanol (about 12 mL), isolated
by filtration, rinsed with methanol (3.times.5 mL), and dried under
high vacuum to provide 112 mg of
2-ethyl-1-[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]-2H-pyrazolo[3,4-c]qu-
inolin-4-amine as a tan powder, mp 275-277.degree. C. .sup.1H NMR
(500 MHz, DMSO-d.sub.6): .delta. 8.15 (d, J=7.6 Hz, 1H), 7.48 (dd,
J=1.2, 8.1 Hz, 1H), 7.20 (m, 1H), 7.17 (m, 1H), 6.64 (br s, 2H),
4.44 (q, J=7.2 Hz, 2H), 3.73 (m, 4H), 3.44 (t, J=11.3 Hz, 2H), 2.10
(ddd, J=5.4, 13.5, 13.5 Hz, 1H), 1.97 (ddd, J=5.6, 13.6, 13.6 Hz,
1H), 1.64 (m, 2H), 1.48 (t, J=7.1 Hz, 3H); MS (ESI) 329 m/z
(M+H).sup.+; Anal. calcd for C.sub.18H.sub.21FN.sub.4O: C, 65.84;
H, 6.45; N, 17.06. Found: C, 65.56; H, 6.24; N, 16.93.
Example 10
4-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahydro-2H-p-
yran-4-ol
##STR00049##
[0351] Part A
[0352]
Di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimido-
dicarbonate was prepared according to the method of Example 1 Part
E using 2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-amine
(International Publication Number WO 2005/079195, Example 35) in
lieu of 1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-amine. The
crude product was triturated with hexanes to provide 13.34 g
di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarb-
onate as a white granular solid.
Part B
[0353]
Di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimido-
dicarbonate was reacted with tetrahydro-4H-pyran-4-one according to
the method of Example 2 using
di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarb-
onate in lieu of
di(tert-butyl)1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicar-
bonate. The crude product was recrystallized acetonitrile provide
0.349 g
4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahydro-2H--
pyran-4-ol as off-white crystals, mp 253-255.degree. C.
[0354] MS (ESI) m/z 327.28 (M+H).sup.+
[0355] Anal. Calcd for C.sub.18H.sub.22N.sub.4O.sub.2: C, 66.24; H,
6.79; N, 17.16. Found: C, 66.45; H, 7.05; N, 17.24.
Example 11
1-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclohexanol
##STR00050##
[0357]
1-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclohex-
anol was prepared according to the method of Example 1 Part F using
di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarb-
onate in lieu of
di(tert-butyl)1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicab-
onate and cyclohexanone in lieu of cyclobutanone. The crude product
was recrystallized from acetonitrile to provide 0.560 g of
1-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclohexanol
as a white powder, mp 211.5-213.degree. C.
[0358] MS (ESI) m/z 325.23 (M+H).sup.+
[0359] Anal. Calcd for C.sub.19H.sub.24N.sub.4O: C, 70.34; H, 7.46;
N, 17.27. Found: C, 70.19; H, 7.57; N, 17.35.
Example 12
1-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclopentanol
##STR00051##
[0361]
1-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclopen-
tanol was prepared according to the method of Example 1 Part F
using
di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarb-
onate in lieu of
di(tert-butyl)1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicar-
bonate and cycpentanone in lieu of cyclobutanone. The crude product
was triturated with acetonitrile and isolated by filtration to
provide 0.414 g of
1-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclopent-
anol as a white powder, mp 256-259.degree. C.
[0362] MS (ESI) m/z 311.32 (M+H).sup.+
[0363] Anal. Calcd for C.sub.18H.sub.22N.sub.4O.0.02CHCl.sub.3: C,
69.20; H, 7.10; N, 17.91. Found: C, 68.95; H, 6.79; N, 17.83.
Example 13
1-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclobutanol
##STR00052##
[0365]
1-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclobut-
anol was prepared according to the method of Example 1 Part F using
di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarb-
onate in lieu of
di(tert-butyl)1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicar-
bonate. The crude product was triturated with acetonitrile and
isolated by filtration to provide 0.396 g of
1-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclobutanol
as a white solid, mp 245-247.degree. C.
[0366] MS (ESI) m/z 297.26 (M+H).sup.+
[0367] Anal. Calcd for C.sub.17H.sub.20N.sub.4O: C, 68.90; H, 6.80;
N, 18.90. Found: C, 68.66; H, 6.72; N, 18.83.
Example 14
4-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahydro-2H-t-
hiopyran-4-ol
##STR00053##
[0369]
4-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahyd-
ro-2H-thiopyran-4-ol was prepared according to the method of
Example 1 Part F using
di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarb-
onate in lieu of
di(tert-butyl)1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicar-
bonate and 4-oxothiane in lieu of cyclobutanone. The crude product
was recrystallized from acetonitrile to provide 0.475 g of
4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]tetrahydro-2H--
thiopyran-4-ol as a white powder, mp 251.5-255.degree. C.
[0370] MS (ESI) m/z 343.29 (M+H).sup.+
[0371] Anal. Calcd for C.sub.18H.sub.22N.sub.4OS: C, 63.13; H,
6.48; N, 16.36; S, 9.36. Found: C, 63.02; H, 6.67; N, 16.37; S,
9.36.
Example 15
1-Acetyl-4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]piperi-
din-4-ol
##STR00054##
[0372] Part A
[0373]
4-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]piperidi-
n-4-ol was prepared according to the method of Example 1 Part F
using
di(tert-butyl)2-ethyl-1-methyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicarb-
onate in lieu of
di(tert-butyl)1-methyl-2-propyl-2H-pyrazolo[3,4-c]quinolin-4-ylimidodicar-
bonate and tert-butyl 4-oxopiperidine-1-carboxylate in lieu of
cyclobutanone. The crude product was recrystallized from
acetonitrile to provide 1.09 g of
1-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]piperidin-4-ol
as an off-white solid.
Part B
[0374] Acetic anhydride (88 .mu.L, 0.922 mmol) was added to a
slurry of
4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]piperidin-4-ol
(0.300 g, 0.922 mmol) in chloroform (10 mL). After 16 hours, the
solution was purified via automated flash chromatography eluting
with a linear gradient of 2-25% CMA in chloroform. The residue was
triturated in acetonitrile and isolated by filtration to provide
0.209 g of
1-acetyl-4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]piper-
idin-4-ol as a white solid, mp 231-232.5.degree. C.
[0375] MS (ESI) m/z 368.20 (M+H).sup.+
[0376] Anal. Calcd for C.sub.20H.sub.25N.sub.5O.sub.2: C, 65.37; H,
6.86; N, 19.06. Found: C, 65.14; H, 7.03; N, 19.25.
Example 16
4-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-1-(methylsulfo-
nyl)piperidin-4-ol
##STR00055##
[0378] Methanesulfonic anhydride (0.160 g, 0.922 mmol) was added to
a slurry of
4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]pipe-
ridin-4-ol (0.300 g, 0.922 mmol) in chloroform (10 mL). After 16
hours, 2M aqueous sodium carbonate was added and the biphasic
mixture was stirred for 30 minutes resulting in a white
precipitate. The mixture was extracted with 10% methanol in
dichloromethane. The solution was concentrated. The residue was
purified via automated flash chromatography and recrystallized from
acetonitrile to provide 0.165 g of
4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-1-(methylsulf-
onyl)piperidin-4-ol as a white solid, mp 268-270.degree. C.
[0379] MS (ESI) m/z 404.30 (M+H).sup.+
[0380] Anal. Calcd for
C.sub.19H.sub.25N.sub.5O.sub.3S.0.3H.sub.2O.0.15 CH.sub.3CN: C,
55.97; H, 6.32; N, 17.43; S, 7.74. Found: C, 56.33; H, 6.23; N,
17.56; S, 7.73.
Example 17
4-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-4-hydroxy-N-pr-
opylpiperidine-1-carboxamide
##STR00056##
[0382] n-Propyl isocyanate (86 .mu.L, 0.922 mmol) was added to a
slurry of
4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]piperidin-4-ol
(0.300 g, 0.922 mmol) in chloroform (10 mL). After 16 hours, the
solution was purified via automated flash chromatography eluting
with a linear gradient of 2-25% CMA in chloroform. The residue was
triturated in acetonitrile and isolated by filtration to provide
0.277 g of
4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-4-hydroxy-N-p-
ropylpiperidine-1-carboxamide as a flocculent white solid, mp
208.5-210.degree. C.
[0383] MS (ESI) m/z 411.28 (M+H).sup.+
[0384] Anal. Calcd for C.sub.22H.sub.30N.sub.6O.sub.2.0.3H.sub.2O:
C, 63.53; H, 7.42; N, 20.21. Found: C, 63.49; H, 7.16; N,
20.09.
Example 18
2-Ethyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c]quinolin-4-am-
ine
##STR00057##
[0386]
2-Ethyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c]quinol-
in-4-amine was prepared according to the methods of Example 3 parts
A-I. Ethylhydrazine oxalate was used in lieu of propylhydrazine
oxalate in part C. The crude product was recrystallized from
acetonitrile to provide 0.371 g of
2-ethyl-1-(tetrahydro-2H-pyran-4-ylmethyl)-2H-pyrazolo[3,4-c]quinolin-4-a-
mine as tan crystals, m.p. 226.0-228.0.degree. C.
[0387] MS (ESI) m/z 311.29 (M+H).sup.+
[0388] Anal. Calcd for C.sub.18H.sub.22N.sub.4O: C, 69.65; H, 7.14;
N, 18.05. Found: C, 69.81; H, 7.26; N, 18.29.
Example 19
1-[(4-Amino-2-ethyl-6,7,8,9-tetrahydro-2H-pyrazolo[3,4-c]quinolin-1-yl)met-
hyl]cyclohexanol
##STR00058##
[0390]
1-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]cyclohex-
anol (0.226 g, 0.70 mmol) and platinum(IV) oxide (0.107 g, 0.47
mmol) were slurried in trifluoroacetic acid (10 mL). The flask was
degassed three times and charged to 50 psi hydrogen
(3.45.times.10.sup.5 Pa). After 16 hours, the catalyst was removed
via filtration through a bed of CELITE filter agent, rinsing with
methanol. The filtrate was concentrated. The oily residue was
dissolved in 6N hydrochloric acid (3 mL). The acidic mixture was
brought to pH 14 using 50% aqueous sodium hydroxide. The mixture
was extracted with 10% methanol in dichloromethane, dried over
anhydrous sodium sulfate, and concentrated. The material was
purified via automated flash chromatography eluting with a linear
gradient of 2-20% CMA in chloroform. The resulting white solid was
triturated in acetonitrile and then isolated by filtration to
provide 0.085 g of
1-[(4-amino-2-ethyl-6,7,8,9-tetrahydro-2H-pyrazolo[3,4-c]quinolin-1-yl)me-
thyl]cyclohexanol as a white solid, m.p. 232-234.degree. C.
[0391] MS (ESI) m/z 329.44 (M+H).sup.+
[0392] Anal. Calcd for C.sub.19H.sub.28N.sub.4O: C, 69.48; H, 8.59;
N, 17.06. Found: C, 69.28; H, 8.51; N, 17.06.
Example 20
1-{[4-Fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-2-methyl-2H-pyrazolo-
[3,4-c]quinolin-4-amine
##STR00059##
[0393] Part A
[0394] The method described in Part A of Example 3 was followed
using 1-Boc-4-piperidinone (46.6 g, 0.234 mol) instead of
tetrahydro-4H-pyran-4-one. The crude product was purified by column
chromatography on silica gel (eluting with 5% ethyl acetate in
hexanes) and then concentrated from ethyl acetate/hexanes to
provide 23.7 g of tert-butyl
4-(2-oxopropylidene)piperidine-1-carboxylate as a white solid.
Part B
[0395] A solution of tert-butyl
4-(2-oxopropylidene)piperidine-1-carboxylate (20.0 g, 83.6 mmol)
and diethyl oxalate (24.9 mL, 2.2 equivalents (eq.)) in ethanol (15
mL) was added to a solution of potassium ethoxide (15.47 g, 2.2
eq.) in ethanol (170 mL) at room temperature. The addition vessel
was rinsed with ethanol (2.times.5 mL), and the rinses were added
to the reaction. The reaction was stirred for 1 hour and then
cooled in an ice bath to 4.degree. C. Acetic acid (100 mL) was
added, and the reaction was stirred for several minutes to allow
internal temp to return to 4.degree. C. Methyl hydrazine (19.4 mL,
4.4 eq) was added dropwise over a period of five minutes. After 15
minutes the ice bath was removed, and the reaction mixture was
stirred for 1 hour. The reaction mixture was concentrated under
reduced pressure and the residue was partitioned between water (300
mL) and dichloromethane (400 mL). Saturated aqueous sodium
carbonate (100 mL) was added portionwise followed by 50% aqueous
sodium hydroxide (40 mL) and 5% aqueous sodium hydroxide (100 mL)
to adjust the mixture to pH 8. The aqueous layer was separated and
extracted with dichloromethane (2.times.300 mL). The combined
organics were dried over magnesium sulfate and then concentrated
under reduced pressure to provide 38 g of brown oil. This material
was purified by automated flash chromatography (eluting with
tert-butyl methyl ether) to provide 6.2 g of tert-butyl
4-[(5-ethoxycarbonyl-2-methyl-2H-pyrazol-3-yl)methylene]piperidine-1-carb-
oxylate as a yellow oil.
Part C
[0396] The material from Part B (6.03 g, 17.2 mmol) was treated
according to the method of Part C of Example 7 with the
modification that at the end of the reaction, the reaction mixture
was cooled to 0.degree. C., and hydrochloric acid (40 mL of 1 M)
was added dropwise. Approximately half the solvent was removed
under reduced pressure, and a precipitate formed and was collected
by filtration, washed with cold water (2.times.25 mL), and dried
under high vacuum to provide 3.71 g of tert-butyl
4-[(5-carboxy-2-methyl-2H-pyrazol-3-yl)methylene]piperidine-1-carboxylate
as a white solid.
Part D
[0397] The material from Part C was treated according to the
methods of Parts D, E, and F of Example 7. The crude solid obtained
from Part F was partitioned between dichloromethane (200 mL) and
water (100 mL). The aqueous solution was separated and extracted
with chloroform (3.times.100 mL). The organic fractions were
combined, dried over magnesium sulfate, and filtered. The filter
cake was washed with chloroform (5.times.60 mL). The combined
filtrates were concentrated under reduced pressure to provide 6.33
g of white foam, which was suspended in chloroform (125 mL),
isolated by filtration, washed with chloroform (2.times.110 mL),
and dried to provide 3.8 g of tert-butyl
4-[(5-carbamoyl-2-methyl-2H-pyrazol-3-yl)methyl]-4-hydroxypiperidine-1-ca-
rboxylate as a white solid. The filtrate was concentrated and dried
to give an additional 3.0 g of product. Both solids contained
chloroform and a trace impurity.
Part E
[0398] The material from Part D was treated with triethylamine and
trifluoroacetic anhydride according to the method of Part G of
Example 7. The crude yellow oil that was obtained was purified by
automated flash chromatography (eluting with a gradient of 30%
hexanes in tert-butyl methyl ether to 100% tert-butyl methyl ether
over 4 column volumes and then 100% tert-butyl methyl ether for 3
column volumes) and dried under high vacuum to provide 3.62 of the
trifluoroacetate ester of tert-butyl
4-[(5-cyano-2-methyl-2H-pyrazol-3-yl)methyl]-4-hydroxypiperidine-1-carbox-
ylate as a colorless oil. A portion of the oil (3.43 g) was
dissolved in methanol (80 mL), and concentrated ammonium hydroxide
(1.6 mL) was added. The reaction was stirred for 1 hour and
concentrated under reduced pressure. The residue was concentrated
from chloroform (2.times.100 mL) and purified by automated flash
chromatography (eluting with 20% CMA in chloroform) to provide 2.50
g of tert-butyl 4-[(5-cyano-2-methyl-2H-pyrazol-3-yl)methyl]-4
hydroxypiperidine-1-carboxylate as a sticky white solid, which was
converted to tert-butyl
4-[(4-bromo-5-cyano-2-methyl-2H-pyrazol-3-yl)methyl]-4-fluoropiperidine-1-
-carboxylate according to the methods of Parts H and I of Example
7.
Part F
[0399] Hydrochloric acid (0.55 mL of 6 M) was added to a suspension
of tert-butyl
4-[(4-bromo-5-cyano-2-methyl-2H-pyrazol-3-yl)methyl]-4-fluoropiperidine-1-
-carboxylate (446 mg, 1.11 mmol) in ethanol (10 mL), and the
reaction was heated at 70.degree. C. for 1.5 hours, allowed to cool
to room temperature, and concentrated under reduced pressure to
provide
4-bromo-5-[(4-fluoropiperidin-4-yl)methyl]-1-methyl-1H-pyrazole-3-carboni-
trile hydrochloride as a white solid.
Part G
[0400] Triethylamine (0.62 mL, 4.0 eq.) was added to a stirred
suspension of the material from Part F in dichloromethane (11 mL),
and the mixture was cooled to 0.degree. C. Methanesulfonyl chloride
(0.095 mL, 1.1 eq.) was added, and the resulting solution was
stirred for 1.5 hours. Saturated aqueous sodium bicarbonate (20 mL)
was added, and the mixture was allowed to warm to room temperature
and diluted with dichloromethane (75 mL). The organic layer was
separated, dried over magnesium sulfate, filtered, and concentrated
under reduced pressure to provide 0.43 g of a white solid. The
solid was triturated with hot ethanol (15 mL), allowed to cool to
room temperature, isolated by filtration, washed with ethanol
(2.times.5 mL), and dried under high vacuum to provide 351 mg of
4-bromo-5-{[4-fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-1-methyl-1H-
-pyrazole-3-carbonitrile as a white solid.
Part H
[0401] The reaction conditions and purification methods described
in Part J of Example 7 were used to treat the material from Part G.
1-{[4-Fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-2-methyl-2H-pyrazol-
o[3,4-c]quinolin-4-amine (71 mg) was obtained as a tan powder, mp
283-285.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.17 (d, J=7.8 Hz, 1H), 7.47 (dd, J=1.2, 8.1 Hz, 1H), 7.32 (m, 1H),
7.17 (m, 1H), 6.67 (br s, 2H), 4.11 (s, 3H), 3.76 (dd, J=22.8 Hz,
2H), 3.46 (m, 2H), 2.86 (s, 3H), 2.80 (m, 2H), 1.98-2.28 (m, 2H),
1.86 (m, 2H); MS (APCI) 392 m/z (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.22FN.sub.5O.sub.2S: C, 55.23; H, 5.66; N, 17.89.
Found: C, 54.99; H, 5.55; N, 17.70.
Example 21
1-[(1-Acetyl-4-fluoropiperidin-4-yl)methyl]-2-methyl-2H-pyrazolo[3,4-c]qui-
nolin-4-amine
##STR00060##
[0402] Part A
[0403] Triethylamine (3.4 mL, 3.0 eq.) was added to a stirred
suspension of
4-bromo-5-[(4-fluoropiperidin-4-yl)methyl]-1-methyl-1H-pyrazole-3-carb-
onitrile hydrochloride (2.7 g, 8.0 mmol) in dichloromethane (80
mL), and the mixture was cooled to 0.degree. C. Acetyl chloride
(0.74 mL, 1.3 eq.) was added, and the resulting solution was
stirred for 1.5 hours and concentrated under reduced pressure. The
residue was dissolved in dichloromethane (300 mL), and the
resulting solution was washed with water (100 mL), dried over
magnesium sulfate, filtered, and concentrated under reduced
pressure to provide 2.58 g of a white foam. The foam was purified
by automated flash chromatography (eluting with a gradient of 0-20%
CMA in chloroform over 8 column volumes) to provide 0.94 g of
5-[(1-acetyl-4-fluoropiperidin-4-yl)methyl]-4-bromo-1-methyl-1H-pyrazole--
3-carbonitrile, which was concentrated from 1,2-dimethoxyethane (75
mL) prior to the next step.
Part B
[0404] The reaction conditions and purification methods described
in Part J of Example 7 were used to treat the material from Part A.
1-[(1-Acetyl-4-fluoropiperidin-4-yl)methyl]-2-methyl-2H-pyrazolo[3,4-c]qu-
inolin-4-amine (176 mg) was obtained as a white powder, mp
241-243.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta.
8.14 (d, J=7.9 Hz, 1H), 7.47 (dd, J=1.1, 8.1 Hz, 1H), 7.32 (m, 1H),
7.16 (m, 1H), 6.66 (br s, 2H), 4.30 (br d, J=12.7 Hz, 1H), 4.11 (s,
3H), 3.71 (d, J=22.4 Hz, 2H), 3.70 (m, 1H), 3.12 (m, 1H), 2.61 (m,
1H), 2.00 (s, 3H), 1.74-2.14 (m, 4H); MS (ESI) 356 m/z (M+H).sup.+;
Anal. calcd for C.sub.19H.sub.22FN.sub.5O: C, 64.21; H, 6.24; N,
19.70. Found: C, 64.21; H, 6.04; N, 19.73.
Example 22
4-[(4-Amino-2-methyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-4-fluoro-N-is-
opropylpiperidine-1-carboxamide
##STR00061##
[0405] Part A
[0406] Triethylamine (1.5 mL, 1.5 eq.) was added to a stirred
suspension of
4-bromo-5-[(4-fluoropiperidin-4-yl)methyl]-1-methyl-1H-pyrazole-3-carb-
onitrile hydrochloride (2.28 g, 6.75 mmol) in dichloromethane (67
mL), and isopropyl isocyanate (1.34 mL, 2.0 eq.) was added to the
resulting solution. The reaction was stirred for 1.5 hours and
concentrated under reduced pressure. The residue was dissolved in
dichloromethane (300 mL), and the resulting solution was washed
with water (100 mL), dried over magnesium sulfate, filtered, and
concentrated under reduced pressure to provide 2.45 g of a white
foam. The foam was purified by automated flash chromatography
(eluting with a gradient of 0-10% CMA in chloroform over 8 column
volumes) to provide 1.39 g of
4-[(4-bromo-5-cyano-2-methyl-2H-pyrazol-3-yl)methyl]-4-fluoro-N-isopropyl-
piperidine-1-carboxamide.
Part B
[0407] The reaction conditions and purification methods described
in Part J of Example 7 were used to treat the material from Part A.
4-[(4-Amino-2-methyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-4-fluoro-N-i-
sopropylpiperidine-1-carboxamide (0.14 g) was obtained as a white
powder, mp 241-244.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.14 (d, J=7.4 Hz, 1H), 7.47 (dd, J=1.2, 8.1 Hz, 1H), 7.32
(m, 1H), 7.16 (m, 1H), 6.65 (br s, 2H), 6.17 (d, J=7.6 Hz, 1H),
4.11 (s, 3H), 3.67-3.89 (m, 5H), 2.73 (m, 2H), 1.64-2.00 (m, 4H),
1.03 (d, J=6.6 Hz, 6H); MS (ESI) m/z 399 (M+H).sup.+; Anal. calcd
for C.sub.21H.sub.27FN.sub.6O.0.02CHCl.sub.3: C, 62.98; H, 6.79; N,
20.96. Found: C, 62.59; H, 6.60; N, 20.69.
Example 23
2-Ethyl-1-{[4-fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-2H-pyrazolo[-
3,4-c]quinolin-4-amine
##STR00062##
[0408] Part A
[0409] Starting with tert-butyl
4-(2-oxopropylidene)piperidine-1-carboxylate (25.0 g, 105 mmol) in
lieu of 1-tetrahydro-4H-pyran-4-ylideneacetone and ethyl hydrazine
oxalate (69.0 g, 460 mmol) in lieu of methyl hydrazine, the general
methods of Parts B through F of Example 7 were followed to provide
tert-butyl
4-[(5-carbamoyl-2-ethyl-2H-pyrazol-3-yl)methyl]-4-hydroxypiperidine-1-car-
boxylate (3.25 g, 9.22 mmol), which was treated with triethylamine
and trifluoroacetic anhydride according to the method of Part G of
Example 7. The crude yellow oil that was obtained was dissolved in
methanol (50 ml), and concentrated ammonium hydroxide (1.84 mL) was
added. The reaction was stirred for 1 hour and concentrated under
reduced pressure. The residue was partitioned between water (100
mL) and chloroform (100 mL). The aqueous layer was separated and
extracted with chloroform (2.times.100 mL). The combined organic
fractions were dried over magnesium sulfate, filtered, and
concentrated under reduced pressure. The residue was purified by
automated flash chromatography (eluting with chloroform for 4
column volumes and then a gradient of 0-20% CMA in chloroform over
6 column volumes) and dried under high vacuum to provide 2.56 g of
tert-butyl
4-[(5-cyano-2-ethyl-2H-pyrazol-3-yl)methyl]-4-hydroxypiperidine-1-carboxy-
late as a yellow oil, which was converted to tert-butyl
4-[(4-bromo-5-cyano-2-ethyl-2H-pyrazol-3-yl)methyl]-4-fluoropiperidine-1--
carboxylate according to the methods of Parts H and I of Example
7.
Part B
[0410] Hydrochloric acid (2.64 mL of 6 M) was added to a suspension
of tert-butyl
4-[(4-bromo-5-cyano-2-ethyl-2H-pyrazol-3-yl)methyl]-4-fluoropiperidine-1--
carboxylate (3.3 g, 7.95 mmol) in ethanol (80 mL), and the reaction
was heated at 80.degree. C. for 2 hours, allowed to cool to room
temperature, and concentrated under reduced pressure to provide
4-bromo-1-ethyl-5-[(4-fluoropiperidin-4-yl)methyl-1H-pyrazole-3-carbonitr-
ile hydrochloride as a white solid.
Part C
[0411] Triethylamine (11.1 mL, 79.5 mmol) and methanesulfonyl
chloride (1.24 mL, 15.9 mmol) were sequentially added to a mixture
of the material from Part B in dichloromethane (80 mL), and the
reaction was stirred for 5 minutes. Brine (40 mL) was added, and
the aqueous layer was separated and extracted with dichloromethane
(2.times.100 mL). The combined organic fractions were dried over
magnesium sulfate, filtered, and concentrated under reduced
pressure to provide a brown foam. The foam was purified by
automated flash chromatography (eluting with a gradient of 0-10%
CMA in chloroform over 8 column volumes) to provide 1.9 g of
4-bromo-1-ethyl-5-{[4-fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-1H--
pyrazole-3-carbonitrile as a tan foam.
Part D
[0412] The general reaction conditions and purification methods
described in Part J of Example 7 were used to treat the material
from Part C (1.0 g).
2-Ethyl-1-{[4-fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-2H-pyra-
zolo[3,4-c]quinolin-4-amine (150 mg) was obtained as a light tan
solid, mp 269-271.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
8.16 (d, J=7.7 Hz, 1H), 7.48 (dd, J=8.0, 1.1 Hz, 1H), 7.32 (td,
J=7.5, 1.0 Hz, 1H), 7.18 (td, J=7.5, 1.2 Hz, 1H), 6.64 (s, 2H),
4.44 (q, J=7.2 Hz, 2H), 3.76 (d, J=22.9 Hz, 2H), 3.46 (d, J=11.2
Hz, 2H), 2.86 (s, 3H), 2.80 (t, J=12.3 Hz, 2H), 2.03 (m, 4H), 1.49
(t, J=7.1 Hz, 3H), 1.03 (d, J=6.6 Hz, 6H); MS (EI) m/z 406
(M+H).sup.+; Anal. calcd for C.sub.19H.sub.24FN.sub.5O.sub.2S: C,
56.28; H, 5.97; N, 17.27. Found: C, 55.99; H, 5.71; N, 17.05.
Example 24
1-[(1-Acetyl-4-fluoropiperidin-4-yl)methyl]-2-ethyl-2H-pyrazolo[3,4-c]quin-
olin-4-amine
##STR00063##
[0413] Part A
[0414] Triethylamine (3.35 mL, 24.0 mmol) was added to a stirred
suspension of
4-bromo-1-ethyl-5-[(4-fluoropiperidin-4-yl)methyl-1H-pyrazole-3-carbonitr-
ile hydrochloride (2.52 g, 8.0 mmol) in dichloromethane (80 mL),
and the resulting solution was cooled to 0.degree. C. Acetyl
chloride (0.74 mL, 10.4 mmol) was added dropwise, and the resulting
solution was stirred for 1 hour. Water (50 mL) was added, and then
the aqueous layer was separated and extracted with dichloromethane
(2.times.100 mL). The combined organic fractions were dried over
magnesium sulfate, filtered, and concentrated under reduced
pressure to provide a brown foam. The foam was purified by
automated flash chromatography (eluting with a gradient of 0-10%
CMA in chloroform over 8 column volumes) and dried under high
vacuum to provide 1.6 g of
5-[(1-acetyl-4-fluoropiperidin-4-yl)methyl]-4-bromo-1-ethyl-1H-p-
yrazole-3-carbonitrile.
Part B
[0415] The reaction conditions described in Part J of Example 7
were used to treat the material from Part A. Following
chromatographic purification (eluting with chloroform for 4 column
volumes, followed by a gradient of 0-40% CMA in chloroform over 6
column volumes, followed by 40% CMA in chloroform) the resulting
oil was recrystallized from acetonitrile. The solid was isolated by
filtration, washed with acetonitrile, and dried under high vacuum
to provide 121 mg of
1-[(1-acetyl-4-fluoropiperidin-4-yl)methyl]-2-ethyl-2H-pyrazolo[3,4-c]qui-
nolin-4-amine as a light tan solid, mp 228-230.degree. C. .sup.1H
NMR (300 MHz, DMSO-d.sub.6): 8.14 (d, J=7.8 Hz, 1H), 7.48 (dd,
J=8.1, 1.2 Hz, 1H), 7.31 (td, J=7.5, 1.1 Hz, 1H), 7.16 (td, J=7.4,
1.2 Hz, 1H), 6.64 (s, 2H), 4.44 (q, J=7.2 Hz, 2H), 4.30 (d, J=12.2
Hz, 1H), 3.71 (m, 3H), 3.12 (t, J=12.4 Hz, 1H), 2.60 (t, J=12.8 Hz,
1H), 2.00 (s, 3H), 1.93 (m, 4H), 1.48 (t, J=7.1 Hz, 3H); MS (EI)
m/z 370 (M+H).sup.+; Anal. calcd for C.sub.20H.sub.24FN.sub.5O: C,
65.02; H, 6.55; N, 18.96. Found: C, 65.07; H, 6.32; N, 19.12.
Example 25
4-[(4-Amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-4-fluoro-N-iso-
propylpiperidine-1-carboxamide
##STR00064##
[0416] Part A
[0417] Triethylamine (2.23 mL, 16.0 mmol) and isopropyl isocyanate
(1.01 mL, 10.4 mmol) were sequentially added to a mixture of
4-bromo-1-ethyl-5-[(4-fluoropiperidin-4-yl)methyl-1H-pyrazole-3-carbonitr-
ile hydrochloride (2.52 g, 8.0 mmol) and dichloromethane (40 mL).
The reaction was stirred for 1.5 hours and diluted with
dichloromethane (250 mL), washed with water (100 mL), dried over
magnesium sulfate, filtered, and concentrated under reduced
pressure to provide a brown foam. The foam was purified by
automated flash chromatography (eluting with a gradient of 0-10%
CMA in chloroform over 8 column volumes). The resulting off-white
foam was concentrated from 1,2-dimethoxyethane (50 mL), and dried
under high vacuum to provide 1.6 g of
4-[(4-bromo-5-cyano-2-ethyl-2H-pyrazol-3-yl)methyl]-4-fluoro-N-isopropylp-
iperidine-1-carboxamide.
Part B
[0418] The reaction conditions described in Part J of Example 7
were used to treat the material from Part A. Following
chromatographic purification using the conditions described in Part
B of Example 24, the resulting brown solid was recrystallized from
ethanol and dried to provide 93 mg of
4-[(4-amino-2-ethyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-4-fluoro-N-is-
opropylpiperidine-1-carboxamide as a white solid, mp
205-207.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): 8.14 (d,
J=7.8 Hz, 1H), 7.48 (dd, J=8.1, 1.1 Hz, 1H), 7.31 (td, J=7.5, 1.1
Hz, 1H), 7.16 (td, J=7.4, 1.2 Hz, 1H), 6.63 (s, 2H), 6.17 (d, J=7.6
Hz, 1H), 4.44 (q, J=7.2 Hz, 2H), 3.78 (m, 5H), 2.73 (t, J=12.1 Hz,
2H), 1.81 (m, 4H), 1.47 (t, J=7.1 Hz, 3H), 1.03 (6, J=6.6 Hz, 6H);
MS (EI) m/z 413 (M+H).sup.+; Anal. calcd for
C.sub.22H.sub.29FN.sub.6O: C, 64.06; H, 7.09; N, 20.37. Found: C,
63.93; H, 7.17; N, 20.30.
Example 26
1-{[4-Fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-2-propyl-2H-pyrazolo-
[3,4-c]quinolin-4-amine
##STR00065##
[0419] Part A
[0420] Starting with tert-butyl
4-(2-oxopropylidene)piperidine-1-carboxylate (20.0 g, 83.6 mmol) in
lieu of 1-tetrahydro-4H-pyran-4-ylideneacetone and propyl hydrazine
oxalate (34.3 g, 2.5 eq.) in lieu of methyl hydrazine, the general
methods of Parts B through F of Example 7 were followed to provide
tert-butyl
4-[(5-carbamoyl-2-propyl-2H-pyrazol-3-yl)methyl]-4-hydroxypiperidine-1-ca-
rboxylate (6.20 g, 16.9 mmol), which was treated with triethylamine
and trifluoroacetic anhydride according to the method of Part G of
Example 7. The crude yellow oil that was obtained was dissolved in
methanol (45 mL), and concentrated ammonium hydroxide (3.4 mL) was
added. The reaction was stirred for 1 hour and concentrated under
reduced pressure. The residue was partitioned between water (150
mL) and chloroform (200 mL). The organic layer was separated and
dried over magnesium sulfate, filtered, and concentrated under
reduced pressure. The residue was purified twice by automated flash
chromatography (eluting first with a gradient of 0-40% CMA in
chloroform over 5 column volumes and second with a gradient of
0-50% ethyl acetate in chloroform over 5 column volumes) to provide
4.52 g of tert-butyl
4-[(5-cyano-2-propyl-2H-pyrazoly-3-yl)methyl]-4-hydroxypiperidine-1-carbo-
xylate as a viscous semisolid, which was converted to tert-butyl
4-[(4-bromo-5-cyano-2-propyl-2H-pyrazol-3-yl)methyl]-4-fluoropiperidine-1-
-carboxylate according to the methods of Parts H and I of Example
7.
Part B
[0421] Hydrochloric acid (3.9 mL of 6 M) was added to a solution of
tert-butyl
4-[(4-bromo-5-cyano-2-propyl-2H-pyrazol-3-yl)methyl]-4-fluoropiperidine-1-
-carboxylate (3.34 g, 7.78 mmol) in ethanol (40 mL), and the
reaction was heated at 70.degree. C. for 1.5 hours, allowed to cool
to room temperature, and concentrated under reduced pressure to
provide 2.9 g of
4-bromo-5-[(4-fluoropiperidin-4-yl)methyl]-1-propyl-1H-pyrazole-3-carboni-
trile hydrochloride. The salt was suspended in dichloromethane (40
mL), and triethylamine (4.9 mL, 4.5 eq.) was added. The mixture was
stirred for ten minutes to provide a 0.2 M solution of
4-bromo-5-[(4-fluoropiperidin-4-yl)methyl]-1-propyl-1H-pyrazole-3-carboni-
trile.
Part C
[0422] A portion of the solution from Part B (24 mL) was cooled to
0.degree. C. Methanesulfonyl chloride (0.42 mL, 1.3 eq.) was added
dropwise, and the resulting solution was stirred for 1 hour,
diluted with dichloromethane (150 mL), and allowed to warm to room
temperature. The solution was washed with saturated aqueous sodium
bicarbonate (100 mL), dried over magnesium sulfate, filtered, and
concentrated under reduced pressure to provide a white foam. The
foam was purified by automated flash chromatography (eluting with a
gradient of 0-15% CMA in chloroform) to provide 1.5 g of
4-bromo-5-{[4-fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-1-propyl-1H-
-pyrazole-3-carbonitrile as a white foam. The foam was concentrated
from 1,2-dimethoxyethane (40 mL) before it was used in Part D.
Part D
[0423] The reaction conditions and purification methods described
in Part J of Example 7 were used to treat the material from Part C.
1-{[4-Fluoro-1-(methylsulfonyl)piperidin-4-yl]methyl}-2-propyl-2H-pyrazol-
o[3,4-c]quinolin-4-amine (0.32 g) was obtained as a white powder,
mp 268-270.degree. C., dec. .sup.1H NMR (300 MHz, DMSO-d.sub.6):
.delta. 8.16 (d, J=7.9 Hz, 1H), 7.48 (dd, J=1.2, 8.1 Hz, 1H), 7.32
(m, 1H), 7.17 (m, 1H), 6.64 (br s, 2H), 4.36 (t, J=7.2 Hz, 2H),
3.76 (d, J=22.3 Hz, 2H), 3.46 (m, 2H), 2.85 (s, 3H), 2.80 (m, 2H),
1.80 (m, 6H), 0.90 (t J=7.5 Hz, 3H); MS (ESI) m/z 420 (M+H).sup.+;
Anal. calcd for C.sub.20H.sub.26FN.sub.5O.sub.2S: C, 57.26; H,
6.25; N, 16.69. Found: C, 57.03; H, 6.33; N, 16.71.
Example 27
4-[(4-Amino-2-propyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-4-fluoro-N-is-
opropylpiperidine-1-carboxamide
##STR00066##
[0424] Part A
[0425] Isopropyl isocyanate (0.46 mL, 1.3 eq.) was added dropwise
to a portion of the solution from Part B of Example 26 (21 mL) at
room temperature. The resulting solution was stirred for 1 hour,
diluted with dichloromethane (100 mL), washed with water (70 mL),
dried over magnesium sulfate, filtered, and concentrated under
reduced pressure to provide 1.48 g of a tan foam. The foam was
purified by automated flash chromatography (eluting with a gradient
of 0-10% CMA in chloroform over 8 column volumes) to provide 1.05 g
of
4-(4-bromo-5-cyano-2-propyl-2H-pyrazol-3-ylmethyl)-4-fluoro-N-isopropylpi-
peridine-1-carboxamide as a white foam.
Part B
[0426] The reaction conditions and purification methods described
in Part J of Example 7 were used to treat the material from Part A.
4-[(4-Amino-2-propyl-2H-pyrazolo[3,4-c]quinolin-1-yl)methyl]-4-fluoro-N-i-
sopropylpiperidine-1-carboxamide (105 mg) was obtained as a white
powder, mp 227-229.degree. C., dec. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): .delta. 8.13 (d, J=7.6 Hz, 1H), 7.47 (dd, J=1.1, 8.1
Hz, 1H), 7.31 (m, 1H), 7.16 (m, 1H), 6.63 (br s, 2H), 6.17 (d,
J=7.6 Hz, 1H), 4.36 (t, J=7.6 Hz, 2H), 3.68-3.89 (m, 5H), 2.72 (t,
J=11.9 Hz, 2H), 1.62-1.98 (m, 6H), 1.03 (d, J=6.6 Hz, 6H), 0.09 (t,
J=7.6 Hz, 3H); MS (ESI) m/z 427 (M+H).sup.+; Anal. calcd for
C.sub.23H.sub.31FN.sub.6O: C, 64.77; H, 7.33; N, 19.70. Found: C,
64.67; H, 7.23; N, 19.65.
Exemplary Compounds
[0427] Certain exemplary compounds, including some of those
described above in the Examples, have the following Formulas
(III-1, IV-1, V-1, or VIII-1) and the following R.sub.2, Z,
R.sub.1, and m substituents or variables, wherein each line of the
table is matched with Formula III-1, IV-1, V-1, or VIII-1 to
represent a specific embodiment of the invention.
TABLE-US-00001 III-1 ##STR00067## IV-1 ##STR00068## V-1
##STR00069## VIII-1 ##STR00070## R.sub.2 Z R.sub.1 m methyl Bond
--OH 1 methyl Bond --OH 2 methyl Bond --OCH.sub.3 1 methyl Bond
--OCH.sub.3 2 methyl Bond --F 1 methyl Bond --F 2 methyl
--CH.sub.2-- --OH 1 methyl --CH.sub.2-- --OH 2 methyl --CH.sub.2--
--OCH.sub.3 1 methyl --CH.sub.2-- --OCH.sub.3 2 methyl --CH.sub.2--
--F 1 methyl --CH.sub.2-- --F 2 methyl --CH.sub.2CH.sub.2-- --OH 1
methyl --CH.sub.2CH.sub.2-- --OH 2 methyl --CH.sub.2CH.sub.2--
--OCH.sub.3 1 methyl --CH.sub.2CH.sub.2-- --OCH.sub.3 2 methyl
--CH.sub.2CH.sub.2-- --F 1 methyl --CH.sub.2CH.sub.2-- --F 2 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 1 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 1 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 2 methyl --CH.sub.2--O--CH.sub.2--
--OH 1 methyl --CH.sub.2--O--CH.sub.2-- --OH 2 methyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 methyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 methyl
--CH.sub.2--O--CH.sub.2-- --F 1 methyl --CH.sub.2--O--CH.sub.2--
--F 2 ethyl Bond --OH 1 ethyl Bond --OH 2 ethyl Bond --OCH.sub.3 1
ethyl Bond --OCH.sub.3 2 ethyl Bond --F 1 ethyl Bond --F 2 ethyl
--CH.sub.2-- --OH 1 ethyl --CH.sub.2-- --OH 2 ethyl --CH.sub.2--
--OCH.sub.3 1 ethyl --CH.sub.2-- --OCH.sub.3 2 ethyl --CH.sub.2--
--F 1 ethyl --CH.sub.2-- --F 2 ethyl --CH.sub.2CH.sub.2-- --OH 1
ethyl --CH.sub.2CH.sub.2-- --OH 2 ethyl --CH.sub.2CH.sub.2--
--OCH.sub.3 1 ethyl --CH.sub.2CH.sub.2-- --OCH.sub.3 2 ethyl
--CH.sub.2CH.sub.2-- --F 1 ethyl --CH.sub.2CH.sub.2-- --F 2 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 1 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 1 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 2 ethyl --CH.sub.2--O--CH.sub.2--
--OH 1 ethyl --CH.sub.2--O--CH.sub.2-- --OH 2 ethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 ethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 ethyl
--CH.sub.2--O--CH.sub.2-- --F 1 ethyl --CH.sub.2--O--CH.sub.2-- --F
2 n-propyl Bond --OH 1 n-propyl Bond --OH 2 n-propyl Bond
--OCH.sub.3 1 n-propyl Bond --OCH.sub.3 2 n-propyl Bond --F 1
n-propyl Bond --F 2 n-propyl --CH.sub.2-- --OH 1 n-propyl
--CH.sub.2-- --OH 2 n-propyl --CH.sub.2-- --OCH.sub.3 1 n-propyl
--CH.sub.2-- --OCH.sub.3 2 n-propyl --CH.sub.2-- --F 1 n-propyl
--CH.sub.2-- --F 2 n-propyl --CH.sub.2CH.sub.2-- --OH 1 n-propyl
--CH.sub.2CH.sub.2-- --OH 2 n-propyl --CH.sub.2CH.sub.2--
--OCH.sub.3 1 n-propyl --CH.sub.2CH.sub.2-- --OCH.sub.3 2 n-propyl
--CH.sub.2CH.sub.2-- --F 1 n-propyl --CH.sub.2CH.sub.2-- --F 2
n-propyl --CH.sub.2CH.sub.2CH.sub.2-- --OH 1 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 1 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 2 n-propyl
--CH.sub.2--O--CH.sub.2-- --OH 1 n-propyl --CH.sub.2--O--CH.sub.2--
--OH 2 n-propyl --CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 n-propyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 yn-propyl
--CH.sub.2--O--CH.sub.2-- --F 1 n-propyl --CH.sub.2--O--CH.sub.2--
--F 2 n-butyl Bond --OH 1 n-butyl Bond --OH 2 n-butyl Bond
--OCH.sub.3 1 n-butyl Bond --OCH.sub.3 2 n-butyl Bond --F 1 n-bulyl
Bond --F 2 n-butyl --CH.sub.2-- --OH 1 n-butyl --CH.sub.2-- --OH 2
n-butyl --CH.sub.2-- --OCH.sub.3 1 n-butyl --CH.sub.2-- --OCH.sub.3
2 n-butyl --CH.sub.2-- --F 1 n-butyl --CH.sub.2-- --F 2 n-butyl
--CH.sub.2CH.sub.2-- --OH 1 n-butyl --CH.sub.2CH.sub.2-- --OH 2
n-butyl --CH.sub.2CH.sub.2-- --OCH.sub.3 1 n-butyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 2 n-butyl --CH.sub.2CH.sub.2-- --F
1 n-butyl --CH.sub.2CH.sub.2-- --F 2 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 1 n-bulyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 1 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 2 n-butyl
--CH.sub.2--O--CH.sub.2-- --OH 1 n-butyl --CH.sub.2--O--CH.sub.2--
--OH 2 n-butyl --CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 n-butyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 n-butyl
--CH.sub.2--O--CH.sub.2-- --F 1 n-butyl --CH.sub.2--O--CH.sub.2--
--F 2 2-hydroxyethyl Bond --OH 1 2-hydroxyethyl Bond --OH 2
2-hydroxyethyl Bond --OCH.sub.3 1 2-hydroxyethyl Bond --OCH.sub.3 2
2-hydroxyethyl Bond --F 1 2-hydroxyethyl Bond --F 2 2-hydroxyethyl
--CH.sub.2-- --OH 1 2-hydroxyethyl --CH.sub.2-- --OH 2
2-hydroxyethyl --CH.sub.2-- --OCH.sub.3 1 2-hydroxyethyl
--CH.sub.2-- --OCH.sub.3 2 2-hydroxyethyl --CH.sub.2-- --F 1
2-hydroxyethyl --CH.sub.2-- --F 2 2-hydroxyethyl
--CH.sub.2CH.sub.2-- --OH 1 2-hydroxyethyl --CH.sub.2CH.sub.2--
--OH 2 2-hydroxyethyl --CH.sub.2CH.sub.2-- --OCH.sub.3 1
2-hydroxyethyl --CH.sub.2CH.sub.2-- --OCH.sub.3 2 2-hydroxyethyl
--CH.sub.2CH.sub.2-- --F 1 2-hydroxyethyl --CH.sub.2CH.sub.2-- --F
2 2-hydroxyethyl --CH.sub.2CH.sub.2CH.sub.2-- --OH 1 2-hydroxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 2-hydroxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 2-hydroxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 2-hydroxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 1 2-hydroxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 2 2-hydroxyethyl
--CH.sub.2--O--CH.sub.2-- --OH 1 2-hydroxyethyl
--CH.sub.2--O--CH.sub.2-- --OH 2 2-hydroxyethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 2-hydroxyethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 2-hydroxyethyl
--CH.sub.2--O--CH.sub.2-- --F 1 2-hydroxyethyl
--CH.sub.2--O--CH.sub.2-- --F 2 2-methoxyethyl Bond --OH 1
2-methoxyethyl Bond --OH 2 2-methoxyethyl Bond --OCH.sub.3 1
2-methoxyethyl Bond --OCH.sub.3 2 2-methoxyethyl Bond --F 1
2-methoxyethyl Bond --F 2 2-methoxyethyl --CH.sub.2-- --OH 1
2-methoxyethyl --CH.sub.2 --OH 2 2-methoxyethyl --CH.sub.2
--OCH.sub.3 1 2-methoxyethyl --CH.sub.2-- --OCH.sub.3 2
2-methoxyethyl --CH.sub.2 --F 1 2-methoxyethyl --CH.sub.2-- --F 2
2-methoxyethyl --CH.sub.2CH.sub.2-- --OH 1 2-methoxyethyl
--CH.sub.2CH.sub.2-- --OH 2 2-methoxyethyl --CH.sub.2CH.sub.2--
--OCH.sub.3 1 2-methoxyethyl --CH.sub.2CH.sub.2-- --OCH.sub.3 2
2-methoxyethyl --CH.sub.2CH.sub.2-- --F 1 2-methoxyethyl
--CH.sub.2CH.sub.2-- --F 2 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 1 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 1 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --F 2 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OH 1 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OH 2 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --F 1 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --F 2
[0428] Certain exemplary compounds, including some of those
described above in the Examples, have the following Formulas
(III-2, IV-2, V-2, and VIII-2) wherein R.sub.2, Q, R.sub.4,
R.sub.1, and m are defined immediately below in the table. Each row
of the table is matched with Formula III-2, IV-2, V-2, or VIII-2 to
represent a specific embodiment of the invention.
TABLE-US-00002 III-2 ##STR00071## IV-2 ##STR00072## V-2
##STR00073## VIII-2 ##STR00074## R.sub.2 Q R.sub.4 R.sub.1 m methyl
Bond methyl --OH 1 methyl Bond methyl --OH 2 methyl Bond methyl
--OCH.sub.3 1 methyl Bond methyl --OCH.sub.3 2 methyl Bond ethyl
--OH 1 methyl Bond ethyl --OH 2 methyl Bond ethyl --OCH.sub.3 1
methyl Bond ethyl --OCH.sub.3 2 methyl Bond isopropyl --OH 1 methyl
Bond isopropyl --OH 2 methyl Bond isopropyl --OCH.sub.3 1 methyl
Bond isopropyl --OCH.sub.3 2 methyl Bond phenyl --OH 1 methyl Bond
phenyl --OH 2 methyl Bond phenyl --OCH.sub.3 1 methyl Bond phenyl
--OCH.sub.3 2 methyl --C(O)-- methyl --OH 1 methyl --C(O)-- methyl
--OH 2 methyl --C(O)-- methyl --OCH.sub.3 1 methyl --C(O)-- methyl
--OCH.sub.3 2 methyl --C(O)-- ethyl --OH 1 methyl --C(O)-- ethyl
--OH 2 methyl --C(O)-- ethyl --OCH.sub.3 1 methyl --C(O)-- ethyl
--OCH.sub.3 2 methyl --C(O)-- isopropyl --OH 1 methyl --C(O)--
isopropyl --OH 2 methyl --C(O)-- isopropyl --OCH.sub.3 1 methyl
--C(O)-- isopropyl --OCH.sub.3 2 methyl --C(O)-- phenyl --OH 1
methyl --C(O)-- phenyl --OH 2 methyl --C(O)-- phenyl --OCH.sub.3 1
methyl --C(O)-- phenyl --OCH.sub.3 2 methyl --S(O).sub.2-- methyl
--OH 1 methyl --S(O).sub.2-- methyl --OH 2 methyl --S(O).sub.2--
methyl --OCH.sub.3 1 methyl --S(O).sub.2-- methyl --OCH.sub.3 2
methyl --S(O).sub.2-- ethyl --OH 1 methyl --S(O).sub.2-- ethyl --OH
2 methyl --S(O).sub.2-- ethyl --OCH.sub.3 1 methyl --S(O).sub.2--
ethyl --OCH.sub.3 2 methyl --S(O).sub.2-- isopropyl --OH 1 methyl
--S(O).sub.2-- isopropyl --OH 2 methyl --S(O).sub.2-- isopropyl
--OCH.sub.3 1 methyl --S(O).sub.2-- isopropyl --OCH.sub.3 2 methyl
--S(O).sub.2-- phenyl --OH 1 methyl --S(O).sub.2-- phenyl --OH 2
methyl --S(O).sub.2-- phenyl --OCH.sub.3 1 methyl --S(O).sub.2--
phenyl --OCH.sub.3 2 methyl --C(O)--NH-- methyl --OH 1 methyl
--C(O)--NH-- methyl --OH 2 methyl --C(O)--NH-- methyl --OCH.sub.3 1
methyl --C(O)--NH-- methyl --OCH.sub.3 2 methyl --C(O)--NH-- ethyl
--OH 1 methyl --C(O)--NH-- ethyl --OH 2 methyl --C(O)--NH-- ethyl
--OCH.sub.3 1 methyl --C(O)--NH-- ethyl --OCH.sub.3 2 methyl
--C(O)--NH-- isopropyl --OH 1 methyl --C(O)--NH-- isopropyl --OH 2
methyl --C(O)--NH-- isopropyl --OCH.sub.3 1 methyl --C(O)--NH--
isopropyl --OCH.sub.3 2 methyl --C(O)--NH-- phenyl --OH 1 methyl
--C(O)--NH-- phenyl --OH 2 methyl --C(O)--NH-- phenyl --OCH.sub.3 1
methyl --C(O)--NH-- phenyl --OCH.sub.3 2 ethyl Bond methyl --OH 1
ethyl Bond methyl --OH 2 ethyl Bond methyl --OCH.sub.3 1 ethyl Bond
methyl --OCH.sub.3 2 ethyl Bond ethyl --OH 1 ethyl Bond ethyl --OH
2 ethyl Bond ethyl --OCH.sub.3 1 ethyl Bond ethyl --OCH.sub.3 2
ethyl Bond isopropyl --OH 1 ethyl Bond isopropyl --OH 2 ethyl Bond
isopropyl --OCH.sub.3 1 ethyl Bond isopropyl --OCH.sub.3 2 ethyl
Bond phenyl --OH 1 ethyl Bond phenyl --OH 2 ethyl Bond phenyl
--OCH.sub.3 1 ethyl Bond phenyl --OCH.sub.3 2 ethyl --C(O)-- methyl
--OH 1 ethyl --C(O)-- methyl --OH 2 ethyl --C(O)-- methyl
--OCH.sub.3 1 ethyl --C(O)-- methyl --OCH.sub.3 2 ethyl --C(O)--
ethyl --OH 1 ethyl --C(O)-- ethyl --OH 2 ethyl --C(O)-- ethyl
--OCH.sub.3 1 ethyl --C(O)-- ethyl --OCH.sub.3 2 ethyl --C(O)--
isopropyl --OH 1 ethyl --C(O)-- isopropyl --OH 2 ethyl --C(O)--
isopropyl --OCH.sub.3 1 ethyl --C(O)-- isopropyl --OCH.sub.3 2
ethyl --C(O)-- phenyl --OH 1 ethyl --C(O)-- phenyl --OH 2 ethyl
--C(O)-- phenyl --OCH.sub.3 1 ethyl --C(O)-- phenyl --OCH.sub.3 2
ethyl --S(O).sub.2-- methyl --OH 1 ethyl --S(O).sub.2-- methyl --OH
2 ethyl --S(O).sub.2-- methyl --OCH.sub.3 1 ethyl --S(O).sub.2--
methyl --OCH.sub.3 2 ethyl --S(O).sub.2-- ethyl --OH 1 ethyl
--S(O).sub.2-- ethyl --OH 2 ethyl --S(O).sub.2-- ethyl --OCH.sub.3
1 ethyl --S(O).sub.2-- ethyl --OCH.sub.3 2 ethyl --S(O).sub.2--
isopropyl --OH 1 ethyl --S(O).sub.2-- isopropyl --OH 2 ethyl
--S(O).sub.2-- isopropyl --OCH.sub.3 1 ethyl --S(O).sub.2--
isopropyl --OCH.sub.3 2 ethyl --S(O).sub.2-- phenyl --OH 1 ethyl
--S(O).sub.2-- phenyl --OH 2 ethyl --S(O).sub.2-- phenyl
--OCH.sub.3 1 ethyl --S(O).sub.2-- phenyl --OCH.sub.3 2 ethyl
--C(O)--NH-- methyl --OH 1 ethyl --C(O)--NH-- methyl --OH 2 ethyl
--C(O)--NH-- methyl --OCH.sub.3 1 ethyl --C(O)--NH-- methyl
--OCH.sub.3 2 ethyl --C(O)--NH-- ethyl --OH 1 ethyl --C(O)--NH--
ethyl --OH 2 ethyl --C(O)--NH-- ethyl --OCH.sub.3 1 ethyl
--C(O)--NH-- ethyl --OCH.sub.3 2 ethyl --C(O)--NH-- isopropyl --OH
1 ethyl --C(O)--NH-- isopropyl --OH 2 ethyl --C(O)--NH-- isopropyl
--OCH.sub.3 1 ethyl --C(O)--NH-- isopropyl --OCH.sub.3 2 ethyl
--C(O)--NH-- phenyl --OH 1 ethyl --C(O)--NH-- phenyl --OH 2 ethyl
--C(O)--NH-- phenyl --OCH.sub.3 1 ethyl --C(O)--NH-- phenyl
--OCH.sub.3 2 n-propyl Bond methyl --OH 1 n-propyl Bond methyl --OH
2 n-propyl Bond methyl --OCH.sub.3 1 n-propyl Bond methyl
--OCH.sub.3 2 n-propyl Bond ethyl --OH 1 n-propyl Bond ethyl --OH 2
n-propyl Bond ethyl --OCH.sub.3 1 n-propyl Bond ethyl --OCH.sub.3 2
n-propyl Bond isopropyl --OH 1 n-propyl Bond isopropyl --OH 2
n-propyl Bond isopropyl --OCH.sub.3 1 n-propyl Bond isopropyl
--OCH.sub.3 2 n-propyl Bond phenyl --OH 1 n-propyl Bond phenyl --OH
2 n-propyl Bond phenyl --OCH.sub.3 1 n-propyl Bond phenyl
--OCH.sub.3 2 n-propyl --C(O)-- methyl --OH 1 n-propyl --C(O)--
methyl --OH 2 n-propyl --C(O)-- methyl --OCH.sub.3 1 n-propyl
--C(O)-- methyl --OCH.sub.3 2 n-propyl --C(O)-- ethyl --OH 1
n-propyl --C(O)-- ethyl --OH 2 n-propyl --C(O)-- ethyl --OCH.sub.3
1 n-propyl --C(O)-- ethyl --OCH.sub.3 2 n-propyl --C(O)-- isopropyl
--OH 1 n-propyl --C(O)-- isopropyl --OH 2 n-propyl --C(O)--
isopropyl --OCH.sub.3 1 n-propyl --C(O)-- isopropyl --OCH.sub.3 2
n-propyl --C(O)-- phenyl --OH 1 n-propyl --C(O)-- phenyl --OH 2
n-propyl --C(O)-- phenyl --OCH.sub.3 1 n-propyl --C(O)-- phenyl
--OCH.sub.3 2 n-propyl --S(O).sub.2-- methyl --OH 1 n-propyl
--S(O).sub.2-- methyl --OH 2 n-propyl --S(O).sub.2-- methyl
--OCH.sub.3 1 n-propyl --S(O).sub.2-- methyl --OCH.sub.3 2 n-propyl
--S(O).sub.2-- ethyl --OH 1 n-propyl --S(O).sub.2-- ethyl --OH 2
n-propyl --S(O).sub.2-- ethyl --OCH.sub.3 1 n-propyl --S(O).sub.2--
ethyl --OCH.sub.3 2 n-propyl --S(O).sub.2-- isopropyl --OH 1
n-propyl --S(O).sub.2-- isopropyl --OH 2 n-propyl --S(O).sub.2--
isopropyl --OCH.sub.3 1 n-propyl --S(O).sub.2-- isopropyl
--OCH.sub.3 2 n-propyl --S(O).sub.2-- phenyl --OH 1 n-propyl
--S(O).sub.2-- phenyl --OH 2 n-propyl --S(O).sub.2-- phenyl
--OCH.sub.3 1 n-propyl --S(O).sub.2-- phenyl --OCH.sub.3 2 n-propyl
--C(O)--NH-- methyl --OH 1 n-propyl --C(O)--NH-- methyl --OH 2
n-propyl --C(O)--NH-- methyl --OCH.sub.3 1 n-propyl --C(O)--NH--
methyl --OCH.sub.3 2 n-propyl --C(O)--NH-- ethyl --OH 1 n-propyl
--C(O)--NH-- ethyl --OH 2 n-propyl --C(O)--NH-- ethyl --OCH.sub.3 1
n-propyl --C(O)--NH-- ethyl --OCH.sub.3 2 n-propyl --C(O)--NH--
isopropyl --OH 1 n-propyl --C(O)--NH-- isopropyl --OH 2 n-propyl
--C(O)--NH-- isopropyl --OCH.sub.3 1 n-propyl --C(O)--NH--
isopropyl --OCH.sub.3 2 n-propyl --C(O)--NH-- phenyl --OH 1
n-propyl --C(O)--NH-- phenyl --OH 2 n-propyl --C(O)--NH-- phenyl
--OCH.sub.3 1 n-propyl --C(O)--NH-- phenyl --OCH.sub.3 2 n-butyl
Bond methyl --OH 1 n-butyl Bond methyl --OH 2 n-butyl Bond methyl
--OCH.sub.3 1 n-butyl Bond methyl --OCH.sub.3 2 n-butyl Bond ethyl
--OH 1 n-butyl Bond ethyl --OH 2 n-butyl Bond ethyl --OH 3 n-butyl
Bond ethyl --OCH.sub.3 1 n-butyl Bond ethyl --OCH.sub.3 2 n-butyl
Bond isopropyl --OH 1 n-butyl Bond isopropyl --OH 2 n-butyl Bond
isopropyl --OCH.sub.3 1 n-butyl Bond isopropyl --OCH.sub.3 2
n-butyl Bond phenyl --OH 1 n-butyl Bond phenyl --OH 2 n-butyl Bond
phenyl --OCH.sub.3 1 n-butyl Bond phenyl --OCH.sub.3 2 n-butyl
--C(O)-- methyl --OH 1 n-butyl --C(O)-- methyl --OH 2 n-butyl
--C(O)-- methyl --OCH.sub.3 1 n-butyl --C(O)-- methyl --OCH.sub.3 2
n-butyl --C(O)-- ethyl --OH 1 n-butyl --C(O)-- ethyl --OH 2 n-butyl
--C(O)-- ethyl --OCH.sub.3 1 n-butyl --C(O)-- ethyl --OCH.sub.3 2
n-butyl --C(O)-- isopropyl --OH 1 n-butyl --C(O)-- isopropyl --OH 2
n-butyl --C(O)-- isopropyl --OCH.sub.3 1 n-butyl --C(O)-- isopropyl
--OCH.sub.3 2 n-butyl --C(O)-- phenyl --OH 1 n-butyl --C(O)--
phenyl --OH 2 n-butyl --C(O)-- phenyl --OCH.sub.3 1 n-butyl
--C(O)-- phenyl --OCH.sub.3 2 n-butyl --S(O).sub.2-- methyl --OH 1
n-butyl --S(O).sub.2-- methyl --OH 2 n-butyl --S(O).sub.2-- methyl
--OCH.sub.3 1 n-butyl --S(O).sub.2-- methyl --OCH.sub.3 2 n-butyl
--S(O).sub.2-- ethyl --OH 1 n-butyl --S(O).sub.2-- ethyl --OH 2
n-butyl --S(O).sub.2-- ethyl --OCH.sub.3 1 n-butyl --S(O).sub.2--
ethyl --OCH.sub.3 2 n-butyl --S(O).sub.2-- isopropyl --OH 1 n-butyl
--S(O).sub.2-- isopropyl --OH 2
n-butyl --S(O).sub.2-- isopropyl --OCH.sub.3 1 n-butyl
--S(O).sub.2-- isopropyl --OCH.sub.3 2 n-butyl --S(O).sub.2--
phenyl --OH 1 n-butyl --S(O).sub.2-- phenyl --OH 2 n-butyl
--S(O).sub.2-- phenyl --OCH.sub.3 1 n-butyl --S(O).sub.2-- phenyl
--OCH.sub.3 2 n-butyl --C(O)--NH-- methyl --OH 1 n-butyl
--C(O)--NH-- methyl --OH 2 n-butyl --C(O)--NH-- methyl --OCH.sub.3
1 n-butyl --C(O)--NH-- methyl --OCH.sub.3 2 n-butyl --C(O)--NH--
ethyl --OH 1 n-butyl --C(O)--NH-- ethyl --OH 2 n-butyl --C(O)--NH--
ethyl --OCH.sub.3 1 n-butyl --C(O)--NH-- ethyl --OCH.sub.3 2
n-butyl --C(O)--NH-- isopropyl --OH 1 n-butyl --C(O)--NH--
isopropyl --OH 2 n-butyl --C(O)--NH-- isopropyl --OCH.sub.3 1
n-butyl --C(O)--NH-- isopropyl --OCH.sub.3 2 n-butyl --C(O)--NH--
phenyl --OH 1 n-butyl --C(O)--NH-- phenyl --OH 2 n-butyl
--C(O)--NH-- phenyl --OCH.sub.3 1 n-butyl --C(O)--NH-- phenyl
--OCH.sub.3 2 2-hydroxyethyl Bond methyl --OH 1 2-hydroxyethyl Bond
methyl --OH 2 2-hydroxyethyl Bond methyl --OCH.sub.3 1
2-hydroxyethyl Bond methyl --OCH.sub.3 2 2-hydroxyethyl Bond ethyl
--OH 1 2-hydroxyethyl Bond ethyl --OH 2 2-hydroxyethyl Bond ethyl
--OCH.sub.3 1 2-hydroxyethyl Bond ethyl --OCH.sub.3 2
2-hydroxyethyl Bond isopropyl --OH 1 2-hydroxyethyl Bond isopropyl
--OH 2 2-hydroxyethyl Bond isopropyl --OCH.sub.3 1 2-hydroxyethyl
Bond isopropyl --OCH.sub.3 2 2-hydroxyethyl Bond phenyl --OH 1
2-hydroxyethyl Bond phenyl --OH 2 2-hydroxyethyl Bond phenyl
--OCH.sub.3 1 2-hydroxyethyl Bond phenyl --OCH.sub.3 2
2-hydroxyethyl --C(O)-- methyl --OH 1 2-hydroxyethyl --C(O)--
methyl --OH 2 2-hydroxyethyl --C(O)-- methyl --OCH.sub.3 1
2-hydroxyethyl --C(O)-- methyl --OCH.sub.3 2 2-hydroxyethyl
--C(O)-- ethyl --OH 1 2-hydroxyethyl --C(O)-- ethyl --OH 2
2-hydroxyethyl --C(O)-- ethyl --OCH.sub.3 1 2-hydroxyethyl --C(O)--
ethyl --OCH.sub.3 2 2-hydroxyethyl --C(O)-- isopropyl --OH 1
2-hydroxyethyl --C(O)-- isopropyl --OH 2 2-hydroxyethyl --C(O)--
isopropyl --OCH.sub.3 1 2-hydroxyethyl --C(O)-- isopropyl
--OCH.sub.3 2 2-hydroxyethyl --C(O)-- phenyl --OH 1 2-hydroxyethyl
--C(O)-- phenyl --OH 2 2-hydroxyethyl --C(O)-- phenyl --OCH.sub.3 1
2-hydroxyethyl --C(O)-- phenyl --OCH.sub.3 2 2-hydroxyethyl
--S(O).sub.2-- methyl --OH 1 2-hydroxyethyl --S(O).sub.2-- methyl
--OH 2 2-hydroxyethyl --S(O).sub.2-- methyl --OCH.sub.3 1
2-hydroxyethyl --S(O).sub.2-- methyl --OCH.sub.3 2 2-hydroxyethyl
--S(O).sub.2-- ethyl --OH 1 2-hydroxyethyl --S(O).sub.2-- ethyl
--OH 2 2-hydroxyethyl --S(O).sub.2-- ethyl --OCH.sub.3 1
2-hydroxyethyl --S(O).sub.2-- ethyl --OCH.sub.3 2 2-hydroxyethyl
--S(O).sub.2-- isopropyl --OH 1 2-hydroxyethyl --S(O).sub.2--
isopropyl --OH 2 2-hydroxyethyl --S(O).sub.2-- isopropyl
--OCH.sub.3 1 2-hydroxyethyl --S(O).sub.2-- isopropyl --OCH.sub.3 2
2-hydroxyethyl --S(O).sub.2-- phenyl --OH 1 2-hydroxyethyl
--S(O).sub.2-- phenyl --OH 2 2-hydroxyethyl --S(O).sub.2-- phenyl
--OCH.sub.3 1 2-hydroxyethyl --S(O).sub.2-- phenyl --OCH.sub.3 2
2-hydroxyethyl --C(O)--NH-- methyl --OH 1 2-hydroxyethyl
--C(O)--NH-- methyl --OH 2 2-hydroxyethyl --C(O)--NH-- methyl
--OCH.sub.3 1 2-hydroxyethyl --C(O)--NH-- methyl --OCH.sub.3 2
2-hydroxyethyl --C(O)--NH-- ethyl --OH 1 2-hydroxyethyl
--C(O)--NH-- ethyl --OH 2 2-hydroxyethyl --C(O)--NH-- ethyl
--OCH.sub.3 1 2-hydroxyethyl --C(O)--NH-- ethyl --OCH.sub.3 2
2-hydroxyethyl --C(O)--NH-- isopropyl --OH 1 2-hydroxyethyl
--C(O)--NH-- isopropyl --OH 2 2-hydroxyethyl --C(O)--NH-- isopropyl
--OCH.sub.3 1 2-hydroxyethyl --C(O)--NH-- isopropyl --OCH.sub.3 2
2-hydroxyethyl --C(O)--NH-- phenyl --OH 1 2-hydroxyethyl
--C(O)--NH-- phenyl --OH 2 2-hydroxyethyl --C(O)--NH-- phenyl
--OCH.sub.3 1 2-hydroxyethyl --C(O)--NH-- phenyl --OCH.sub.3 2
2-methoxyethyl Bond methyl --OH 1 2-methoxyethyl Bond methyl --OH 2
2-methoxyethyl Bond methyl --OCH.sub.3 1 2-methoxyethyl Bond methyl
--OCH.sub.3 2 2-methoxyethyl Bond ethyl --OH 1 2-methoxyethyl Bond
ethyl --OH 2 2-methoxyethyl Bond ethyl --OCH.sub.3 1 2-methoxyethyl
Bond ethyl --OCH.sub.3 2 2-methoxyethyl Bond isopropyl --OH 1
2-methoxyethyl Bond isopropyl --OH 2 2-methoxyethyl Bond isopropyl
--OCH.sub.3 1 2-methoxyethyl Bond isopropyl --OCH.sub.3 2
2-methoxyethyl Bond phenyl --OH 1 2-methoxyethyl Bond phenyl --OH 2
2-methoxyethyl Bond phenyl --OCH.sub.3 1 2-methoxyethyl Bond phenyl
--OCH.sub.3 2 2-methoxyethyl --C(O)-- methyl --OH 1 2-methoxyethyl
--C(O)-- methyl --OH 2 2-methoxyethyl --C(O)-- methyl --OCH.sub.3 1
2-methoxyethyl --C(O)-- methyl --OCH.sub.3 2 2-methoxyethyl
--C(O)-- ethyl --OH 1 2-methoxyethyl --C(O)-- ethyl --OH 2
2-methoxyethyl --C(O)-- ethyl --OCH.sub.3 1 2-methoxyethyl --C(O)--
ethyl --OCH.sub.3 2 2-methoxyethyl --C(O)-- isopropyl --OH 1
2-methoxyethyl --C(O)-- isopropyl --OH 2 2-methoxyethyl --C(O)--
isopropyl --OCH.sub.3 1 2-methoxyethyl --C(O)-- isopropyl
--OCH.sub.3 2 2-methoxyethyl --C(O)-- phenyl --OH 1 2-methoxyethyl
--C(O)-- phenyl --OH 2 2-methoxyethyl --C(O)-- phenyl --OCH.sub.3 1
2-methoxyethyl --C(O)-- phenyl --OCH.sub.3 2 2-methoxyethyl
--S(O).sub.2-- methyl --OH 1 2-methoxyethyl --S(O).sub.2-- methyl
--OH 2 2-methoxyethyl --S(O).sub.2-- methyl --OCH.sub.3 1
2-methoxyethyl --S(O).sub.2-- methyl --OCH.sub.3 2 2-methoxyethyl
--S(O).sub.2-- ethyl --OH 1 2-methoxyethyl --S(O).sub.2-- ethyl
--OH 2 2-methoxyethyl --S(O).sub.2-- ethyl --OCH.sub.3 1
2-methoxyethyl --S(O).sub.2-- ethyl --OCH.sub.3 2 2-methoxyethyl
--S(O).sub.2-- isopropyl --OH 1 2-methoxyethyl --S(O).sub.2--
isopropyl --OH 2 2-methoxyethyl --S(O).sub.2-- isopropyl
--OCH.sub.3 1 2-methoxyethyl --S(O).sub.2-- isopropyl --OCH.sub.3 2
2-methoxyethyl --S(O).sub.2-- phenyl --OH 1 2-methoxyethyl
--S(O).sub.2-- phenyl --OH 2 2-methoxyethyl --S(O).sub.2-- phenyl
--OCH.sub.3 1 2-methoxyethyl --S(O).sub.2-- phenyl --OCH.sub.3 2
2-methoxyethyl --C(O)--NH-- methyl --OH 1 2-methoxyethyl
--C(O)--NH-- methyl --OH 2 2-methoxyethyl --C(O)--NH-- methyl
--OCH.sub.3 1 2-methoxyethyl --C(O)--NH-- methyl --OCH.sub.3 2
2-methoxyethyl --C(O)--NH-- ethyl --OH 1 2-methoxyethyl
--C(O)--NH-- ethyl --OH 2 2-methoxyethyl --C(O)--NH-- ethyl
--OCH.sub.3 1 2-methoxyethyl --C(O)--NH-- ethyl --OCH.sub.3 2
2-methoxyethyl --C(O)--NH-- isopropyl --OH 1 2-methoxyethyl
--C(O)--NH-- isopropyl --OH 2 2-methoxyethyl --C(O)--NH-- isopropyl
--OCH.sub.3 1 2-methoxyethyl --C(O)--NH-- isopropyl --OCH.sub.3 2
2-methoxyethyl --C(O)--NH-- phenyl --OH 1 2-methoxyethyl
--C(O)--NH-- phenyl --OH 2 2-methoxyethyl --C(O)--NH-- phenyl
--OCH.sub.3 1 2-methoxyethyl --C(O)--NH-- phenyl --OCH.sub.3 2
[0429] Certain exemplary compounds, including some of those
described above in the Examples, have the following Formulas
(III-3, IV-3, V-3, and VIII-3) wherein R.sub.2, Q, Z, R.sub.4, and
m are defined immediately below in the table. Each row of the table
is matched with Formula III-3, IV-3, V-3, or VIII-3 to represent a
specific embodiment of the invention.
TABLE-US-00003 III-3 ##STR00075## IV-3 ##STR00076## V-3
##STR00077## VIII-3 ##STR00078## R.sub.3 Q Z R.sub.4 m methyl Bond
--CH.sub.2 methyl 1 methyl Bond --CH.sub.2 methyl 2 methyl Bond
--CH.sub.2 ethyl 1 methyl Bond --CH.sub.2 ethyl 2 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 methyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 methyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 methyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 methyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 methyl --C(O)-- --CH.sub.2--
methyl 1 methyl --C(O)-- --CH.sub.2-- methyl 2 methyl --C(O)--
--CH.sub.2-- ethyl 1 methyl --C(O)-- --CH.sub.2-- ethyl 2 methyl
--C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 methyl --S(O).sub.2--
--CH.sub.2-- methyl 1 methyl --S(O).sub.2-- --CH.sub.2-- methyl 2
methyl --S(O).sub.2-- --CH.sub.2-- ethyl 1 methyl --S(O).sub.2--
--CH.sub.2-- ethyl 2 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 methyl --C(O)--NH-- --CH.sub.2--
methyl 1 methyl --C(O)--NH-- --CH.sub.2-- methyl 2 methyl
--C(O)--NH-- --CH.sub.2-- ethyl 1 methyl --C(O)--NH-- --CH.sub.2--
ethyl 2 methyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1
methyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 2 methyl
--C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 methyl
--C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 methyl
--C(O)--NH-- --CH.sub.2--O--CH.sub.2-- methyl 1 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethyl Bond --CH.sub.2-- methyl 1
ethyl Bond --CH.sub.2-- methyl 2 ethyl Bond --CH.sub.2-- ethyl 1
ethyl Bond --CH.sub.2-- ethyl 2 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 ethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 ethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethyl --C(O)-- --CH.sub.2--
methyl 1 ethyl --C(O)-- --CH.sub.2-- methyl 2 ethyl --C(O)--
--CH.sub.2-- ethyl 1 ethyl --C(O)-- --CH.sub.2-- ethyl 2 ethyl
--C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethyl --S(O).sub.2-- --CH.sub.2--
methyl 1 ethyl --S(O).sub.2-- --CH.sub.2-- methyl 2 ethyl
--S(O).sub.2-- --CH.sub.2-- ethyl 1 ethyl --S(O).sub.2--
--CH.sub.2-- ethyl 2 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethyl --C(O)--NH-- --CH.sub.2--
methyl 1 ethyl --C(O)--NH-- --CH.sub.2-- methyl 2 ethyl
--C(O)--NH-- --CH.sub.2-- ethyl 1 ethyl --C(O)--NH-- --CH.sub.2--
ethyl 2 ethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1
ethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethyl
--C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethyl
--C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethyl
--C(O)--NH-- --CH.sub.2--O--CH.sub.2-- methyl 1 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-propyl Bond --CH.sub.2-- methyl
1 n-propyl Bond --CH.sub.2-- methyl 2 n-propyl Bond --CH.sub.2--
ethyl 1 n-propyl Bond --CH.sub.2-- ethyl 2 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-propyl --C(O)-- --CH.sub.2--
methyl 1 n-propyl --C(O)-- --CH.sub.2-- methyl 2 n-propyl --C(O)--
--CH.sub.2-- ethyl 1 n-propyl --C(O)-- --CH.sub.2-- ethyl 2
n-propyl --C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-propyl
--C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-propyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-propyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-propyl --S(O).sub.2--
--CH.sub.2-- methyl 1 n-propyl --S(O).sub.2-- --CH.sub.2-- methyl 2
n-propyl --S(O).sub.2-- --CH.sub.2-- ethyl 1 n-propyl
--S(O).sub.2-- --CH.sub.2-- ethyl 2 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-propyl --C(O)--NH--
--CH.sub.2-- methyl 1 n-propyl --C(O)--NH-- --CH.sub.2-- methyl 2
n-propyl --C(O)--NH-- --CH.sub.2-- ethyl 1 n-propyl --C(O)--NH--
--CH.sub.2-- ethyl 2 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-butyl Bond --CH.sub.2-- methyl
1 n-butyl Bond --CH.sub.2-- methyl 2 n-butyl Bond --CH.sub.2--
ethyl 1 n-butyl Bond --CH.sub.2-- ethyl 2 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-butyl --C(O)-- --CH.sub.2--
methyl 1 n-butyl --C(O)-- --CH.sub.2-- methyl 2 n-butyl --C(O)--
--CH.sub.2-- ethyl 1 n-butyl --C(O)-- --CH.sub.2-- ethyl 2 n-butyl
--C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-butyl --S(O).sub.2--
--CH.sub.2-- methyl 1 n-butyl --S(O).sub.2-- --CH.sub.2-- methyl 2
n-butyl --S(O).sub.2-- --CH.sub.2-- ethyl 1 n-butyl --S(O).sub.2--
--CH.sub.2-- ethyl 2 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-butyl --C(O)--NH-- --CH.sub.2--
methyl 1 n-butyl --C(O)--NH-- --CH.sub.2-- methyl 2 n-butyl
--C(O)--NH-- --CH.sub.2-- ethyl 1 n-butyl --C(O)--NH-- --CH.sub.2--
ethyl 2 n-butyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2 methyl 1
n-butyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2 methyl 2 n-butyl
--C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2 ethyl 1 n-butyl
--C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2 ethyl 2 n-butyl
--C(O)--NH-- --CH.sub.2--O--CH.sub.2-- methyl 1 n-butyl
--C(O)--NH-- --CH.sub.2--O--CH.sub.2-- methyl 2 n-butyl
--C(O)--NH-- --CH.sub.2--O--CH.sub.2-- ethyl 1 n-butyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 2-hydroxyethyl Bond --CH.sub.2--
methyl 1 2-hydroxyethyl Bond --CH.sub.2-- methyl 2 2-hydroxyethyl
Bond --CH.sub.2-- ethyl 1 2-hydroxyethyl Bond --CH.sub.2-- ethyl 2
2-hydroxyethyl Bond --CH.sub.2CH.sub.2CH.sub.2-- methyl 1
2-hydroxyethyl Bond --CH.sub.2CH.sub.2CH.sub.2-- methyl 2
2-hydroxyethyl Bond --CH.sub.2CH.sub.2CH.sub.2-- ethyl 1
2-hydroxyethyl Bond --CH.sub.2CH.sub.2CH.sub.2-- ethyl 2
2-hydroxyethyl Bond --CH.sub.2--O--CH.sub.2-- methyl 1
2-hydroxyethyl Bond --CH.sub.2--O--CH.sub.2-- methyl 2
2-hydroxyethyl Bond --CH.sub.2--O--CH.sub.2-- ethyl 1
2-hydroxyethyl Bond --CH.sub.2--O--CH.sub.2-- ethyl 2
2-hydroxyethyl --C(O)-- --CH.sub.2-- methyl 1 2-hydroxyethyl
--C(O)-- --CH.sub.2-- methyl 2 2-hydroxyethyl --C(O)-- --CH.sub.2--
ethyl 1 2-hydroxyethyl --C(O)-- --CH.sub.2-- ethyl 2 2-hydroxyethyl
--C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-hydroxyethyl
--C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-hydroxyethyl
--C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-hydroxyethyl
--C(O)-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-hydroxyethyl
--C(O)-- --CH.sub.2--O--CH.sub.2-- methyl 1 2-hydroxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 2-hydroxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 2-hydroxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 2-hydroxyethyl --S(O).sub.2--
--CH.sub.2-- methyl 1 2-hydroxyethyl --S(O).sub.2-- --CH.sub.2--
methyl 2 2-hydroxyethyl --S(O).sub.2-- --CH.sub.2-- ethyl 1
2-hydroxyethyl --S(O).sub.2-- --CH.sub.2-- ethyl 2 2-hydroxyethyl
--S(O).sub.2-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-hydroxyethyl
--S(O).sub.2-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-hydroxyethyl
--S(O).sub.2-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-hydroxyethyl
--S(O).sub.2-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-hydroxyethyl
--S(O).sub.2-- --CH.sub.2--O--CH.sub.2-- methyl 1 2-hydroxyethyl
--S(O).sub.2-- --CH.sub.2--O--CH.sub.2-- methyl 2 2-hydroxyethyl
--S(O).sub.2-- --CH.sub.2--O--CH.sub.2-- ethyl 1 2-hydroxyethyl
--S(O).sub.2-- --CH.sub.2--O--CH.sub.2-- ethyl 2 2-hydroxyethyl
--C(O)--NH-- --CH.sub.2-- methyl 1 2-hydroxyethyl --C(O)--NH--
--CH.sub.2-- methyl 2 2-hydroxyethyl --C(O)--NH-- --CH.sub.2--
ethyl 1 2-hydroxyethyl --C(O)--NH-- --CH.sub.2-- ethyl 2
2-hydroxyethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1
2-hydroxyethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 2
2-hydroxyethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl
1
2-hydroxyethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 2
2-hydroxyethyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- methyl 1
2-hydroxyethyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- methyl 2
2-hydroxyethyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- ethyl 1
2-hydroxyethyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- ethyl 2
2-methoxyethyl Bond --CH.sub.2-- methyl 1 2-methoxyethyl Bond
--CH.sub.2-- methyl 2 2-methoxyethyl Bond --CH.sub.2-- ethyl 1
2-methoxyethyl Bond --CH.sub.2-- ethyl 2 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 2-methoxyethyl --C(O)--
--CH.sub.2-- methyl 1 2-methoxyethyl --C(O)-- --CH.sub.2-- methyl 2
2-methoxyethyl --C(O)-- --CH.sub.2-- ethyl 1 2-methoxyethyl
--C(O)-- --CH.sub.2-- ethyl 2 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 2-methoxyethyl --S(O).sub.2--
--CH.sub.2-- methyl 1 2-methoxyethyl --S(O).sub.2-- --CH.sub.2--
methyl 2 2-methoxyethyl --S(O).sub.2-- --CH.sub.2-- ethyl 1
2-methoxyethyl --S(O).sub.2-- --CH.sub.2-- ethyl 2 2-methoxyethyl
--S(O).sub.2-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-methoxyethyl
--S(O).sub.2-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-methoxyethyl
--S(O).sub.2-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-methoxyethyl
--S(O).sub.2-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-methoxyethyl
--S(O).sub.2-- --CH.sub.2--O--CH.sub.2-- methyl 1 2-methoxyethyl
--S(O).sub.2-- --CH.sub.2--O--CH.sub.2-- methyl 2 2-methoxyethyl
--S(O).sub.2-- --CH.sub.2--O--CH.sub.2-- ethyl 1 2-methoxyethyl
--S(O).sub.2-- --CH.sub.2--O--CH.sub.2-- ethyl 2 2-methoxyethyl
--C(O)--NH-- --CH.sub.2-- methyl 1 2-methoxyethyl --C(O)--NH--
--CH.sub.2-- methyl 2 2-methoxyethyl --C(O)--NH-- --CH.sub.2--
ethyl 1 2-methoxyethyl --C(O)--NH-- --CH.sub.2-- ethyl 2
2-methoxyethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 1
2-methoxyethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- methyl 2
2-methoxyethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 1
2-methoxyethyl --C(O)--NH-- --CH.sub.2CH.sub.2CH.sub.2-- ethyl 2
2-methoxyethyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- methyl 1
2-methoxyethyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- methyl 2
2-methoxyethyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- ethyl 1
2-methoxyethyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- ethyl 2
[0430] Certain exemplary compounds, including some of those
described above in the Examples, have the following Formulas
(III-4, IV-4, V-4, and VIII-4) wherein R.sub.2 and m are defined
immediately below in the table. Each row of the table is matched
with Formula III-4, IV-4, V-4, or VIII-4 to represent a specific
embodiment of the invention.
TABLE-US-00004 III-4 ##STR00079## IV-4 ##STR00080## V-4
##STR00081## VIII-4 ##STR00082## R.sub.2 m methyl 1 methyl 2 ethyl
1 ethyl 2 n-propyl 1 n-propyl 2 n-butyl 1 n-butyl 2 2-hydroxyethyl
1 2-hydroxyethyl 2 2-methoxyethyl 1 2-methoxyethyl 2
[0431] Compounds of the invention have been found to modulate
cytokine biosynthesis by inducing the production of interferon
.alpha. and/or tumor necrosis factor .alpha. in human cells when
tested using one of the methods described below.
Cytokine Induction in Human Cells
[0432] An in vitro human blood cell system is used to assess
cytokine induction. Activity is based on the measurement of
interferon (.alpha.) and tumor necrosis factor (.alpha.)
(IFN-.alpha. and TNF-.alpha., respectively) secreted into culture
media as described by Testerman et al. in "Cytokine Induction by
the Immunomodulators Imiquimod and S-27609," Journal of Leukocyte
Biology, 58, 365-372 (September, 1995).
Blood Cell Preparation for Culture
[0433] Whole blood from healthy human donors is collected by
venipuncture into vacutainer tubes or syringes containing EDTA.
Peripheral blood mononuclear cells (PBMC) are separated from whole
blood by density gradient centrifugation using HISTOPAQUE-1077
(Sigma, St. Louis, Mo.) or Ficoll-Paque Plus (Amersham Biosciences
Piscataway, N.J.). Blood is diluted 1:1 with Dulbecco's Phosphate
Buffered Saline (DPBS) or Hank's Balanced Salts Solution (HBSS).
Alternately, whole blood is placed in Accuspin (Sigma) or LeucoSep
(Greiner Bio-One, Inc., Longwood, Fla.) centrifuge frit tubes
containing density gradient medium. The PBMC layer is collected and
washed twice with DPBS or HBSS and re-suspended at 4.times.10.sup.6
cells/mL in RPMI complete. The PBMC suspension is added to 96 well
flat bottom sterile tissue culture plates containing an equal
volume of RPMI complete media containing test compound.
Compound Preparation
[0434] The compounds are solubilized in dimethyl sulfoxide (DMSO).
The DMSO concentration should not exceed a final concentration of
1% for addition to the culture wells. The compounds are generally
tested at concentrations ranging from 30-0.014 .mu.M. Controls
include cell samples with media only, cell samples with DMSO only
(no compound), and cell samples with reference compound.
Incubation
[0435] The solution of test compound is added at 60 .mu.M to the
first well containing RPMI complete and serial 3 fold dilutions are
made in the wells. The PBMC suspension is then added to the wells
in an equal volume, bringing the test compound concentrations to
the desired range (usually 30-0.014 .mu.M). The final concentration
of PBMC suspension is 2.times.10.sup.6 cells/mL. The plates are
covered with sterile plastic lids, mixed gently and then incubated
for 18 hours to 24 hours at 37.degree. C. in a 5% carbon dioxide
atmosphere.
Separation
[0436] Following incubation the plates are centrifuged for 10
minutes at 1000 rpm (approximately 200.times.g) at 4.degree. C. The
cell-free culture supernatant is removed and transferred to sterile
polypropylene tubes. Samples are maintained at -30.degree. C. to
-70.degree. C. until analysis. The samples are analyzed for
IFN-.alpha. by ELISA and for TNF-.alpha. by IGEN/BioVeris
Assay.
Interferon (.alpha.) and Tumor Necrosis Factor (.alpha.)
Analysis
[0437] IFN-.alpha. concentration is determined with a human
multi-subtype calorimetric sandwich ELISA (Catalog Number 41105)
from PBL Biomedical Laboratories, Piscataway, N.J. Results are
expressed in pg/mL.
[0438] The TNF-.alpha. concentration is determined by ORIGEN
M-Series Immunoassay and read on an IGEN M-8 analyzer from BioVeris
Corporation, formerly known as IGEN to International, Gaithersburg,
Md. The immunoassay uses a human TNF-.alpha. capture and detection
antibody pair (Catalog Numbers AHC3419 and AHC3712) from Biosource
International, Camarillo, Calif. Results are expressed in
pg/mL.
Assay Data and Analysis
[0439] In total, the data output of the assay consists of
concentration values of TNF-.alpha. and IFN-.alpha. (y-axis) as a
function of compound concentration (x-axis).
[0440] Analysis of the data has two steps. First, the greater of
the mean DMSO (DMSO control wells) or the experimental background
(usually 20 pg/mL for IFN-.alpha. and 40 pg/mL for TNF-.alpha.) is
subtracted from each reading. If any negative values result from
background subtraction, the reading is reported as "*", and is
noted as not reliably detectable. In subsequent calculations and
statistics, "*", is treated as a zero. Second, all background
subtracted values are multiplied by a single adjustment ratio to
decrease experiment to experiment variability. The adjustment ratio
is the area of the reference compound in the new experiment divided
by the expected area of the reference compound based on the past 61
experiments (unadjusted readings). This results in the scaling of
the reading (y-axis) for the new data without changing the shape of
the dose-response curve. The reference compound used is
2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-.alpha.,.alpha.-dimethyl-1H--
imidazo[4,5-c]quinolin 1-yl]ethanol hydrate (U.S. Pat. No.
5,352,784; Example 91) and the expected area is the sum of the
median dose values from the past 61 experiments.
[0441] The minimum effective concentration is calculated based on
the background-subtracted, reference-adjusted results for a given
experiment and compound. The minimum effective concentration
(.mu.molar) is the lowest of the tested compound concentrations
that induces a response over a fixed cytokine concentration for the
tested cytokine (usually 20 pg/mL for IFN-.alpha. and 40 pg/mL for
TNF-.alpha.). The maximal response is the maximal amount of
cytokine (pg/ml) produced in the dose-response.
Cytokine Induction in Human Cells
High Throughput Screen
[0442] The CYTOKINE INDUCTION IN HUMAN CELLS test method described
above was modified as follows for high throughput screening.
Blood Cell Preparation for Culture
[0443] Whole blood from healthy human donors is collected by
venipuncture into vacutainer tubes or syringes containing EDTA.
Peripheral blood mononuclear cells (PBMC) are separated from whole
blood by density gradient centrifugation using HISTOPAQUE-1077
(Sigma, St. Louis, Mo.) or Ficoll-Paque Plus (Amersham Biosciences
Piscataway, N.J.). Whole blood is placed in Accuspin (Sigma) or
LeucoSep (Greiner Bio-One, Inc., Longwood, Fla.) centrifuge frit
tubes containing density gradient medium. The PBMC layer is
collected and washed twice with DPBS or HBSS and re-suspended at
4.times.10.sup.6 cells/mL in RPMI complete (2-fold the final cell
density). The PBMC suspension is added to 96-well flat bottom
sterile tissue culture plates.
Compound Preparation
[0444] The compounds are solubilized in dimethyl sulfoxide (DMSO).
The compounds are generally tested at concentrations ranging from
30-0.014 .mu.M. Controls include cell samples with media only, cell
samples with DMSO only (no compound), and cell samples with a
reference compound
2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-.alpha.,.alpha.-dimethyl-1H--
imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No.
5,352,784; Example 91) on each plate. The solution of test compound
is added at 7.5 mM to the first well of a dosing plate and serial 3
fold dilutions are made for the 7 subsequent concentrations in
DMSO. RPMI Complete media is then added to the test compound
dilutions in order to reach a final compound concentration of
2-fold higher (60-0.028 .mu.M) than the final tested concentration
range.
Incubation
[0445] Compound solution is then added to the wells containing the
PBMC suspension bringing the test compound concentrations to the
desired range (usually 30 .mu.M-0.014 .mu.M) and the DMSO
concentration to 0.4%. The final concentration of PBMC suspension
is 2.times.10.sup.6 cells/mL. The plates are covered with sterile
plastic lids, mixed gently and then incubated for 18 to 24 hours at
37.degree. C. in a 5% carbon dioxide atmosphere.
Separation
[0446] Following incubation the plates are centrifuged for 10
minutes at 1000 rpm (approximately 200 g) at 4.degree. C. 4-plex
Human Panel MSD MULTI-SPOT 96-well plates are pre-coated with the
appropriate capture antibodies by MesoScale Discovery, Inc. (MSD,
Gaithersburg, Md.). The cell-free culture supernatants are removed
and transferred to the MSD plates. Fresh samples are typically
tested, although they may be maintained at -30.degree. C. to
-70.degree. C. until analysis.
Interferon-.alpha. and Tumor Necrosis Factor-.alpha.Analysis
[0447] MSD MULTI-SPOT plates contain within each well capture
antibodies for human TNF-.alpha. and human IFN-.alpha. that have
been pre-coated on specific spots. Each well contains four spots:
one human TNF-.alpha. capture antibody (MSD) spot, one human
IFN-.alpha. capture antibody (PBL Biomedical Laboratories,
Piscataway, N.J.) spot, and two inactive bovine serum albumin
spots. The human TNF-.alpha. capture and detection antibody pair is
from MesoScale Discovery. The human IFN-.alpha. multi-subtype
antibody (PBL Biomedical Laboratories) captures all IFN-.alpha.
subtypes except IFN-.alpha. F (IFNA21). Standards consist of
recombinant human TNF-.alpha. (R&D Systems, Minneapolis, Minn.)
and IFN-.alpha. (PBL Biomedical Laboratories). Samples and separate
standards are added at the time of analysis to each MSD plate. Two
human IFN-.alpha. detection antibodies (Cat. Nos. 21112 &
21100, PBL) are used in a two to one ratio (weight:weight) to each
other to determine the IFN-.alpha. concentrations. The
cytokine-specific detection antibodies are labeled with the
SULFO-TAG reagent (MSD). After adding the SULFO-TAG labeled
detection antibodies to the wells, each well's
electrochemiluminescent levels are read using MSD's SECTOR HTS
READER. Results are expressed in pg/mL upon calculation with known
cytokine standards.
Assay Data and Analysis
[0448] In total, the data output of the assay consists of
concentration values of TNF-.alpha. or IFN-.alpha. (y-axis) as a
function of compound concentration (x-axis).
[0449] A plate-wise scaling is performed within a given experiment
aimed at reducing plate-to-plate variability associated within the
same experiment. First, the greater of the median DMSO (DMSO
control wells) or the experimental background (usually 20 pg/mL for
IFN-.alpha. and 40 pg/mL for TNF-.alpha.) is subtracted from each
reading. Negative values that may result from background
subtraction are set to zero. Each plate within a given experiment
has a reference compound that serves as a control. This control is
used to calculate a median expected area under the curve across all
plates in the assay. A plate-wise scaling factor is calculated for
each plate as a ratio of the area of the reference compound on the
particular plate to the median expected area for the entire
experiment. The data from each plate are then multiplied by the
plate-wise scaling factor for all plates. Only data from plates
bearing a scaling factor of between 0.5 and 2.0 (for both cytokines
IFN-.alpha., TNF-.alpha.) are reported. Data from plates with
scaling factors outside the above-mentioned interval are retested
until they bear scaling factors inside the above mentioned
interval. The above method produces a scaling of the y-values
without altering the shape of the curve. The reference compound
used is
2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-.alpha.,.alpha.-dimethyl-1H--
imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No.
5,352,784; Example 91). The median expected area is the median area
across all plates that are part of a given experiment.
[0450] A second scaling may also be performed to reduce
inter-experiment variability (across multiple experiments). All
background-subtracted values are multiplied by a single adjustment
ratio to decrease experiment-to-experiment variability. The
adjustment ratio is the area of the reference compound in the new
experiment divided by the expected area of the reference compound
based on an average of previous experiments (unadjusted readings).
This results in the scaling of the reading (y-axis) for the new
data without changing the shape of the dose-response curve. The
reference compound used is
2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-.alpha.,.alpha.-dimethyl-1H--
imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No.
5,352,784; Example 91) and the expected area is the sum of the
median dose values from an average of previous experiments.
[0451] The minimum effective concentration is calculated based on
the background-subtracted, reference-adjusted results for a given
experiment and compound. The minimum effective concentration
(.mu.molar) is the lowest of the tested compound concentrations
that induces a response over a fixed cytokine concentration for the
tested cytokine (usually 20 pg/mL for IFN-.alpha. and 40 pg/mL for
TNF-.alpha.). The maximal response is the maximal amount of
cytokine (pg/ml) produced in the dose-response.
[0452] The complete disclosures of the patents, patent documents,
and publications cited herein are incorporated by reference in
their entirety as if each were individually incorporated. Various
modifications and alterations to this invention will become
apparent to those skilled in the art without departing from the
scope and spirit of this invention. It should be understood that
this invention is not intended to be unduly limited by the
illustrative embodiments and examples set forth herein and that
such examples and embodiments are presented by way of example only
with the scope of the invention intended to be limited only by the
claims set forth herein as follows.
* * * * *